0000765880 false--12-31 2025 Q3 http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember P1Y xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure peak:property peak:joint_venture peak:squareFeet utr:sqft peak:loan peak:extension_option utr:bbl peak:derivative_held peak:building peak:renewal_option peak:facility peak:obligation peak:plan_participant peak:unit peak:entity peak:hospital peak:asset 0000765880 2025-01-01 2025-09-30 0000765880 2025-10-22 0000765880 2025-09-30 0000765880 2024-12-31 0000765880 2025-07-01 2025-09-30 0000765880 2024-07-01 2024-09-30 0000765880 2024-01-01 2024-09-30 0000765880 us-gaap:CommonStockMember 2025-06-30 0000765880 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2025-06-30 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0000765880 us-gaap:ParentMember 2025-06-30 0000765880 us-gaap:NoncontrollingInterestMember 2025-06-30 0000765880 2025-06-30 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2025-07-01 2025-09-30 0000765880 us-gaap:ParentMember 2025-07-01 2025-09-30 0000765880 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0000765880 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000765880 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000765880 us-gaap:CommonStockMember 2025-09-30 0000765880 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2025-09-30 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0000765880 us-gaap:ParentMember 2025-09-30 0000765880 us-gaap:NoncontrollingInterestMember 2025-09-30 0000765880 us-gaap:CommonStockMember 2024-06-30 0000765880 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-06-30 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000765880 us-gaap:ParentMember 2024-06-30 0000765880 us-gaap:NoncontrollingInterestMember 2024-06-30 0000765880 2024-06-30 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-07-01 2024-09-30 0000765880 us-gaap:ParentMember 2024-07-01 2024-09-30 0000765880 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000765880 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000765880 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000765880 us-gaap:CommonStockMember 2024-09-30 0000765880 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-09-30 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000765880 us-gaap:ParentMember 2024-09-30 0000765880 us-gaap:NoncontrollingInterestMember 2024-09-30 0000765880 2024-09-30 0000765880 us-gaap:CommonStockMember 2024-12-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-12-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000765880 us-gaap:ParentMember 2024-12-31 0000765880 us-gaap:NoncontrollingInterestMember 2024-12-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2025-01-01 2025-09-30 0000765880 us-gaap:ParentMember 2025-01-01 2025-09-30 0000765880 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-09-30 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-09-30 0000765880 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0000765880 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0000765880 us-gaap:CommonStockMember 2023-12-31 0000765880 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-12-31 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000765880 us-gaap:ParentMember 2023-12-31 0000765880 us-gaap:NoncontrollingInterestMember 2023-12-31 0000765880 2023-12-31 0000765880 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-01-01 2024-09-30 0000765880 us-gaap:ParentMember 2024-01-01 2024-09-30 0000765880 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-09-30 0000765880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0000765880 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000765880 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0000765880 peak:PhysiciansRealtyTrustMember 2024-03-01 2024-03-01 0000765880 peak:OutpatientMedicalBuildingsMember peak:PhysiciansRealtyTrustMember 2024-03-01 2024-03-01 0000765880 peak:PhysiciansRealtyTrustMember 2024-03-01 0000765880 peak:PhysiciansRealtyTrustMember peak:RestrictedSharesMember 2024-03-01 2024-03-01 0000765880 peak:PhysiciansRealtyTrustMember us-gaap:CommonStockMember 2024-03-01 2024-03-01 0000765880 peak:PhysiciansRealtyTrustMember us-gaap:RestrictedStockUnitsRSUMember 2024-03-01 2024-03-01 0000765880 peak:PhysiciansRealtyTrustMember srt:ScenarioPreviouslyReportedMember 2024-03-01 0000765880 peak:PhysiciansRealtyTrustMember srt:RestatementAdjustmentMember 2024-03-01 0000765880 peak:PhysiciansRealtyTrustMember srt:ScenarioPreviouslyReportedMember 2024-03-01 2024-03-01 0000765880 peak:PhysiciansRealtyTrustMember srt:RestatementAdjustmentMember 2024-03-01 2024-03-01 0000765880 srt:MinimumMember peak:PhysiciansRealtyTrustMember 2024-03-01 2024-03-01 0000765880 srt:MaximumMember peak:PhysiciansRealtyTrustMember 2024-03-01 2024-03-01 0000765880 peak:PhysiciansRealtyTrustMember 2025-07-01 2025-09-30 0000765880 peak:PhysiciansRealtyTrustMember 2025-01-01 2025-09-30 0000765880 peak:PhysiciansRealtyTrustMember 2024-07-01 2024-09-30 0000765880 peak:PhysiciansRealtyTrustMember 2024-01-01 2024-09-30 0000765880 peak:FeesPaidToInvestmentBanksAndAdvisorsMember peak:PhysiciansRealtyTrustMember 2024-01-01 2024-09-30 0000765880 peak:SuccessBasedPaymentsRelatedToServiceProvidersMember peak:PhysiciansRealtyTrustMember 2024-01-01 2024-09-30 0000765880 peak:SeveranceExpenseDueToDualTriggerSeveranceArrangementsMember peak:PhysiciansRealtyTrustMember 2024-01-01 2024-09-30 0000765880 peak:PostCombinationExpenseAcceleratedVestingOfAcquireeEquityAwardsMember peak:PhysiciansRealtyTrustMember 2024-01-01 2024-09-30 0000765880 peak:LegalAccountingTaxAndOtherCostsMember peak:PhysiciansRealtyTrustMember 2024-01-01 2024-09-30 0000765880 peak:SeveranceExpenseRelatedToEliminationOfCertainPositionsMember peak:PhysiciansRealtyTrustMember 2024-01-01 2024-09-30 0000765880 peak:OutpatientMedicalBuildingsMember stpr:NY 2025-02-01 2025-02-28 0000765880 stpr:MA peak:LabBuildingsMember 2025-02-01 2025-02-28 0000765880 peak:OutpatientMedicalBuildingsMember stpr:GA 2025-09-01 2025-09-30 0000765880 peak:LandParcelMember 2025-04-01 2025-06-30 0000765880 peak:OutpatientMedicalBuildingsMember 2025-07-01 2025-09-30 0000765880 peak:OutpatientMedicalBuildingsMember 2024-01-01 2024-03-31 0000765880 peak:LabBuildingsMember 2024-04-01 2024-06-30 0000765880 peak:LandParcelMember 2024-04-01 2024-06-30 0000765880 peak:OutpatientMedicalBuildingsMember 2024-04-01 2024-06-30 0000765880 peak:OutpatientMedicalBuildingsAndLabBuildingsMember 2024-04-01 2024-06-30 0000765880 peak:OutpatientMedicalBuildingsMember 2024-07-01 2024-09-30 0000765880 peak:OneOutpatientMedicalBuildingMember 2024-01-01 2024-12-31 0000765880 peak:TwoOutpatientMedicalBuildingsMember 2024-01-01 2024-12-31 0000765880 peak:CCRCMember 2024-01-01 2024-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember peak:LabBuildingsMember 2025-09-30 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember 2025-09-30 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember peak:OutpatientMedicalBuildingsMember 2024-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember 2024-12-31 0000765880 2024-07-01 2024-07-31 0000765880 2024-07-31 0000765880 peak:CommonSpiritMember peak:OutpatientMedicalMember 2025-07-01 2025-09-30 0000765880 peak:CommonSpiritMember peak:OutpatientMedicalMember 2025-01-01 2025-09-30 0000765880 peak:CommonSpiritMember 2025-01-01 2025-09-30 0000765880 peak:CommonSpiritMember 2025-07-01 2025-09-30 0000765880 peak:GraphiteBioIncMember 2023-10-26 0000765880 peak:GraphiteBioIncMember 2023-10-26 2023-10-26 0000765880 peak:SecuredMortgageLoansMember 2025-09-30 0000765880 peak:SecuredMortgageLoansMember 2024-12-31 0000765880 peak:CCRCResidentLoansMember 2025-09-30 0000765880 peak:CCRCResidentLoansMember 2024-12-31 0000765880 peak:MezzanineLoansMember 2025-09-30 0000765880 peak:MezzanineLoansMember 2024-12-31 0000765880 peak:OutpatientMedicalBuildingsMember 2024-12-31 0000765880 peak:SecuredMortgageLoansMember 2024-03-01 2024-03-01 0000765880 peak:MezzanineLoansMember 2024-03-01 2024-03-01 0000765880 2024-03-01 0000765880 srt:MinimumMember peak:SecuredMortgageLoansMember 2024-03-01 0000765880 srt:MaximumMember peak:SecuredMortgageLoansMember 2024-03-01 0000765880 srt:MinimumMember peak:MezzanineLoansMember 2024-03-01 0000765880 srt:MaximumMember peak:MezzanineLoansMember 2024-03-01 0000765880 peak:SunriseSeniorHousingPortfolioMember 2024-02-01 2024-02-29 0000765880 peak:SunriseSeniorHousingPortfolioMember 2024-05-01 2024-05-31 0000765880 peak:SunriseSeniorHousingPortfolioMember 2024-12-31 0000765880 peak:OtherSHOPSellerFinancingMember 2024-12-31 0000765880 peak:OutpatientMedicalBuildingsMember 2024-07-01 2024-07-31 0000765880 peak:TwoOutpatientMedicalBuildingsMember 2024-11-01 2024-11-30 0000765880 srt:MinimumMember peak:OutpatientMedicalBuildingsMember 2024-07-31 0000765880 srt:MaximumMember peak:OutpatientMedicalBuildingsMember 2024-07-31 0000765880 peak:OutpatientMedicalBuildingsMember 2024-01-01 2024-12-31 0000765880 peak:OutpatientMedicalBuildingsMember 2025-01-01 2025-09-30 0000765880 peak:OutpatientMedicalBuildingsMember 2024-01-01 2024-09-30 0000765880 peak:OutpatientMedicalBuildingsMember 2025-09-30 0000765880 peak:SecuredMortgageLoansMember peak:LabMember peak:OtherMember 2025-01-01 2025-09-30 0000765880 peak:SecuredMortgageLoansMember peak:OutpatientMedicalMember peak:OtherMember 2025-01-01 2025-09-30 0000765880 peak:SecuredMortgageLoansMember peak:LandParcelMember peak:OtherMember 2025-01-01 2025-09-30 0000765880 peak:OtherMember peak:MezzanineLoansMember 2025-01-01 2025-09-30 0000765880 peak:OtherMember peak:SecuredMortgageLoansMember 2025-01-01 2025-09-30 0000765880 peak:OtherMember peak:SecuredMortgageLoans1Member 2025-01-01 2025-09-30 0000765880 peak:OtherMember peak:ConstructionLoanMember 2024-01-01 2024-12-31 0000765880 peak:OtherMember peak:MezzanineLoansMember 2024-01-01 2024-12-31 0000765880 peak:LessorAssetUnderOperatingLeaseMember peak:BrookdaleMTCAMember peak:CCRVJVInvestmentMember peak:OtherNonReportingSegmentMember 2025-09-30 0000765880 peak:LessorAssetUnderOperatingLeaseMember peak:BrookdaleMTCAMember peak:CCRVJVInvestmentMember peak:OtherNonReportingSegmentMember 2024-12-31 0000765880 us-gaap:PerformingFinancingReceivableMember us-gaap:MortgageReceivablesMember 2025-09-30 0000765880 peak:WatchListFinancingReceivableMember us-gaap:MortgageReceivablesMember 2025-09-30 0000765880 peak:WorkoutFinancingReceivableMember us-gaap:MortgageReceivablesMember 2025-09-30 0000765880 us-gaap:MortgageReceivablesMember 2025-09-30 0000765880 peak:CurrentPeriodGrossWriteOffsMember us-gaap:MortgageReceivablesMember 2025-09-30 0000765880 peak:CurrentPeriodRecoveriesMember us-gaap:MortgageReceivablesMember 2025-09-30 0000765880 peak:CurrentPeriodNetWriteOffsMember us-gaap:MortgageReceivablesMember 2025-09-30 0000765880 us-gaap:PerformingFinancingReceivableMember peak:MezzanineLoansMember 2025-09-30 0000765880 peak:WatchListFinancingReceivableMember peak:MezzanineLoansMember 2025-09-30 0000765880 peak:WorkoutFinancingReceivableMember peak:MezzanineLoansMember 2025-09-30 0000765880 peak:MezzanineLoansMember 2025-09-30 0000765880 peak:CurrentPeriodGrossWriteOffsMember peak:MezzanineLoansMember 2025-09-30 0000765880 peak:CurrentPeriodRecoveriesMember peak:MezzanineLoansMember 2025-09-30 0000765880 peak:CurrentPeriodNetWriteOffsMember peak:MezzanineLoansMember 2025-09-30 0000765880 us-gaap:PerformingFinancingReceivableMember peak:CCRCResidentLoansMember 2025-09-30 0000765880 peak:WatchListFinancingReceivableMember peak:CCRCResidentLoansMember 2025-09-30 0000765880 peak:WorkoutFinancingReceivableMember peak:CCRCResidentLoansMember 2025-09-30 0000765880 peak:CCRCResidentLoansMember 2025-09-30 0000765880 peak:CurrentPeriodGrossWriteOffsMember peak:CCRCResidentLoansMember 2025-09-30 0000765880 peak:CurrentPeriodRecoveriesMember peak:CCRCResidentLoansMember 2025-09-30 0000765880 peak:CurrentPeriodNetWriteOffsMember peak:CCRCResidentLoansMember 2025-09-30 0000765880 peak:MezzanineLoansAndOtherMember 2024-12-31 0000765880 peak:SecuredMortgageLoansMember 2023-12-31 0000765880 peak:MezzanineLoansAndOtherMember 2023-12-31 0000765880 peak:SecuredMortgageLoansMember 2025-01-01 2025-09-30 0000765880 peak:MezzanineLoansAndOtherMember 2025-01-01 2025-09-30 0000765880 peak:SecuredMortgageLoansMember 2024-01-01 2024-12-31 0000765880 peak:MezzanineLoansAndOtherMember 2024-01-01 2024-12-31 0000765880 2024-01-01 2024-12-31 0000765880 peak:MezzanineLoansAndOtherMember 2025-09-30 0000765880 peak:SHOPJVMember peak:OtherNonReportingSegmentMember 2025-09-30 0000765880 peak:SHOPJVMember peak:OtherNonReportingSegmentMember 2024-12-31 0000765880 peak:SouthSanFranciscoJVsMember peak:LabBuildingsMember 2025-09-30 0000765880 peak:SouthSanFranciscoJVsMember peak:LabBuildingsMember 2024-12-31 0000765880 peak:CallanRidgeJVMember peak:LabBuildingsMember 2025-09-30 0000765880 peak:CallanRidgeJVMember peak:LabBuildingsMember 2024-12-31 0000765880 peak:HQPointInvestmentMember peak:OtherNonReportingSegmentMember 2025-09-30 0000765880 peak:HQPointInvestmentMember peak:OtherNonReportingSegmentMember 2024-12-31 0000765880 peak:LabJVMember peak:LabBuildingsMember 2025-09-30 0000765880 peak:LabJVMember peak:LabBuildingsMember 2024-12-31 0000765880 peak:PMAKJVMember peak:OutpatientMedicalBuildingsMember 2025-09-30 0000765880 peak:PMAKJVMember peak:OutpatientMedicalBuildingsMember 2024-12-31 0000765880 peak:NeedhamLandParcelJVMember peak:LabBuildingsMember 2025-09-30 0000765880 peak:NeedhamLandParcelJVMember peak:LabBuildingsMember 2024-12-31 0000765880 peak:MedicalOfficeJVsMember peak:OutpatientMedicalBuildingsMember 2025-09-30 0000765880 peak:MedicalOfficeJVsMember srt:MinimumMember peak:OutpatientMedicalBuildingsMember 2025-09-30 0000765880 peak:MedicalOfficeJVsMember srt:MaximumMember peak:OutpatientMedicalBuildingsMember 2025-09-30 0000765880 peak:MedicalOfficeJVsMember peak:OutpatientMedicalBuildingsMember 2024-12-31 0000765880 peak:DavisJVMember peak:OutpatientMedicalBuildingsMember 2025-09-30 0000765880 peak:DavisJVMember peak:OutpatientMedicalBuildingsMember 2024-12-31 0000765880 peak:MedicalOfficeJVsMember 2025-09-30 0000765880 peak:HCPVenturesIVLLCMember 2025-09-30 0000765880 peak:SuburbanPropertiesLLCMember 2025-09-30 0000765880 peak:SouthSanFranciscoJVsMember 2025-09-30 0000765880 peak:SouthSanFranciscoJVsMember 2025-01-01 2025-09-30 0000765880 peak:NeedhamLandParcelJVMember 2025-01-01 2025-09-30 0000765880 peak:MeasurementInputTerminalCapitalizationRateMember us-gaap:FairValueInputsLevel3Member 2025-09-30 0000765880 us-gaap:FairValueInputsLevel3Member srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2025-09-30 0000765880 us-gaap:FairValueInputsLevel3Member srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2025-09-30 0000765880 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member 2025-09-30 0000765880 peak:HQPointInvestmentMember 2025-02-28 0000765880 peak:HQPointInvestmentMember peak:LabBuildingsMember 2025-01-01 2025-09-30 0000765880 peak:CallanRidgeJointVentureMember peak:CallanRidgeJointVentureMember peak:LabBuildingsMember 2024-01-31 0000765880 peak:CallanRidgeJointVentureMember peak:LabBuildingsMember 2024-01-31 0000765880 peak:CallanRidgeJointVentureMember peak:CallanRidgeJointVentureMember peak:LabBuildingsMember 2024-01-01 2024-01-31 0000765880 peak:CallanRidgeJointVentureMember peak:CallanRidgeJointVentureMember 2024-01-31 0000765880 srt:OtherPropertyMember 2025-01-01 2025-09-30 0000765880 2024-03-01 2024-03-01 0000765880 peak:OutpatientMedicalMember 2025-09-30 0000765880 peak:OutpatientMedicalMember 2024-12-31 0000765880 peak:CCRCMember 2025-09-30 0000765880 peak:CCRCMember 2024-12-31 0000765880 peak:OtherNonReportingSegmentMember 2025-09-30 0000765880 peak:OtherNonReportingSegmentMember 2024-12-31 0000765880 peak:A2028TermLoanMember peak:SeniorUnsecuredTermLoanMember 2024-03-01 0000765880 us-gaap:DesignatedAsHedgingInstrumentMember peak:A2028TermLoanMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember peak:SeniorUnsecuredTermLoanMember 2024-03-01 0000765880 peak:A2028TermLoanMember peak:SeniorUnsecuredTermLoanMember 2025-09-30 0000765880 peak:VariableRateComponentOneMember peak:A2028TermLoanMember peak:SeniorUnsecuredTermLoanMember 2024-03-01 2024-03-01 0000765880 peak:VariableRateComponentOneMember peak:A2028TermLoanMember srt:MinimumMember peak:SeniorUnsecuredTermLoanMember 2024-03-01 2024-03-01 0000765880 peak:VariableRateComponentOneMember peak:A2028TermLoanMember srt:MaximumMember peak:SeniorUnsecuredTermLoanMember 2024-03-01 2024-03-01 0000765880 peak:VariableRateComponentOneMember peak:A2028TermLoanMember peak:SeniorUnsecuredTermLoanMember 2025-01-01 2025-09-30 0000765880 peak:SeniorUnsecuredTermLoanMember 2024-03-01 0000765880 peak:SeniorUnsecuredNotesDue2027Member 2024-03-01 0000765880 peak:SeniorUnsecuredNotesDue2028Member 2024-03-01 0000765880 peak:SeniorUnsecuredNotesDue2031Member 2024-03-01 0000765880 peak:MortgageDebtMember 2024-03-01 0000765880 peak:MortgageDebtMember peak:OutpatientMedicalBuildingsMember 2024-03-01 0000765880 peak:MortgageDebtMember 2024-03-01 2024-03-01 0000765880 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember peak:MortgageDebtMember us-gaap:CashFlowHedgingMember 2024-03-01 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-05-23 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-05-23 2019-05-23 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-09-30 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-09-01 2021-09-30 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-02-10 2023-02-10 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-12-31 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-12-01 2024-12-31 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2025-01-01 2025-09-30 0000765880 us-gaap:RevolvingCreditFacilityMember peak:VariableRateComponentOneMember us-gaap:LineOfCreditMember 2025-01-01 2025-09-30 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2025-09-30 0000765880 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2025-10-01 2025-10-24 0000765880 peak:TermLoanAgreementMember 2022-08-22 2022-08-22 0000765880 peak:A2027TermLoanFacilitiesMember peak:TermLoanAgreementMember us-gaap:LineOfCreditMember 2022-08-22 0000765880 peak:A2027TermLoanFacilitiesMember peak:TermLoanAgreementMember us-gaap:LineOfCreditMember 2022-08-22 2022-08-22 0000765880 peak:A2027TermLoanFacilitiesMember peak:TermLoanAgreementMember us-gaap:LineOfCreditMember 2022-10-31 0000765880 peak:A2027TermLoanFacilitiesOneMember peak:TermLoanAgreementMember us-gaap:LineOfCreditMember 2022-08-22 0000765880 peak:A2027TermLoanFacilitiesTwoMember peak:TermLoanAgreementMember us-gaap:LineOfCreditMember 2022-08-22 0000765880 peak:A2027TermLoanFacilitiesTwoMember peak:TermLoanAgreementMember us-gaap:LineOfCreditMember 2022-08-22 2022-08-22 0000765880 peak:A2027TermLoanFacilitiesMember peak:VariableRateComponentOneMember peak:TermLoanAgreementMember us-gaap:LineOfCreditMember 2025-01-01 2025-09-30 0000765880 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-08-31 0000765880 peak:TermLoanAgreementMember us-gaap:InterestRateSwapMember 2025-09-30 0000765880 peak:TermLoanAgreementMember 2024-02-29 0000765880 peak:TermLoanAgreementMember 2024-03-01 0000765880 peak:UnsecuredTermLoanMember 2024-03-01 0000765880 peak:UnsecuredTermLoanMember 2024-03-01 2024-03-01 0000765880 peak:UnsecuredTermLoanMember 2025-09-30 0000765880 peak:VariableRateComponentOneMember peak:A2029TermLoanMember peak:UnsecuredTermLoanMember 2025-01-01 2025-09-30 0000765880 peak:A2029TermLoanMember peak:UnsecuredTermLoanMember 2025-09-30 0000765880 peak:TermLoanAgreementMember 2024-12-31 0000765880 peak:TermLoanAgreementMember 2025-09-30 0000765880 peak:CommercialPaperProgramMember 2025-09-30 0000765880 peak:CommercialPaperProgramMember 2024-12-31 0000765880 peak:CommercialPaperProgramMember 2024-07-01 2024-09-30 0000765880 peak:CommercialPaperProgramMember 2025-07-01 2025-09-30 0000765880 peak:CommercialPaperProgramMember 2025-01-01 2025-09-30 0000765880 peak:CommercialPaperProgramMember 2024-01-01 2024-09-30 0000765880 us-gaap:CommercialPaperMember 2025-09-30 0000765880 peak:CommercialPaperProgramMember 2024-01-01 2024-12-31 0000765880 us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 us-gaap:UnsecuredDebtMember 2024-12-31 0000765880 peak:SeniorUnsecuredNotes5.38Member us-gaap:UnsecuredDebtMember 2025-02-14 0000765880 peak:SeniorUnsecuredNotes4.75Member us-gaap:UnsecuredDebtMember 2025-08-14 0000765880 peak:SeniorUnsecuredNotes5.38Member us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 peak:SeniorUnsecuredNotes4.75Member us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 peak:SeniorUnsecuredNotes3.40Member us-gaap:UnsecuredDebtMember 2025-02-03 0000765880 peak:SeniorUnsecuredNotes4.00Member us-gaap:UnsecuredDebtMember 2025-06-02 0000765880 peak:SeniorUnsecuredNotes3.40Member us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 peak:SeniorUnsecuredNotes4.00Member us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 us-gaap:UnsecuredDebtMember 2024-03-01 0000765880 us-gaap:SecuredDebtMember 2025-09-30 0000765880 us-gaap:SecuredDebtMember 2024-12-31 0000765880 us-gaap:SecuredDebtMember peak:OutpatientMedicalBuildingsMember 2025-09-30 0000765880 us-gaap:SecuredDebtMember peak:CCRCMember 2025-09-30 0000765880 us-gaap:SecuredDebtMember peak:OutpatientMedicalBuildingsMember 2024-12-31 0000765880 us-gaap:SecuredDebtMember peak:CCRCMember 2024-12-31 0000765880 us-gaap:SecuredDebtMember 2025-07-01 2025-09-30 0000765880 us-gaap:SecuredDebtMember 2024-07-01 2024-09-30 0000765880 us-gaap:SecuredDebtMember 2025-01-01 2025-09-30 0000765880 us-gaap:SecuredDebtMember 2024-01-01 2024-09-30 0000765880 us-gaap:SecuredDebtMember peak:OutpatientMedicalMember 2025-01-01 2025-09-30 0000765880 us-gaap:SecuredDebtMember peak:OutpatientMedicalMember 2025-09-30 0000765880 us-gaap:SecuredDebtMember peak:OutpatientMedicalBuildingsMember 2025-09-30 0000765880 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2022-04-30 0000765880 us-gaap:LineOfCreditMember 2025-09-30 0000765880 us-gaap:LoansPayableMember 2025-09-30 0000765880 peak:DebtInstrumentRedemptionRemainderOfFiscalYearMember us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 peak:DebtInstrumentRedemptionRemainderOfFiscalYearMember us-gaap:SecuredDebtMember 2025-09-30 0000765880 us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SecuredDebtMember 2025-09-30 0000765880 us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SecuredDebtMember 2025-09-30 0000765880 us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:SecuredDebtMember 2025-09-30 0000765880 us-gaap:DebtInstrumentRedemptionPeriodFourMember us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 us-gaap:DebtInstrumentRedemptionPeriodFourMember us-gaap:SecuredDebtMember 2025-09-30 0000765880 peak:DebtInstrumentRedemptionPeriodThereafterMember us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 peak:DebtInstrumentRedemptionPeriodThereafterMember us-gaap:SecuredDebtMember 2025-09-30 0000765880 srt:MinimumMember us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 srt:MaximumMember us-gaap:UnsecuredDebtMember 2025-09-30 0000765880 us-gaap:UnsecuredDebtMember 2025-01-01 2025-09-30 0000765880 srt:MinimumMember us-gaap:SecuredDebtMember 2025-09-30 0000765880 srt:MaximumMember us-gaap:SecuredDebtMember 2025-09-30 0000765880 us-gaap:LetterOfCreditMember 2025-01-01 2025-09-30 0000765880 us-gaap:LetterOfCreditMember 2025-09-30 0000765880 us-gaap:IndemnificationGuaranteeMember 2025-09-30 0000765880 us-gaap:SubsequentEventMember 2025-10-06 2025-10-06 0000765880 us-gaap:CommonStockMember 2024-03-01 2024-03-01 0000765880 peak:AtTheMarketProgramMember 2025-01-01 2025-09-30 0000765880 srt:MinimumMember peak:AtTheMarketProgramMember 2025-01-01 2025-09-30 0000765880 srt:MaximumMember peak:AtTheMarketProgramMember 2025-01-01 2025-09-30 0000765880 peak:A2023AtTheMarketProgramMember 2025-01-01 2025-09-30 0000765880 peak:AtTheMarketProgramMember 2024-07-01 2024-09-30 0000765880 peak:AtTheMarketProgramMember 2025-07-01 2025-09-30 0000765880 peak:AtTheMarketProgramMember 2024-01-01 2024-09-30 0000765880 us-gaap:CommonStockMember peak:ATMDirectIssuancesMember 2025-07-01 2025-09-30 0000765880 us-gaap:CommonStockMember peak:ATMDirectIssuancesMember 2024-07-01 2024-09-30 0000765880 us-gaap:CommonStockMember peak:ATMDirectIssuancesMember 2024-01-01 2024-09-30 0000765880 us-gaap:CommonStockMember peak:ATMDirectIssuancesMember 2025-01-01 2025-09-30 0000765880 peak:A2022ShareRepurchaseProgramMember 2022-08-01 0000765880 peak:A2022ShareRepurchaseProgramMember 2024-07-01 2024-09-30 0000765880 peak:A2022ShareRepurchaseProgramMember 2024-01-01 2024-09-30 0000765880 peak:A2024ShareRepurchaseProgramMember 2024-07-24 0000765880 peak:A2024ShareRepurchaseProgramMember 2025-07-01 2025-09-30 0000765880 peak:A2024ShareRepurchaseProgramMember 2025-01-01 2025-09-30 0000765880 peak:A2024ShareRepurchaseProgramMember 2025-09-30 0000765880 peak:OutpatientMedicalMember 2025-01-01 2025-09-30 0000765880 2024-04-30 0000765880 peak:HealthpeakOPMember us-gaap:NoncontrollingInterestMember 2024-01-01 2024-09-30 0000765880 peak:HealthpeakOPMember us-gaap:NoncontrollingInterestMember 2025-01-01 2025-09-30 0000765880 peak:DownREITMember 2025-09-30 0000765880 peak:DownREITMember 2024-12-31 0000765880 peak:DownREITMember 2025-07-01 2025-09-30 0000765880 peak:DownREITMember 2025-01-01 2025-09-30 0000765880 peak:DownREITMember 2024-01-01 2024-09-30 0000765880 peak:DownREITMember 2024-07-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:OutpatientMedicalBuildingsMember 2025-07-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:LabBuildingsMember 2025-07-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:CCRCMember 2025-07-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember 2025-07-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:OutpatientMedicalMember 2025-07-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:LabMember 2025-07-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:OutpatientMedicalBuildingsMember 2024-07-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:LabBuildingsMember 2024-07-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:CCRCMember 2024-07-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember 2024-07-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:OutpatientMedicalMember 2024-07-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:LabMember 2024-07-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:OutpatientMedicalBuildingsMember 2025-01-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:LabBuildingsMember 2025-01-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:CCRCMember 2025-01-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember 2025-01-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:OutpatientMedicalMember 2025-01-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:LabMember 2025-01-01 2025-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:OutpatientMedicalBuildingsMember 2024-01-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:LabBuildingsMember 2024-01-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:CCRCMember 2024-01-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember 2024-01-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:OutpatientMedicalMember 2024-01-01 2024-09-30 0000765880 us-gaap:OperatingSegmentsMember peak:LabMember 2024-01-01 2024-09-30 0000765880 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2025-09-30 0000765880 peak:OtherEquityMember 2025-09-30 0000765880 peak:OtherEquityMember 2024-12-31 0000765880 peak:NeedhamLandParcelJVMember peak:LabBuildingsMember 2021-12-31 0000765880 peak:NeedhamLandParcelJVMember peak:LabBuildingsMember 2021-12-01 2021-12-31 0000765880 peak:VariableInterestEntityNotPrimaryBeneficiaryEquityInvestmentMember 2025-09-30 0000765880 peak:VariableInterestEntityNotPrimaryBeneficiaryInvestmentInJointVentureMember 2025-09-30 0000765880 peak:VariableInterestEntityNotPrimaryBeneficiaryLoansReceivableInvestmentsMember 2025-09-30 0000765880 peak:VenturesVLLCMember 2025-01-01 2025-09-30 0000765880 peak:MorganStanleyRealEstateInvestmentJVMember 2025-01-01 2025-09-30 0000765880 peak:DownreitPartnershipsMember 2024-12-31 0000765880 peak:DownreitPartnershipsMember 2025-09-30 0000765880 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-09-30 0000765880 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-12-31 0000765880 us-gaap:DiscontinuedOperationsHeldforsaleMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-09-30 0000765880 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-09-30 0000765880 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2025-09-30 0000765880 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-12-31 0000765880 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000765880 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-09-30 0000765880 us-gaap:InterestRateSwapMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2025-09-30 0000765880 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-12-31 0000765880 us-gaap:InterestRateSwapMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000765880 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member 2025-09-30 0000765880 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000765880 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember peak:MortgageDebtMember 2022-04-30 0000765880 us-gaap:InterestRateSwapMember us-gaap:SecuredOvernightFinancingRateSofrMember 2023-02-28 0000765880 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2022-08-31 0000765880 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-31 0000765880 peak:InterestRateSwap499PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap499PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-31 0000765880 peak:InterestRateSwap454PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap454PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-31 0000765880 peak:InterestRateSwap260PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap260PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-31 0000765880 peak:InterestRateSwap254PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap254PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-31 0000765880 peak:InterestRateSwap3.59PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap3.59PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-31 0000765880 peak:InterestRateSwap3.59PayRateOneMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap3.59PayRateOneMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-31 0000765880 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-09-30 0000765880 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000765880 peak:InterestRateSwap3.59PayRateTwoMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap3.59PayRateTwoMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-31 0000765880 peak:InterestRateSwap3.59PayRateThreeMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap3.59PayRateThreeMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-31 0000765880 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-01 0000765880 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-07-01 2025-09-30 0000765880 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-07-01 2024-09-30 0000765880 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-01-01 2025-09-30 0000765880 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-09-30 0000765880 peak:TwoInterestRateSwapInstrumentsMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:OneInterestRateSwapInstrumentMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap3.56PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap3.57PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap3.58PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap3.60PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30 0000765880 peak:InterestRateSwap3.61PayRateMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-09-30
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025
or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission file number 001-08895

Healthpeak Properties, Inc.
(Exact name of registrant as specified in its charter)

Maryland |  | 33-0091377
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

4600 South Syracuse Street, Suite 500
Denver, CO 80237
(Address of principal executive offices) (Zip Code)
(720) 428-5050
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $1.00 par value | DOC | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ | Accelerated filer | ☐
Non-accelerated filer | ☐ | Smaller reporting company | ☐
|  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of October 22, 2025, there were 694,949,823 shares of the registrant’s $1.00 par value common stock outstanding.

Table of Contents
HEALTHPEAK PROPERTIES, INC.
INDEX

PART I. FINANCIAL INFORMATION
Item 1. | Financial Statements (Unaudited): | 3
| Consolidated Balance Sheets | 3
| Consolidated Statements of Operations | 4
| Consolidated Statements of Comprehensive Income (Loss) | 5
| Consolidated Statements of Equity and Redeemable Noncontrolling Interests | 6
| Consolidated Statements of Cash Flows | 8
| Notes to the Consolidated Financial Statements | 9
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 44
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 70
Item 4. | Controls and Procedures | 71
PART II. OTHER INFORMATION
Item 1A. | Risk Factors | 72
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 72
Item 5. | Other Information | 72
Item 6. | Exhibits | 73
Signatures | 75

2

Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Healthpeak Properties, Inc.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
(Unaudited)

| September 30, 2025 |  | December 31, 2024
ASSETS |  |  |
Real estate: |  |  |
Buildings and improvements | $ | 16,192,972 |  |  | $ | 16,115,283 |
Development costs and construction in progress | 1,148,903 |  |  | 880,393 |
Land and improvements | 2,927,571 |  |  | 2,918,758 |
Accumulated depreciation and amortization | (4,438,273) |  |  | (4,083,030) |
Net real estate | 15,831,173 |  |  | 15,831,404 |
Loans receivable, net of reserves of $11,602 and $10,499 | 673,502 |  |  | 717,190 |
Investments in and advances to unconsolidated joint ventures | 796,171 |  |  | 936,814 |
Accounts receivable, net of allowance of $1,933 and $2,243 | 80,845 |  |  | 76,810 |
Cash and cash equivalents | 91,038 |  |  | 119,818 |
Restricted cash | 68,694 |  |  | 64,487 |
Intangible assets, net | 610,513 |  |  | 817,254 |
Assets held for sale, net | 67,593 |  |  | 7,840 |
Right-of-use asset, net | 417,365 |  |  | 424,173 |
Other assets, net | 945,507 |  |  | 942,465 |
Total assets | $ | 19,582,401 |  |  | $ | 19,938,255 |
LIABILITIES AND EQUITY |  |  |
Bank line of credit and commercial paper | $ | 368,125 |  |  | $ | 150,000 |
Term loans | 1,646,912 |  |  | 1,646,043 |
Senior unsecured notes | 6,766,350 |  |  | 6,563,256 |
Mortgage debt | 350,174 |  |  | 356,750 |
Intangible liabilities, net | 155,557 |  |  | 191,884 |
Liabilities related to assets held for sale, net | 12,371 |  |  | — |
Lease liability | 301,302 |  |  | 307,220 |
Accounts payable, accrued liabilities, and other liabilities | 746,229 |  |  | 725,342 |
Deferred revenue | 970,077 |  |  | 940,136 |
Total liabilities | 11,317,097 |  |  | 10,880,631 |
Commitments and contingencies (Note 11) |  |  |
Redeemable noncontrolling interests | 27,809 |  |  | 2,610 |
Common stock, $1.00 par value: 1,500,000,000 shares authorized; 694,946,444 and 699,485,139 shares issued and outstanding | 694,946 |  |  | 699,485 |
Additional paid-in capital | 12,765,070 |  |  | 12,847,252 |
Cumulative dividends in excess of earnings | (5,854,766) |  |  | (5,174,279) |
Accumulated other comprehensive income (loss) | (7,975) |  |  | 28,818 |
Total stockholders’ equity | 7,597,275 |  |  | 8,401,276 |
Joint venture partners | 296,477 |  |  | 315,821 |
Non-managing member unitholders | 343,743 |  |  | 337,917 |
Total noncontrolling interests | 640,220 |  |  | 653,738 |
Total equity | 8,237,495 |  |  | 9,055,014 |
Total liabilities and equity | $ | 19,582,401 |  |  | $ | 19,938,255 |

See accompanying Notes to the Unaudited Consolidated Financial Statements.
3

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Revenues: |  |  |  |  |  |  |
Rental and related revenues | $ | 539,886 |  |  | $ | 543,251 |  |  | $ | 1,607,714 |  |  | $ | 1,552,065 |
Resident fees and services | 150,458 |  |  | 142,845 |  |  | 448,240 |  |  | 422,512 |
Interest income and other | 15,529 |  |  | 14,301 |  |  | 47,156 |  |  | 27,884 |
Total revenues | 705,873 |  |  | 700,397 |  |  | 2,103,110 |  |  | 2,002,461 |
Costs and expenses: |  |  |  |  |  |  |
Interest expense | 76,784 |  |  | 74,105 |  |  | 224,540 |  |  | 209,922 |
Depreciation and amortization | 262,317 |  |  | 280,019 |  |  | 796,779 |  |  | 782,736 |
Operating | 291,922 |  |  | 280,279 |  |  | 841,246 |  |  | 797,835 |
General and administrative | 19,907 |  |  | 23,216 |  |  | 66,789 |  |  | 73,233 |
Transaction and merger-related costs | 2,420 |  |  | 7,134 |  |  | 18,169 |  |  | 122,113 |
Impairments and loan loss reserves (recoveries), net | (54) |  |  | 441 |  |  | (117) |  |  | 11,346 |
Total costs and expenses | 653,296 |  |  | 665,194 |  |  | 1,947,406 |  |  | 1,997,185 |
Other income (expense): |  |  |  |  |  |  |
Gain (loss) on sales of real estate, net | 11,500 |  |  | 62,325 |  |  | 13,136 |  |  | 187,624 |
Other income (expense), net | 1,160 |  |  | 982 |  |  | (9,658) |  |  | 83,502 |
Total other income (expense), net | 12,660 |  |  | 63,307 |  |  | 3,478 |  |  | 271,126 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures | 65,237 |  |  | 98,510 |  |  | 159,182 |  |  | 276,402 |
Income tax benefit (expense) | 1,206 |  |  | (1,938) |  |  | (3,256) |  |  | (18,364) |
Equity income (loss) from unconsolidated joint ventures | (176,291) |  |  | (3,834) |  |  | (176,691) |  |  | (1,407) |
Net income (loss) | (109,848) |  |  | 92,738 |  |  | (20,765) |  |  | 256,631 |
Noncontrolling interests’ share in earnings | (7,274) |  |  | (6,866) |  |  | (21,856) |  |  | (18,036) |
Net income (loss) attributable to Healthpeak Properties, Inc. | (117,122) |  |  | 85,872 |  |  | (42,621) |  |  | 238,595 |
Participating securities’ share in earnings | (134) |  |  | (197) |  |  | (714) |  |  | (610) |
Net income (loss) applicable to common shares | $ | (117,256) |  |  | $ | 85,675 |  |  | $ | (43,335) |  |  | $ | 237,985 |
Earnings (loss) per common share: |  |  |  |  |  |  |
Basic | $ | (0.17) |  |  | $ | 0.12 |  |  | $ | (0.06) |  |  | $ | 0.36 |
Diluted | $ | (0.17) |  |  | $ | 0.12 |  |  | $ | (0.06) |  |  | $ | 0.36 |
Weighted average shares outstanding: |  |  |  |  |  |  |
Basic | 694,930 |  |  | 699,349 |  |  | 696,380 |  |  | 667,536 |
Diluted | 694,930 |  |  | 700,146 |  |  | 696,380 |  |  | 668,096 |

See accompanying Notes to the Unaudited Consolidated Financial Statements.
4

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)
(Unaudited)

| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Net income (loss) | $ | (109,848) |  |  | $ | 92,738 |  |  | $ | (20,765) |  |  | $ | 256,631 |
Other comprehensive income (loss): |  |  |  |  |  |  |
Net unrealized gains (losses) on derivatives | (3,027) |  |  | (54,742) |  |  | (37,005) |  |  | (31,944) |
Change in Supplemental Executive Retirement Plan obligation and other | 71 |  |  | 64 |  |  | 212 |  |  | 192 |
Total other comprehensive income (loss) | (2,956) |  |  | (54,678) |  |  | (36,793) |  |  | (31,752) |
Total comprehensive income (loss) | (112,804) |  |  | 38,060 |  |  | (57,558) |  |  | 224,879 |
Total comprehensive (income) loss attributable to noncontrolling interests | (7,274) |  |  | (6,866) |  |  | (21,856) |  |  | (18,036) |
Total comprehensive income (loss) attributable to Healthpeak Properties, Inc. | $ | (120,078) |  |  | $ | 31,194 |  |  | $ | (79,414) |  |  | $ | 206,843 |

See accompanying Notes to the Unaudited Consolidated Financial Statements.
5

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS
(In thousands, except per share data)
(Unaudited)
For the three months ended September 30, 2025:

| Common Stock |  | Additional Paid-In Capital |  | Cumulative Dividends In Excess Of Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Total Stockholders’ Equity |  | Total Noncontrolling Interests |  | Total Equity |  | Redeemable Noncontrolling Interests
| Shares |  | Amount |  |  |  |  |  |  |
July 1, 2025 | 694,916 |  |  | $ | 694,916 |  |  | $ | 12,763,723 |  |  | $ | (5,525,520) |  |  | $ | (5,019) |  |  | $ | 7,928,100 |  |  | $ | 638,737 |  |  | $ | 8,566,837 |  |  | $ | 20,104 |
Net income (loss) | — |  |  | — |  |  | — |  |  | (117,122) |  |  | — |  |  | (117,122) |  |  | 7,381 |  |  | (109,741) |  |  | (107) |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | (2,956) |  |  | (2,956) |  |  | — |  |  | (2,956) |  |  | — |
Issuance of common stock, net | 24 |  |  | 24 |  |  | 359 |  |  | — |  |  | — |  |  | 383 |  |  | — |  |  | 383 |  |  | — |
Conversion of non-managing member units to common stock | 7 |  |  | 7 |  |  | 191 |  |  | — |  |  | — |  |  | 198 |  |  | (198) |  |  | — |  |  | — |
Repurchase of common stock | (1) |  |  | (1) |  |  | (16) |  |  | — |  |  | — |  |  | (17) |  |  | — |  |  | (17) |  |  | — |
Stock-based compensation | — |  |  | — |  |  | 1,636 |  |  | — |  |  | — |  |  | 1,636 |  |  | 3,800 |  |  | 5,436 |  |  | — |
Common dividends ($0.305 per share) | — |  |  | — |  |  | — |  |  | (212,124) |  |  | — |  |  | (212,124) |  |  | — |  |  | (212,124) |  |  | — |
Distributions to noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (9,500) |  |  | (9,500) |  |  | (165) |
Contributions from noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 7,154 |
Adjustments to redeemable noncontrolling interests | — |  |  | — |  |  | (823) |  |  | — |  |  | — |  |  | (823) |  |  | — |  |  | (823) |  |  | 823 |
September 30, 2025 | 694,946 |  |  | $ | 694,946 |  |  | $ | 12,765,070 |  |  | $ | (5,854,766) |  |  | $ | (7,975) |  |  | $ | 7,597,275 |  |  | $ | 640,220 |  |  | $ | 8,237,495 |  |  | $ | 27,809 |

For the three months ended September 30, 2024:

| Common Stock |  | Additional Paid-In Capital |  | Cumulative Dividends In Excess Of Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Total Stockholders’ Equity |  | Total Noncontrolling Interests |  | Total Equity |  | Redeemable Noncontrolling Interests
| Shares |  | Amount |  |  |  |  |  |  |
July 1, 2024 | 700,317 |  |  | $ | 700,317 |  |  | $ | 12,859,567 |  |  | $ | (4,844,683) |  |  | $ | 42,297 |  |  | $ | 8,757,498 |  |  | $ | 659,840 |  |  | $ | 9,417,338 |  |  | $ | 1,433 |
Net income (loss) | — |  |  | — |  |  | — |  |  | 85,872 |  |  | — |  |  | 85,872 |  |  | 6,916 |  |  | 92,788 |  |  | (50) |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | (54,678) |  |  | (54,678) |  |  | — |  |  | (54,678) |  |  | — |
Issuance of common stock, net | 12 |  |  | 12 |  |  | 243 |  |  | — |  |  | — |  |  | 255 |  |  | — |  |  | 255 |  |  | — |
Conversion of non-managing member units to common stock | 112 |  |  | 112 |  |  | 1,874 |  |  | — |  |  | — |  |  | 1,986 |  |  | (1,986) |  |  | — |  |  | — |
Repurchase of common stock | (1,036) |  |  | (1,036) |  |  | (19,099) |  |  | — |  |  | — |  |  | (20,135) |  |  | — |  |  | (20,135) |  |  | — |
Stock-based compensation | — |  |  | — |  |  | 2,049 |  |  | — |  |  | — |  |  | 2,049 |  |  | 2,728 |  |  | 4,777 |  |  | — |
Common dividends ($0.300 per share) | — |  |  | — |  |  | — |  |  | (210,008) |  |  | — |  |  | (210,008) |  |  | — |  |  | (210,008) |  |  | — |
Distributions to noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (9,652) |  |  | (9,652) |  |  | (65) |
September 30, 2024 | 699,405 |  |  | $ | 699,405 |  |  | $ | 12,844,634 |  |  | $ | (4,968,819) |  |  | $ | (12,381) |  |  | $ | 8,562,839 |  |  | $ | 657,846 |  |  | $ | 9,220,685 |  |  | $ | 1,318 |

6

Table of Contents
For the nine months ended September 30, 2025:

| Common Stock |  | Additional Paid-In Capital |  | Cumulative Dividends In Excess Of Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Total Stockholders’ Equity |  | Total Noncontrolling Interests |  | Total Equity |  | Redeemable Noncontrolling Interests
| Shares |  | Amount |  |  |  |  |  |  |
January 1, 2025 | 699,485 |  |  | $ | 699,485 |  |  | $ | 12,847,252 |  |  | $ | (5,174,279) |  |  | $ | 28,818 |  |  | $ | 8,401,276 |  |  | $ | 653,738 |  |  | $ | 9,055,014 |  |  | $ | 2,610 |
Net income (loss) | — |  |  | — |  |  | — |  |  | (42,621) |  |  | — |  |  | (42,621) |  |  | 22,145 |  |  | (20,476) |  |  | (289) |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | (36,793) |  |  | (36,793) |  |  | — |  |  | (36,793) |  |  | — |
Issuance of common stock, net | 521 |  |  | 521 |  |  | 415 |  |  | — |  |  | — |  |  | 936 |  |  | — |  |  | 936 |  |  | — |
Conversion of non-managing member units to common stock | 171 |  |  | 171 |  |  | 3,967 |  |  | — |  |  | — |  |  | 4,138 |  |  | (4,138) |  |  | — |  |  | — |
Repurchase of common stock | (5,231) |  |  | (5,231) |  |  | (91,827) |  |  | — |  |  | — |  |  | (97,058) |  |  | — |  |  | (97,058) |  |  | — |
Stock-based compensation | — |  |  | — |  |  | 4,958 |  |  | — |  |  | — |  |  | 4,958 |  |  | 9,964 |  |  | 14,922 |  |  | — |
Common dividends ($0.915 per share) | — |  |  | — |  |  | — |  |  | (637,866) |  |  | — |  |  | (637,866) |  |  | — |  |  | (637,866) |  |  | — |
Distributions to noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (28,484) |  |  | (28,484) |  |  | (336) |
Contributions from noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 13,124 |
Adjustments to redeemable noncontrolling interests | — |  |  | — |  |  | 305 |  |  | — |  |  | — |  |  | 305 |  |  | (13,005) |  |  | (12,700) |  |  | 12,700 |
September 30, 2025 | 694,946 |  |  | $ | 694,946 |  |  | $ | 12,765,070 |  |  | $ | (5,854,766) |  |  | $ | (7,975) |  |  | $ | 7,597,275 |  |  | $ | 640,220 |  |  | $ | 8,237,495 |  |  | $ | 27,809 |

For the nine months ended September 30, 2024:

| Common Stock |  | Additional Paid-In Capital |  | Cumulative Dividends In Excess Of Earnings |  | Accumulated Other Comprehensive Income (Loss) |  | Total Stockholders’ Equity |  | Total Noncontrolling Interests |  | Total Equity |  | Redeemable Noncontrolling Interests
| Shares |  | Amount |  |  |  |  |  |  |
January 1, 2024 | 547,156 |  |  | $ | 547,156 |  |  | $ | 10,405,780 |  |  | $ | (4,621,861) |  |  | $ | 19,371 |  |  | $ | 6,350,446 |  |  | $ | 525,596 |  |  | $ | 6,876,042 |  |  | $ | 48,828 |
Net income (loss) | — |  |  | — |  |  | — |  |  | 238,595 |  |  | — |  |  | 238,595 |  |  | 17,943 |  |  | 256,538 |  |  | 93 |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | (31,752) |  |  | (31,752) |  |  | — |  |  | (31,752) |  |  | — |
Shares issued as part of the Merger | 162,231 |  |  | 162,231 |  |  | 2,611,916 |  |  | — |  |  | — |  |  | 2,774,147 |  |  | — |  |  | 2,774,147 |  |  | — |
Issuance of common stock, net | 387 |  |  | 387 |  |  | 444 |  |  | — |  |  | — |  |  | 831 |  |  | — |  |  | 831 |  |  | — |
Conversion of non-managing member units to common stock | 208 |  |  | 208 |  |  | 4,150 |  |  | — |  |  | — |  |  | 4,358 |  |  | (4,358) |  |  | — |  |  | — |
Repurchase of common stock | (10,577) |  |  | (10,577) |  |  | (179,787) |  |  | — |  |  | — |  |  | (190,364) |  |  | — |  |  | (190,364) |  |  | — |
Stock-based compensation | — |  |  | — |  |  | 6,243 |  |  | — |  |  | — |  |  | 6,243 |  |  | 9,043 |  |  | 15,286 |  |  | — |
Common dividends ($0.900 per share) | — |  |  | — |  |  | — |  |  | (585,553) |  |  | — |  |  | (585,553) |  |  | — |  |  | (585,553) |  |  | — |
Distributions to noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (27,105) |  |  | (27,105) |  |  | (377) |
Contributions from noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 12 |
Purchase of noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (52,886) |
Noncontrolling interests acquired as part of the Merger | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 136,727 |  |  | 136,727 |  |  | 1,536 |
Adjustments to redeemable noncontrolling interests | — |  |  | — |  |  | (4,112) |  |  | — |  |  | — |  |  | (4,112) |  |  | — |  |  | (4,112) |  |  | 4,112 |
September 30, 2024 | 699,405 |  |  | $ | 699,405 |  |  | $ | 12,844,634 |  |  | $ | (4,968,819) |  |  | $ | (12,381) |  |  | $ | 8,562,839 |  |  | $ | 657,846 |  |  | $ | 9,220,685 |  |  | $ | 1,318 |

See accompanying Notes to the Unaudited Consolidated Financial Statements.
7

Table of Contents
Healthpeak Properties, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

| Nine Months Ended September 30,
| 2025 |  | 2024
Cash flows from operating activities: |  |  |
Net income (loss) | $ | (20,765) |  |  | $ | 256,631 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |  |  |
Depreciation and amortization of real estate, in-place lease, and other intangibles | 796,779 |  |  | 782,736 |
Stock-based compensation amortization expense | 10,410 |  |  | 11,935 |
Merger-related post-combination stock compensation expense | — |  |  | 16,223 |
Amortization of deferred financing costs and debt discounts (premiums) | 23,708 |  |  | 19,247 |
Straight-line rents | (30,836) |  |  | (32,891) |
Amortization of non-refundable entrance fees and above (below) market lease intangibles | (100,215) |  |  | (88,925) |
Equity loss (income) from unconsolidated joint ventures | 176,691 |  |  | 1,407 |
Distributions of earnings from unconsolidated joint ventures | 16,861 |  |  | 11,228 |
Deferred income tax expense (benefit) | (131) |  |  | 11,156 |
Impairments and loan loss reserves (recoveries), net | (117) |  |  | 11,346 |
Loss (gain) on sales of real estate, net | (13,136) |  |  | (187,624) |
Loss (gain) upon change of control, net | — |  |  | (77,548) |
Casualty-related loss (recoveries), net | 9,825 |  |  | (574) |
Other non-cash items | (7,826) |  |  | (1,652) |
Changes in: |  |  |
Decrease (increase) in accounts receivable and other assets, net | 9,756 |  |  | 2,071 |
Increase (decrease) in accounts payable, accrued liabilities, and deferred revenue | 86,871 |  |  | 52,200 |
Net cash provided by (used in) operating activities | 957,875 |  |  | 786,966 |
Cash flows from investing activities: |  |  |
Acquisitions of real estate | (43,880) |  |  | (4,466) |
Development, redevelopment, and other major improvements of real estate | (547,087) |  |  | (399,373) |
Leasing costs, tenant improvements, and recurring capital expenditures | (76,125) |  |  | (76,744) |
Proceeds from sales of real estate, net | 30,839 |  |  | 619,981 |
Proceeds from the Callan Ridge JV transaction, net | — |  |  | 125,662 |
Investments in unconsolidated joint ventures | (76,329) |  |  | (54,450) |
Distributions in excess of earnings from unconsolidated joint ventures | 22,745 |  |  | 20,195 |
Proceeds from insurance recovery | 12,214 |  |  | 6,467 |
Proceeds from sales/principal repayments on loans receivable and other | 125,927 |  |  | 87,259 |
Investments in loans receivable and other | (77,357) |  |  | (25,341) |
Cash paid in connection with the Merger, net | — |  |  | (179,215) |
Net cash provided by (used in) investing activities | (629,053) |  |  | 119,975 |
Cash flows from financing activities: |  |  |
Borrowings under bank line of credit and commercial paper | 9,435,650 |  |  | 3,146,250 |
Repayments under bank line of credit and commercial paper | (9,217,525) |  |  | (3,866,250) |
Issuances and borrowings of term loans, senior unsecured notes, and mortgage debt | 987,260 |  |  | 750,000 |
Repayments and repurchases of term loans, senior unsecured notes, and mortgage debt | (806,492) |  |  | (3,038) |
Payments for deferred financing costs | (2,604) |  |  | (5,438) |
Issuance of common stock and exercise of options, net of offering costs | 304 |  |  | 241 |
Repurchase of common stock | (97,058) |  |  | (190,364) |
Dividends paid on common stock | (637,234) |  |  | (584,964) |
Distributions to and purchase of noncontrolling interests | (28,820) |  |  | (80,368) |
Contributions from and issuance of noncontrolling interests | 13,124 |  |  | 12 |
Net cash provided by (used in) financing activities | (353,395) |  |  | (833,919) |
Net increase (decrease) in cash, cash equivalents, and restricted cash | (24,573) |  |  | 73,022 |
Cash, cash equivalents, and restricted cash, beginning of period | 184,305 |  |  | 169,023 |
Cash, cash equivalents, and restricted cash, end of period | $ | 159,732 |  |  | $ | 242,045 |

See accompanying Notes to the Unaudited Consolidated Financial Statements.
8

Table of Contents
Healthpeak Properties, Inc.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1. Business

Overview
Healthpeak Properties, Inc., a Standard & Poor’s 500 company, is a Maryland corporation that is organized to qualify as a real estate investment trust (“REIT”) and that, together with its consolidated entities (collectively, “Healthpeak” or the “Company”), owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States (“U.S.”). Healthpeak® has a diverse portfolio comprised of investments in the following reportable healthcare segments: (i) outpatient medical; (ii) lab; and (iii) continuing care retirement community (“CCRC”).
The Company’s corporate headquarters are in Denver, Colorado, and it has additional corporate offices in California, Tennessee, Wisconsin, and Massachusetts, and property management offices in several locations throughout the U.S.
The Company is organized as an umbrella partnership REIT (“UPREIT”). Substantially all of the Company’s business is conducted through Healthpeak OP, LLC (“Healthpeak OP”). The Company is the managing member of Healthpeak OP and does not have material assets or liabilities, other than through its investment in Healthpeak OP.
On March 1, 2024, the Company completed its planned merger with Physicians Realty Trust (see Note 3).
NOTE 2. Summary of Significant Accounting Policies

Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management’s estimates.
The consolidated financial statements include the accounts of Healthpeak Properties, Inc., its wholly owned subsidiaries, joint ventures (“JVs”) that it controls, and variable interest entities (“VIEs”) in which the Company has determined it is the primary beneficiary. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations, and cash flows have been included. Operating results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”).
9

Table of Contents
Recent Accounting Pronouncements
Adopted
Segment Reporting. In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), to improve reportable segment disclosure requirements so that investors can better understand an entity’s overall performance and assess potential future cash flows. The amendments in ASU 2023-07 include, but are not limited to: (i) disclosure of, on an annual basis, significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss; (ii) disclosure of, on an annual and interim basis, an amount for other segment items by reportable segment and a description of its composition (the other segment items category is the difference between segment revenue less the significant expenses disclosed and each reported measure of segment profit or loss); (iii) disclosure of, on an interim basis, all currently required annual disclosures about a reportable segment’s profit (loss) and assets; (iv) clarification that if the CODM uses more than one measure of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources, an entity may report one or more of those additional measures of segment profit; and (v) disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. During the year ended December 31, 2024, the amendments in ASU 2023-07 were adopted retrospectively and did not have an impact on the Company’s consolidated financial position, results of operations, or cash flows.
Not Yet Adopted
Income Taxes. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), to provide disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. One of the amendments in ASU 2023-09 includes disclosure of, on an annual basis, a tabular rate reconciliation (using both percentages and reporting currency amounts) of (i) the reported income tax expense (or benefit) from continuing operations, to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires disclosure of, on an annual basis, the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company expects ASU 2023-09 to require additional disclosures in the Notes to the Consolidated Financial Statements. The Company does not expect the amendments to have a material impact to its consolidated financial position, results of operations, or cash flows.
Expense Disaggregation. In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), to address requests from investors for more detailed information about the types of expenses in commonly presented expense captions. ASU 2024-03 requires public companies to provide disaggregated disclosure in tabular format in the notes to financial statements of specific expenses, including but not limited to: (i) employee compensation, (ii) depreciation, and (iii) intangible asset amortization. In January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarifies that the amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is evaluating the impact these ASUs will have on its disclosures.
10

Table of Contents
NOTE 3. The Merger

On March 1, 2024 (the “Closing Date”), pursuant to the Agreement and Plan of Merger dated October 29, 2023 (the “Merger Agreement”), by and among the Company, DOC DR Holdco, LLC, a wholly owned subsidiary of the Company (“DOC DR Holdco”), DOC DR, LLC, a wholly owned subsidiary of Healthpeak OP (“DOC DR OP Sub”), Physicians Realty Trust, and Physicians Realty L.P. (the “Physicians Partnership”): (i) Physicians Realty Trust merged with and into DOC DR Holdco (the “Company Merger”), with DOC DR Holdco surviving as a wholly owned subsidiary of the Company (the “Company Surviving Entity”); (ii) immediately following the effectiveness of the Company Merger, the Company contributed all of the outstanding equity interests in the Company Surviving Entity to Healthpeak OP (the “Contribution”); and (iii) immediately following the Contribution, Physicians Partnership merged with and into DOC DR OP Sub (the “Partnership Merger” and, together with the Company Merger, the “Merger”), with DOC DR OP Sub surviving as a subsidiary of Healthpeak OP (the “Partnership Surviving Entity”). Subsequent to the Closing Date, the “Combined Company” means the Company and its subsidiaries.
On the Closing Date and in connection with the Merger, (i) each outstanding common share of beneficial interest of Physicians Realty Trust (“Physicians Realty Trust common shares”) (other than Physicians Realty Trust common shares that were canceled in accordance with the Merger Agreement) was automatically converted into the right to receive 0.674 (the “Exchange Ratio”) shares of the Company’s common stock, and (ii) each outstanding common unit of the Physicians Partnership was converted into common units in the Partnership Surviving Entity equal to the Exchange Ratio.
As a result of the Merger, the Company acquired 299 outpatient medical buildings. The primary reason for the Merger was to expand the Company’s size, scale, and diversification, in order to further enhance the Company’s competitive advantages and accelerate investment activities.
The Merger was accounted for using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”), which requires, among other things, the assets acquired and the liabilities assumed to be recognized at their acquisition date fair value. For accounting purposes, the Company was treated as the accounting acquirer of Physicians Realty Trust. The Company was considered to be the accounting acquirer primarily because: (i) the Company is the entity that transferred consideration to consummate the Merger; (ii) the Company’s stockholders as a group retained the largest portion of the voting rights of the Combined Company and have the ability to elect, appoint, or remove a majority of the members of the Combined Company’s board of directors; and (iii) its senior management constitutes the majority of management of the Combined Company.
11

Table of Contents
The consideration transferred on the Closing Date was as follows (in thousands, except per share data):

|  | March 1, 2024
Physicians Realty Trust common shares and Physicians Realty Trust restricted shares, PSUs, and RSUs exchanged(1) |  | 240,699
Exchange Ratio |  | 0.674
Shares of Healthpeak common stock issued |  | 162,231
Closing price of Healthpeak common stock on March 1, 2024(2) |  | $ | 17.10 |
Fair value of Healthpeak common stock issued to the former holders of Physicians Realty Trust common shares, restricted shares, PSUs, and RSUs |  | $ | 2,774,147 |
Less: Fair value of share consideration attributable to the post-combination period(3) |  | (16,223) |
Physicians Realty Trust revolving credit facility termination(4) |  | $ | 175,411 |
Settlement of Physicians Realty Trust’s transaction costs |  | 23,913 |
Payments made in connection with share settlement(5) |  | 11,315 |
Cash consideration |  | $ | 210,639 |
Consideration transferred |  | $ | 2,968,563 |

_______________________________________
(1)Includes 241 million Physicians Realty Trust common shares and Physicians Realty Trust restricted shares outstanding as of March 1, 2024, inclusive of: (i) 200 thousand Physicians Realty Trust restricted shares; (ii) 1 million Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust performance-based restricted stock unit (“PSUs”) (reflected at the maximum level of performance); and (iii) 300 thousand Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust restricted stock units (“RSUs”).
(2)The fair value of Healthpeak common stock issued to former holders of Physicians Realty Trust common shares and Physicians Realty Trust restricted shares, PSUs, and RSUs was based on the per share closing price of Healthpeak common stock on March 1, 2024.
(3)Represents the fair value of unvested Physicians Realty Trust restricted shares, PSUs, and RSUs attributable to post-combination services that were converted into Healthpeak common stock on the Closing Date in accordance with the Merger Agreement. Although no future service after the Closing Date is required, the value attributable to post-combination services reflected the incremental fair value provided to the Physicians Realty Trust equity award holders and the accelerated vesting of such awards at the Closing Date in accordance with the Merger Agreement. This amount was recognized as transaction and merger-related costs on the Consolidated Statements of Operations.
(4)Represents the Company’s cash repayment of all outstanding balances under Physicians Realty Trust’s revolving credit facility on the Closing Date in connection with the related termination.
(5)Includes cash settlement of: (i) tax liability related to holdback elections made under the pre-existing terms and conditions of Physicians Realty Trust’s equity programs and (ii) fractional share consideration.
Purchase Price Allocation
For the Company’s real estate acquisitions that are accounted for as business combinations, such as the Merger, the Company allocates the acquisition consideration (excluding acquisition costs) to the assets acquired, liabilities assumed, and noncontrolling interests at fair value as of the acquisition date. Any excess of the consideration transferred relative to the fair value of the net assets acquired is accounted for as goodwill. Acquisition costs related to business combinations are expensed as incurred. The estimated fair values of the assets acquired, liabilities assumed, and noncontrolling interests were based on information that was available at the Closing Date. The fair values were determined using standard valuation methodologies, such as the cost, market, and income approach. These methodologies require various assumptions, including those of a market participant.
12

Table of Contents
The following table summarizes the fair values of the assets acquired, liabilities assumed, and noncontrolling interests at the Closing Date (in thousands):

|  | Preliminary Amounts Recognized on the Closing Date |  | Measurement Period Adjustments |  | Amounts Recognized on the Closing Date (As Adjusted)
ASSETS |  |  |  |  |  |
Real estate: |  |  |  |  |  |
Buildings and improvements |  | $ | 3,199,884 |  |  | $ | (6,889) |  |  | $ | 3,192,995 |
Development costs and construction in progress |  | 68,171 |  |  | — |  |  | 68,171 |
Land and improvements |  | 435,353 |  |  | — |  |  | 435,353 |
Real estate |  | 3,703,408 |  |  | (6,889) |  |  | 3,696,519 |
Loans receivable |  | 118,908 |  |  | — |  |  | 118,908 |
Investments in and advances to unconsolidated joint ventures |  | 58,636 |  |  | — |  |  | 58,636 |
Accounts receivable, net(1) |  | 9,536 |  |  | (254) |  |  | 9,282 |
Cash and cash equivalents |  | 30,417 |  |  | — |  |  | 30,417 |
Restricted cash |  | 1,007 |  |  | — |  |  | 1,007 |
Intangible assets(2) |  | 890,827 |  |  | — |  |  | 890,827 |
Right-of-use asset |  | 191,415 |  |  | (113) |  |  | 191,302 |
Other assets |  | 44,691 |  |  | (668) |  |  | 44,023 |
Total assets |  | $ | 5,048,845 |  |  | $ | (7,924) |  |  | $ | 5,040,921 |
LIABILITIES AND EQUITY |  |  |  |  |  |
Term loans |  | $ | 402,320 |  |  | $ | — |  |  | $ | 402,320 |
Senior unsecured notes |  | 1,139,760 |  |  | — |  |  | 1,139,760 |
Mortgage debt |  | 127,176 |  |  | — |  |  | 127,176 |
Intangible liabilities(3) |  | 149,875 |  |  | — |  |  | 149,875 |
Lease liability |  | 97,160 |  |  | (113) |  |  | 97,047 |
Accounts payable, accrued liabilities, and other liabilities |  | 72,864 |  |  | (2,976) |  |  | 69,888 |
Total liabilities |  | $ | 1,989,155 |  |  | $ | (3,089) |  |  | $ | 1,986,066 |
Redeemable noncontrolling interests |  | 1,536 |  |  | 1,573 |  |  | 3,109 |
Joint venture partners(4) |  | 20,109 |  |  | (3,043) |  |  | 17,066 |
Non-managing member unitholders(5) |  | 116,618 |  |  | — |  |  | 116,618 |
Total noncontrolling interests |  | $ | 136,727 |  |  | $ | (3,043) |  |  | $ | 133,684 |
Fair value of net assets acquired and liabilities assumed, net of noncontrolling interests |  | $ | 2,921,427 |  |  | $ | (3,365) |  |  | $ | 2,918,062 |
Goodwill |  | 47,136 |  |  | 3,365 |  |  | 50,501 |
Total purchase price |  | $ | 2,968,563 |  |  | $ | — |  |  | $ | 2,968,563 |

_______________________________________
(1)Includes $14 million of gross contractual accounts receivable.
(2)The intangible assets acquired had a weighted average amortization period of 6 years (see Note 9).
(3)The intangible liabilities acquired had a weighted average amortization period of 9 years (see Note 9).
(4)Includes six consolidated joint ventures in which the Company held ownership interests ranging from 56.7% to 99.7% on the Closing Date.
(5)In connection with the Merger, Physicians Partnership merged with and into DOC DR OP Sub with DOC DR OP Sub surviving as the Partnership Surviving Entity. The Company controls the Partnership Surviving Entity via its ownership of its managing member, and the Partnership Surviving Entity is consolidated by the Company.
The measurement period adjustments recorded through December 31, 2024 are final and were primarily the result of additional information obtained during the measurement period by the Company related to certain assets acquired and liabilities assumed and updated valuations of noncontrolling interests, resulting in an increase to goodwill of $3 million.
13

Table of Contents
Based on the final purchase price allocation of fair value, approximately $51 million has been allocated to goodwill. The recognized goodwill was attributable to expected synergies, cost savings, acquired workforce, and potential economies of scale benefits from outpatient medical property management and tenant and vendor relationships following the closing of the Merger. None of the goodwill recognized is expected to be deductible for tax purposes.
Merger-Related Costs
During the three and nine months ended September 30, 2025, the Company incurred approximately $2 million and $9 million of merger-related costs, respectively, including severance, legal, accounting, tax, information technology, and other costs of combining operations with Physicians Realty Trust. During the three months ended September 30, 2024, the Company incurred approximately $6 million of merger-related costs, including severance, legal, accounting, tax, information technology, and other costs of combining operations with Physicians Realty Trust. During the nine months ended September 30, 2024, the Company incurred approximately $120 million of merger-related costs, which primarily related to advisory, legal, accounting, information technology, tax, post-combination severance and stock compensation expense, and other costs of combining operations with Physicians Realty Trust. Included in this amount was: (i) $38 million of fees paid to investment banks and advisors to help the Company negotiate the terms of the transactions contemplated by the Merger Agreement and to advise the Company on other merger-related matters, inclusive of $21 million of success-based fees incurred upon consummation of the Merger, (ii) $26 million of severance expense due to certain Physicians Realty Trust dual-trigger severance arrangements that were required to be recognized as post-combination expense in accordance with ASC 805, (iii) $16 million of post-combination stock compensation expense for the accelerated vesting of Physicians Realty Trust equity awards pursuant to the terms of the Merger Agreement, based on the fair value of Healthpeak common stock issued to holders of Physicians Realty Trust equity awards, (iv) $28 million of legal, accounting, tax, information technology, and other costs, and (v) $12 million of severance expense related to legacy Healthpeak employees. These merger-related costs are included in transaction and merger-related costs on the Consolidated Statements of Operations.
Unaudited Pro Forma Financial Information
The Consolidated Statements of Operations for the three months ended September 30, 2024 include $138 million of revenues and $37 million of net income applicable to common shares associated with the results of operations of legacy Physicians Realty Trust. The Consolidated Statements of Operations for the nine months ended September 30, 2024 include $332 million of revenues and $1 million of net loss applicable to common shares associated with the results of operations of legacy Physicians Realty Trust from the Closing Date to September 30, 2024.
The following unaudited pro forma information presents a summary of the results of operations for the Combined Company, as if the Merger had been consummated on January 1, 2023 (in thousands). There are no pro forma adjustments for the three and nine months ended September 30, 2025 as the Merger was completed on March 1, 2024. The following unaudited pro forma financial information is not necessarily indicative of the results of operations had the acquisition been effected on the assumed date, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the unaudited pro forma financial information, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.

| Three Months Ended September 30, 2024 |  |  |  | Nine Months Ended September 30, 2024
Total revenues | $ | 691,327 |  |  |  |  | $ | 2,078,322 |  |  |
Net income (loss) applicable to common shares | 95,234 |  |  |  |  | 337,520 |  |  |

The unaudited pro forma financial information above includes nonrecurring significant adjustments made to account for certain costs incurred as if the Merger had been completed on January 1, 2023. Transaction and merger-related costs of $6 million and $120 million that were incurred during the three and nine months ended September 30, 2024, respectively, were excluded from the unaudited pro forma financial information for the three and nine months ended September 30, 2024, respectively, as if they were incurred on the pro forma completion date of January 1, 2023.
14

Table of Contents
NOTE 4. Real Estate Investments

2025 Real Estate Investment Acquisitions
Middletown Medical Portfolio
In February 2025, the Company acquired a portfolio of three outpatient medical buildings in New York for $17 million.
100 Smith Land Parcel
In February 2025, the Company acquired a lab land parcel in Cambridge, Massachusetts for $20 million.
Atlanta Condominium Interest Acquisition
In September 2025, the Company acquired a condominium interest in eight suites within an outpatient medical building in Atlanta, Georgia for $6 million.
2024 Real Estate Investment Acquisitions
The Merger
As a result of the Merger, the Company acquired 299 outpatient medical buildings (see Note 3).
Development Activities
The Company’s commitments, which are primarily related to development and redevelopment projects and Company-owned tenant improvements, decreased by $28 million to $256 million at September 30, 2025, when compared to December 31, 2024, primarily as a result of construction spend on projects in development and redevelopment, partially offset by commitments on projects placed into development and redevelopment during the period.
NOTE 5. Dispositions of Real Estate

2025 Dispositions of Real Estate
During the three months ended June 30, 2025, the Company sold one outpatient medical land parcel for $4 million, resulting in gain on sale of $3 million.
During the three months ended September 30, 2025, the Company sold two outpatient medical buildings for $27 million, resulting in total gain on sales of $12 million.
2024 Dispositions of Real Estate
During the three months ended March 31, 2024, the Company sold two outpatient medical buildings for $29 million, resulting in total gain on sales of $3 million.
During the three months ended June 30, 2024, the Company sold a portfolio of seven lab buildings for $180 million and 11 outpatient medical buildings for $179 million, resulting in total gain on sales of $122 million.
During the three months ended September 30, 2024, the Company sold a portfolio of 59 outpatient medical buildings for $674 million, resulting in total gain on sales of $60 million, and provided the buyer with a mortgage loan secured by the real estate sold for $405 million (see Note 7).
During the year ended December 31, 2024, the Company also sold: (i) one outpatient medical building for $12 million, (ii) a portfolio of two outpatient medical buildings for $23 million and provided the buyer with a mortgage loan secured by the real estate sold for $14 million (see Note 7), and (iii) a portfolio comprised of a land parcel and various vacant buildings on certain of the Company’s CCRC campuses for $12 million.
Held for Sale
As of September 30, 2025, six lab buildings were classified as held for sale, with a carrying value of $68 million, primarily comprised of net real estate assets, straight-line rent receivable, and right-of-use assets. As of September 30, 2025, liabilities related to the assets held for sale were $12 million, primarily comprised of lease liabilities and deferred revenue. As of December 31, 2024, one outpatient medical building was classified as held for sale, with a carrying value of $8 million, primarily comprised of net real estate assets. As of December 31, 2024, liabilities related to the asset held for sale were zero. This asset was sold during the three months ended September 30, 2025.
15

Table of Contents
Impairments of Real Estate
During the three and nine months ended September 30, 2025 and 2024, the Company did not recognize any impairment charges on its consolidated real estate assets. See Note 8 for discussion of the Company’s other-than-temporary impairment charges.
NOTE 6. Leases

Lease Income
The following table summarizes the Company’s lease income (in thousands):

| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Fixed income from operating leases | $ | 392,915 |  |  | $ | 394,263 |  |  | $ | 1,178,305 |  |  | $ | 1,141,901 |
Variable income from operating leases | 146,971 |  |  | 148,988 |  |  | 429,409 |  |  | 410,164 |

Initial Direct Costs
Initial direct costs incurred in connection with successful property leasing are capitalized as deferred leasing costs. Initial direct costs include only those costs that are incremental to the arrangement and would not have been incurred if the lease had not been obtained, such as leasing commissions paid to employees and external third-party brokers and lease incentives. Initial direct costs are included in other assets, net in the Consolidated Balance Sheets and amortized in depreciation and amortization in the Consolidated Statements of Operations using the straight-line method over the lease term. At September 30, 2025 and December 31, 2024, the balance of net initial direct costs were $210 million and $204 million, respectively.
Straight-Line Rents
For operating leases with minimum scheduled rent increases, the Company recognizes income on a straight-line basis over the lease term when collectibility of future minimum lease payments is probable. If the Company determines that collectibility of future minimum lease payments is not probable, the straight-line rent receivable balance is written off and recognized as a decrease in revenue in that period and future revenue recognition is limited to amounts contractually owed and paid. The Company does not resume recognition of income on a straight-line basis unless it determines that collectibility of future payments related to these leases is probable. For the Company’s portfolio of operating leases that are deemed probable of collection but exhibit a certain level of collectibility risk, the Company may also recognize an incremental allowance as a reduction to revenue. At September 30, 2025 and December 31, 2024, straight-line rent receivable, net of allowance, excluding amounts reported in assets held for sale, net, was $368 million and $338 million, respectively. Straight-line rent receivable is included in other assets, net in the Consolidated Balance Sheets. At September 30, 2025 and December 31, 2024, straight-line rent receivable, net of allowance, reported in assets held for sale, net, was $0.8 million and zero, respectively.
Tenant Updates
In July 2024, the Company executed an early lease renewal for approximately 2 million square feet leased by CommonSpirit Health (“CommonSpirit”). The renewal, which is subject to a master agreement, extended the weighted average lease term of existing leases from July 2027 to December 2035, amended the contractual rents to current market rates, and increased the annual contractual lease escalations from 2.5% to 3.0%. In connection with this extension, CommonSpirit was provided the right to reduce the amount of space leased by up to approximately 200,000 square feet at any time after the original lease maturity dates. These termination rights were evaluated for likelihood of exercise in accordance with ASC 842, Leases, in the determination of the lease term. During each of the three and nine months ended September 30, 2025, CommonSpirit represented 6% of revenues for the outpatient medical segment and 3% of total revenues.
On October 26, 2023, the Company amended its lease with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024 (“Graphite Bio”), at one of its lab buildings in South San Francisco, California. Under the terms of the amended lease agreement, Graphite Bio’s lease expiration date was accelerated from April 2033 to December 2024 in exchange for an upfront cash payment of $37 million, comprised of a $21 million termination fee and $16 million prepayment of Graphite Bio’s contractual rent through the amended term. The $37 million was recognized as rental and related revenues on the Consolidated Statements of Operations on a straight-line basis through the amended term of the lease.
16

Table of Contents
NOTE 7. Loans Receivable

The following table summarizes the Company’s loans receivable (in thousands):

| September 30, 2025 |  | December 31, 2024
Secured loans(1) | $ | 580,912 |  |  | $ | 638,482 |
CCRC resident loans | 66,549 |  |  | 61,273 |
Mezzanine loans | 53,120 |  |  | 50,314 |
Unamortized discounts and fees | (15,477) |  |  | (22,380) |
Reserve for loan losses | (11,602) |  |  | (10,499) |
Loans receivable, net | $ | 673,502 |  |  | $ | 717,190 |

_______________________________________
(1)At September 30, 2025, the Company had $121 million of remaining commitments to fund additional principal on loans for outpatient medical and lab capital expenditure projects. At December 31, 2024, the Company had $85 million of remaining commitments to fund additional principal on loans for outpatient medical capital expenditure projects.
The Merger
On March 1, 2024, upon the consummation of the Merger, the Company acquired nine secured loans with an aggregate outstanding principal balance of $89 million and 10 mezzanine loans with an aggregate outstanding principal balance of $36 million, for a total of $124 million. Typically, each secured loan is secured by a mortgage on a related outpatient medical building, each construction loan (included in secured loans above) is secured by a mortgage on the land and improvements as constructed, generally with guarantees from the borrowers, and each mezzanine loan is collateralized by an ownership interest in the respective borrower. As of the Closing Date, the secured loans had maturities ranging from June 2024 to July 2027 and stated fixed interest rates ranging from 7.00% to 10.00%. The mezzanine loans had maturities ranging from June 2024 to June 2027 and stated fixed interest rates ranging from 8.00% to 10.00%.
As of September 30, 2025, unamortized net discounts on the secured loans and mezzanine loans acquired were $0.3 million and $1 million, respectively. As of December 31, 2024, unamortized net discounts on the secured loans and mezzanine loans acquired were $1 million and $2 million, respectively. These discounts are recognized in interest income and other on the Consolidated Statements of Operations using the effective interest rate method over the remaining term of the loans.
Sunrise Senior Housing Portfolio Seller Financing
In conjunction with the sale of a portfolio of senior housing operating properties (“SHOP”) facilities in January 2021, the Company provided the buyer with financing secured by the buyer’s equity ownership in each property. In February 2024, this secured loan was refinanced with the Company. In connection with the refinance, the Company received a partial principal repayment of $69 million and the maturity date was extended to August 2027. In May 2024, the Company received a partial principal repayment of $5 million in conjunction with the disposition of underlying collateral. At December 31, 2024, this secured loan had an outstanding principal balance of $58 million. In August 2025, the Company received full repayment of the outstanding balance of this seller financing.
Other SHOP Seller Financing
In conjunction with another SHOP portfolio sale in January 2021, the Company provided the buyer with financing secured by the buyer’s equity ownership in each property. This secured loan was most recently refinanced with the Company in January 2024 at which time the maturity date was extended to January 2025. At December 31, 2024, this secured loan had an outstanding principal balance of $48 million. In January 2025, the Company received full repayment of the outstanding balance of this seller financing.
17

Table of Contents
Outpatient Medical Seller Financing
In conjunction with the sale of 59 outpatient medical buildings for $674 million in July 2024 and the two outpatient medical buildings for $23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan secured by the real estate sold for $405 million and $14 million, respectively. The remainder of the sales price was received in cash at the time of sales. The seller financing has an initial term that matures in July 2026 and includes two 12-month extension options. The interest rate on the seller financing is fixed at 6.0% for the initial term and increases to 6.5% during the optional extension periods. The Company also received a $1 million loan origination fee in connection with the loan, which is being recognized in interest income over the remaining term of the loan. In connection with this seller financing, the Company reduced the gain on sales of real estate and recognized a mark-to-market discount of $21 million during the year ended December 31, 2024. This discount is based on the difference between the stated interest rate and the corresponding prevailing market rate as of the transaction date. The discount is recognized as interest income over the term of the discounted loan using the effective interest rate method. During the three and nine months ended September 30, 2025, the Company recognized $2 million and $5 million, respectively, of non-cash interest income related to the amortization of this mark-to-market discount. During each of the three and nine months ended September 30, 2024, the Company recognized $1 million of non-cash interest income related to the amortization of this mark-to-market discount. As of September 30, 2025 and December 31, 2024, the unamortized mark-to-market discount was $13 million and $18 million, respectively.
2025 Other Loans Receivable Transactions
During the nine months ended September 30, 2025, the Company: (i) entered into one secured loan to provide up to $75 million to fund a portion of the acquisition and redevelopment of a lab building, $28 million of which was funded upon closing of the loan, (ii) entered into an agreement to provide aggregate financing of $41 million to fund the development of an outpatient medical building, $4 million of which was funded upon closing of the loan, (iii) entered into and funded a $4 million loan secured by a land parcel, (iv) entered into and funded a $4 million mezzanine loan to one of its unconsolidated joint ventures, and (v) funded $27 million of principal on its existing secured loans.
During the nine months ended September 30, 2025, the Company received full repayment of: (i) the outstanding balance of one $15 million secured loan and (ii) the outstanding balance of one $1 million mezzanine loan. During the nine months ended September 30, 2025, the Company also received partial repayments of $3 million on one secured loan.
2024 Other Loans Receivable Transactions
During the year ended December 31, 2024, the Company entered into one construction loan agreement to provide up to $36 million to fund a portion of the construction of an outpatient medical building, none of which was funded upon closing of the loan. Also during the year ended December 31, 2024, the Company entered into and funded one $15 million mezzanine loan.
CCRC Resident Loans
For certain residents that qualify, CCRCs may offer to lend residents the necessary funds to satisfy the entrance fee requirements so that they are able to move into a community while still continuing the process of selling their previous home. The loans are due upon sale of the resident’s previous home. At September 30, 2025 and December 31, 2024, the Company held $67 million and $61 million, respectively, of such notes receivable.
Loans Receivable Internal Ratings
In connection with the Company’s quarterly review process or upon the occurrence of a significant event, loans receivable are reviewed and assigned an internal rating of Performing, Watch List, or Workout. Loans that are deemed Performing meet all present contractual obligations, and collection and timing of all amounts owed is reasonably assured. Watch List Loans are defined as loans that do not meet the definition of Performing or Workout. Workout Loans are defined as loans in which the Company has determined, based on current information and events, that: (i) it is probable it will be unable to collect all amounts due according to the contractual terms of the agreement, (ii) the borrower is delinquent on making payments under the contractual terms of the agreement, and (iii) the Company has commenced action or anticipates pursuing action in the near term to seek recovery of its investment.
18

Table of Contents
The following table summarizes, by year of origination, the Company’s internal ratings for loans receivable, net of unamortized discounts, fees, and reserves for loan losses, as of September 30, 2025 (in thousands):

Investment Type |  | Year of Origination(1) |  | Total
| 2025 |  | 2024 |  | 2023 |  | 2022 |  | 2021 |  | Prior |
Secured loans |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk rating: |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performing loans |  | $ | 36,445 |  |  | $ | 441,192 |  |  | $ | 53,216 |  |  | $ | 30,302 |  |  | $ | — |  |  | $ | — |  |  | $ | 561,155 |
Watch list loans |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Workout loans |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total secured loans |  | $ | 36,445 |  |  | $ | 441,192 |  |  | $ | 53,216 |  |  | $ | 30,302 |  |  | $ | — |  |  | $ | — |  |  | $ | 561,155 |
Current period gross write-offs |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Current period recoveries |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Current period net write-offs |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Mezzanine loans |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk rating: |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performing loans |  | $ | 4,245 |  |  | $ | 13,406 |  |  | $ | 5,139 |  |  | $ | 4,651 |  |  | $ | 7,158 |  |  | $ | 11,199 |  |  | $ | 45,798 |
Watch list loans |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Workout loans |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total mezzanine loans |  | $ | 4,245 |  |  | $ | 13,406 |  |  | $ | 5,139 |  |  | $ | 4,651 |  |  | $ | 7,158 |  |  | $ | 11,199 |  |  | $ | 45,798 |
Current period gross write-offs |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Current period recoveries |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Current period net write-offs |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
CCRC resident loans |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk rating: |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performing loans |  | $ | 55,461 |  |  | $ | 10,878 |  |  | $ | 175 |  |  | $ | 35 |  |  | $ | — |  |  | $ | — |  |  | $ | 66,549 |
Watch list loans |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Workout loans |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total CCRC resident loans |  | $ | 55,461 |  |  | $ | 10,878 |  |  | $ | 175 |  |  | $ | 35 |  |  | $ | — |  |  | $ | — |  |  | $ | 66,549 |
Current period gross write-offs |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Current period recoveries |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Current period net write-offs |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |

_______________________________________
(1)Additional fundings under existing loans are included in the year of origination of the initial loan.
19

Table of Contents
Reserve for Loan Losses
The Company evaluates the liquidity and creditworthiness of its borrowers on a quarterly basis to determine whether any updates to the future expected losses recognized upon inception are necessary. The Company’s evaluation considers payment history and current credit status, industry conditions, current economic conditions, forecasted economic conditions, individual and portfolio property performance, credit enhancements, liquidity, and other factors. Future economic conditions are based primarily on near-term economic forecasts from the Federal Reserve and reasonable assumptions for long-term economic trends. The determination of loan losses also considers concentration of credit risk associated with the senior housing, outpatient medical, and lab industries to which its loans receivable relate. The Company’s borrowers furnish property, portfolio, and guarantor/operator-level financial statements, among other information, on a monthly or quarterly basis; the Company utilizes this financial information to calculate the debt service coverages in its assessment of internal ratings that it uses as a primary credit quality indicator. Debt service coverage information is evaluated together with other property, portfolio, and operator performance information, including revenue, expense, net operating income, occupancy, rental rates, capital expenditures, and EBITDA (defined as earnings before interest, tax, and depreciation and amortization), along with other liquidity measures. The Company evaluates, on a monthly basis or immediately upon a significant change in circumstance, its borrowers’ ability to service their obligations with the Company.
The following table summarizes the Company’s reserve for loan losses (in thousands):

| September 30, 2025 |  | December 31, 2024
| Secured Loans |  | Mezzanine Loans and Other(1) |  |  |  | Total |  | Secured Loans |  | Mezzanine Loans and Other(1) |  |  |  | Total
Reserve for loan losses, beginning of period | $ | 5,574 |  |  | $ | 4,925 |  |  |  |  | $ | 10,499 |  |  | $ | 2,830 |  |  | $ | — |  |  |  |  | $ | 2,830 |
Provision for expected loan losses (recoveries) on funded loans receivable | 1,153 |  |  | 1,581 |  |  |  |  | 2,734 |  |  | 2,744 |  |  | 4,925 |  |  |  |  | 7,669 |
Expected loan losses (recoveries) related to loans sold or repaid | (1,460) |  |  | (171) |  |  |  |  | (1,631) |  |  | — |  |  | — |  |  |  |  | — |
Reserve for loan losses, end of period | $ | 5,267 |  |  | $ | 6,335 |  |  |  |  | $ | 11,602 |  |  | $ | 5,574 |  |  | $ | 4,925 |  |  |  |  | $ | 10,499 |

_______________________________________
(1)Includes CCRC resident loans.
Additionally, at September 30, 2025 and December 31, 2024, a liability of $1.6 million and $2.9 million, respectively, related to expected credit losses for unfunded loan commitments was included in accounts payable, accrued liabilities, and other liabilities.
The change in the reserve for expected loan losses during the nine months ended September 30, 2025 is primarily due to reserves recognized on new and amended loans during the nine months then ended, partially offset by recoveries related to loans repaid during the same period.
20

Table of Contents
NOTE 8. Investments in and Advances to Unconsolidated Joint Ventures

The Company owns interests in the following entities that are accounted for under the equity method (dollars in thousands):

|  |  |  |  |  |  | Carrying Amount
|  |  |  |  |  |  |  | September 30, |  | December 31,
Entity(1) |  | Segment |  | Property Count(2) |  | Ownership %(2) |  | 2025 |  | 2024
SWF SH JV |  | Other |  | 19 |  | 54 |  | $ | 312,093 |  |  | $ | 322,551 |
South San Francisco JVs(3) |  | Lab |  | 7 |  | 70 |  | 285,044 |  |  | 446,145 |
Callan Ridge JV |  | Lab |  | 2 |  | 35 |  | 75,069 |  |  | 69,709 |
HQ Point Preferred Equity Investment(2) |  | Other |  | 2 |  | 33 |  | 47,017 |  |  | — |
Lab JV |  | Lab |  | 1 |  | 49 |  | 31,848 |  |  | 29,916 |
PMAK JV(2) |  | Outpatient medical |  | 59 |  | 12 |  | 24,229 |  |  | 32,511 |
Needham Land Parcel JV(2) |  | Lab |  | — |  | 38 |  | 12,291 |  |  | 21,348 |
Outpatient Medical JVs(4) |  | Outpatient medical |  | 2 |  | 20 - 67 |  | 7,328 |  |  | 7,199 |
Davis JV |  | Outpatient medical |  | 17 |  | 47 |  | 1,252 |  |  | 7,435 |
|  |  |  |  |  |  |  | $ | 796,171 |  |  | $ | 936,814 |

_______________________________________
(1)These entities are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.
(2)Property counts and ownership percentages are as of September 30, 2025. Land held for development and the properties underlying the PMAK JV and HQ Point Preferred Equity Investment are excluded from the Company’s total property count.
(3)Includes multiple unconsolidated lab joint ventures in South San Francisco, California in which the Company holds a 70% ownership percentage in each joint venture. The Company is entitled to a preferred return, a promote, and certain fees in exchange for development and asset management services provided to these joint ventures when certain conditions are met. These joint ventures have been aggregated herein due to similarity of the investments and operations.
(4)Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV (20%) and (ii) Suburban Properties, LLC (67%). These joint ventures have been aggregated herein due to similarity of the investments and operations.
Other-Than-Temporary Impairments
The Company reviews its investments in unconsolidated joint ventures for indicators of impairment on a quarterly basis and records an impairment charge when a decline in the fair value below the carrying value has been determined to be other-than-temporary. Indicators of impairment have been identified related to the cumulative impact of depressed biotechnology capital raising, lower market rents, increased capitalization rates, and oversupply affecting the life science industry. These conditions are a shift since the time of formation of the South San Francisco JVs, a period marked by historically low interest rates coupled with market rents and valuations at or near industry highs when the JV partner acquired its 30% interest. As the South San Francisco JVs include recently completed and in-process redevelopment properties, these economic conditions have resulted in an increase to the timeframe required to reach stabilized occupancy and changes to management’s estimates of market rents upon completion of redevelopment activities. Additionally, there has been a shift in development plans of the Needham Land Parcel JV from a life science development to a mixed-use project, resulting in an extended timeline and delayed project commencement.
These circumstances have contributed to a sustained decrease in the value of these investments. During the three months ended September 30, 2025, the Company determined that the length of time and extent of the decline in fair values below carrying values represent other-than-temporary impairments. Accordingly, during the three months ended September 30, 2025, the Company recorded impairment charges of $169 million related to its investments in the South San Francisco JVs and $7 million related to its investment in the Needham Land Parcel JV, net of tax. These impairment charges are recognized in equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations. The discounted cash flow models utilized to determine the impairment charges were considered Level 3 measurements within the fair value hierarchy. These discounted cash flow models utilized the following key assumptions: (i) forecasted occupancy and market rents, (ii) a terminal capitalization rate of 6.50%, (iii) discount rates ranging from 7.50% to 8.75%, with a weighted average of 7.95% (weighted by each property’s relative fair value), (iv) expected capital expenditures, and (v) specific to Needham Land Parcel JV, land values based on a comparable sales approach.
21

Table of Contents
HQ Point Preferred Equity Investment
In February 2025, the Company made a preferred equity investment in a joint venture that holds a lab campus under development in San Diego, California. This investment is entitled to a preferred return, and the Company has committed to fund up to a total investment of $50 million. As of September 30, 2025, the Company had funded $45 million of its investment.
Callan Ridge JV
In January 2024, the Company sold a 65% interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35% investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment at the time of the transaction was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the nine months ended September 30, 2024, the Company recognized a gain upon change of control of $78 million, which is recorded in other income (expense), net.
NOTE 9. Intangibles

Intangible assets primarily consist of lease-up intangibles and above market lease intangibles. The following table summarizes the Company’s intangible lease assets (dollars in thousands):

Intangible lease assets |  | September 30, 2025 |  | December 31, 2024
Gross intangible lease assets(1) |  | $ | 1,321,174 |  |  | $ | 1,468,985 |
Accumulated depreciation and amortization(2) |  | (710,661) |  |  | (651,731) |
Intangible assets, net |  | $ | 610,513 |  |  | $ | 817,254 |
Weighted average remaining amortization period in years |  | 5 |  | 5

_______________________________________
(1)At September 30, 2025 and December 31, 2024, includes $1.28 billion and $1.42 billion, respectively, of gross lease-up intangibles and at September 30, 2025 and December 31, 2024, includes $43 million and $45 million, respectively, of gross above market lease intangibles.
(2)At September 30, 2025 and December 31, 2024, includes $694 million and $640 million, respectively, of accumulated depreciation and amortization on lease-up intangibles and $16 million and $12 million, respectively, of accumulated depreciation and amortization on above market lease intangibles.
Intangible liabilities consist of below market lease intangibles. The following table summarizes the Company’s intangible lease liabilities (dollars in thousands):

Intangible lease liabilities |  | September 30, 2025 |  | December 31, 2024
Gross intangible lease liabilities |  | $ | 308,127 |  |  | $ | 351,602 |
Accumulated depreciation and amortization |  | (152,570) |  |  | (159,718) |
Intangible liabilities, net |  | $ | 155,557 |  |  | $ | 191,884 |
Weighted average remaining amortization period in years |  | 9 |  | 9

During the nine months ended September 30, 2025, in conjunction with the Company’s acquisition of real estate, the Company acquired $3 million of intangible assets with a weighted average amortization period at acquisition of 13 years.
On the Closing Date of the Merger, the Company acquired intangible assets of $891 million, inclusive of $852 million of lease-up intangibles and $39 million of above market lease intangibles. Also on the Closing Date of the Merger, the Company assumed intangible liabilities of $150 million (see Note 3). The intangible assets and liabilities acquired had a weighted average amortization period at acquisition of 6 years and 9 years, respectively.
22

Table of Contents
Goodwill
In connection with the Merger, the Company recognized goodwill of $51 million, which was allocated to the Company’s outpatient medical segment (see Note 3). Goodwill is included in other assets, net on the Consolidated Balance Sheets. At September 30, 2025 and December 31, 2024, goodwill was allocated to the Company’s segment assets as follows (in thousands):

Segment |  | September 30, 2025 |  | December 31, 2024
Outpatient medical |  | $ | 64,680 |  |  | $ | 64,680 |
CCRC |  | 1,998 |  |  | 1,998 |
Other non-reportable |  | 1,851 |  |  | 1,851 |
|  | $ | 68,529 |  |  | $ | 68,529 |

NOTE 10. Debt

Healthpeak OP, the Company’s consolidated operating subsidiary, is the borrower under, and the Company, DOC DR Holdco, and DOC DR OP Sub are the guarantors of, the Revolving Facility, 2027 Term Loans, 2029 Term Loan, Commercial Paper Program (each as defined below), and senior unsecured notes issued by the Company. DOC DR OP Sub is the borrower under, and the Company, Healthpeak OP, and DOC DR Holdco are guarantors of, the 2028 Term Loan (as defined below) and senior unsecured notes issued by the Physicians Partnership prior to, and assumed by the Company as part of, the Merger. Guarantees of senior unsecured notes are full and unconditional and applicable to existing and future senior unsecured notes.
The Merger
On March 1, 2024, upon the consummation of the Merger, the Company assumed senior unsecured term loans in an aggregate principal amount of $400 million (the “2028 Term Loan”) that mature in May 2028 (see Note 3) pursuant to an amendment to a term loan agreement originally executed by the Physicians Partnership, as borrower, and the other parties thereto.
In connection with the assumption of the 2028 Term Loan, the Company acquired three related interest rate swap instruments that were redesignated as cash flow hedges as of the Closing Date. The 2028 Term Loan associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on DOC DR OP Sub’s credit ratings as of September 30, 2025, the 2028 Term Loan had a blended fixed effective interest rate of 4.44%, inclusive of the impact of these interest rate swap instruments and amortization of the related premium. See also Note 18 for a discussion of the impact of the related interest rate swap instruments.
Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85% to 1.65% for Daily SOFR loans and is based on the credit ratings of DOC DR OP Sub. Based on the Company’s credit ratings as of September 30, 2025, and inclusive of the adjustment related to SOFR transition, the margin on the 2028 Term Loan was 1.00%.
In October 2025, the Company executed an amendment to the 2028 Term Loan to remove the adjustment related to SOFR transition from the determination of the margin.
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $400 million aggregate principal amount of 4.30% senior unsecured notes due 2027, (ii) $350 million aggregate principal amount of 3.95% senior unsecured notes due 2028, and (iii) $500 million aggregate principal amount of 2.63% senior unsecured notes due 2031. On the Closing Date, the Company capitalized $1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below.
23

Table of Contents
Lastly, on March 1, 2024, concurrently with the consummation of the Merger, the Company assumed $128 million aggregate principal of mortgage debt (see Note 3), which was secured by five outpatient medical buildings, with an aggregate carrying value of $259 million as of March 1, 2024. Of this $128 million, $59 million was fixed rate debt with a weighted average contractual interest rate of 3.77% and maturities ranging from November 2024 through December 2026 and $69 million was variable rate debt with a weighted average contractual interest rate of 7.25% and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $0.5 million on the $128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one related interest rate swap instrument with a notional amount of $36 million of variable rate mortgage debt that was redesignated as a cash flow hedge as of the Closing Date (see Note 18), which matured in October 2024.
Bank Line of Credit and Term Loans
Revolving Facility
On May 23, 2019, the Company executed a $2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “Revolving Facility”) to increase total revolving commitments from $2.5 billion to $3.0 billion and extend the maturity date to January 20, 2026 with two six-month extension options, subject to certain customary conditions. On February 10, 2023, the Company executed an amendment to the Revolving Facility to convert the interest rate benchmark from the London Interbank Offered Rate (“LIBOR”) to SOFR. On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Revolving Facility to, among other things, join DOC DR Holdco and DOC DR OP Sub as guarantors of Healthpeak OP’s obligations under the Revolving Facility. In December 2024, the Company amended and restated its Revolving Facility to extend the maturity date to January 19, 2029. This maturity date may be further extended pursuant to two six-month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at the applicable interest rate benchmark plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The Company also pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at September 30, 2025, and inclusive of a 10 basis point adjustment related to SOFR transition, the margin on the Revolving Facility was 0.88% and the facility fee was 0.15%. The Revolving Facility includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $750 million, subject to securing additional commitments. At each of September 30, 2025 and December 31, 2024, the Company had no balance outstanding under the Revolving Facility.
In October 2025, the Company executed an amendment to the Revolving Facility to, among other immaterial changes, remove the 10 basis point adjustment related to SOFR transition from the determination of the margin.
Term Loan Agreement
On August 22, 2022, the Company executed a term loan agreement (as amended or modified as described herein, the “Term Loan Agreement”) that provided for two senior unsecured delayed draw term loans in an aggregate principal amount of up to $500 million (the “2027 Term Loans”). The 2027 Term Loans were available to be drawn from time to time during a 180-day period after closing, subject to customary borrowing conditions, and the Company drew the entirety of the $500 million under the 2027 Term Loans in October 2022. $250 million of the 2027 Term Loans have an initial stated maturity of 4.5 years, which may be extended for a one-year period subject to certain customary conditions. The other $250 million of the 2027 Term Loans has a stated maturity of five years with no option to extend.
Loans outstanding under the 2027 Term Loans accrue interest at Term SOFR plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The 2027 Term Loans also include a sustainability-linked pricing component whereby the applicable margin under the 2027 Term Loans may be reduced by 0.01% based on the Company’s achievement of specified sustainability-linked metrics. Based on the Company’s credit ratings as of September 30, 2025, and inclusive of achievement of a sustainability-linked metric and an adjustment related to SOFR transition, the margin on the 2027 Term Loans was 0.94%.
In August 2022, the Company entered into two forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 18). The 2027 Term Loans associated with these interest rate swap instruments are reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on the Company’s credit ratings as of September 30, 2025, the 2027 Term Loans had a blended fixed effective interest rate of 3.76%, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs.
24

Table of Contents
On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $1.0 billion to $1.5 billion, subject to securing additional commitments, (ii) the Company borrowed senior unsecured term loans in an aggregate principal amount of $750 million with a stated maturity of five years (the “2029 Term Loan”), and (iii) DOC DR Holdco and DOC DR OP Sub were joined as guarantors of Healthpeak OP’s obligations under the Term Loan Agreement. As of September 30, 2025, the unused borrowing capacity under the Term Loan Agreement was $250 million.
Loans outstanding under the 2029 Term Loan accrue interest at Daily SOFR plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. Based on the Company’s credit ratings as of September 30, 2025, and inclusive of an adjustment related to SOFR transition, the margin on the 2029 Term Loan was 0.95%.
In January 2024, the Company entered into forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 18). The 2029 Term Loan associated with these interest rate swaps is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on the Company’s credit ratings as of September 30, 2025, the 2029 Term Loan had a blended fixed effective interest rate of 4.66%, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs.
At each of September 30, 2025 and December 31, 2024, the Company had $1.25 billion of loans outstanding under the Term Loan Agreement.
In October 2025, the Company executed an amendment to the Term Loan Agreement to remove the adjustment related to SOFR transition from the determination of the margin.
The Revolving Facility, 2027 Term Loans, 2028 Term Loan, and 2029 Term Loan are subject to certain financial restrictions and other customary requirements, including financial covenants and cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the applicable agreement: (i) limit the ratio of Enterprise Total Indebtedness to Enterprise Gross Asset Value to 60%; (ii) limit the ratio of Enterprise Secured Debt to Enterprise Gross Asset Value to 40%; (iii) limit the ratio of Enterprise Unsecured Debt to Enterprise Unencumbered Asset Value to 60%; (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times; and (v) require a minimum Consolidated Tangible Net Worth of $7.7 billion. The Company believes it was in compliance with each of these covenants at September 30, 2025.
Commercial Paper Program
In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At each of September 30, 2025 and December 31, 2024, the maximum aggregate face or principal amount that could be outstanding at any one time was $2.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of short-term unsecured notes issued under the Commercial Paper Program. During each of the three months ended September 30, 2025 and 2024, the Company recognized $2 million of interest expense related to fees and amortization of debt issuance costs in connection with its Commercial Paper Program and Revolving Facility. During each of the nine months ended September 30, 2025 and 2024, the Company recognized $7 million of interest expense related to fees and amortization of debt issuance costs in connection with its Commercial Paper Program and Revolving Facility. At September 30, 2025, the Company had $368 million notes outstanding under the Commercial Paper Program, with original maturities of approximately 22 days and a weighted average interest rate of 4.36%. At December 31, 2024, the Company had $150 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 25 days and a weighted average interest rate of 4.65%.
Senior Unsecured Notes
At September 30, 2025 and December 31, 2024, the Company had senior unsecured notes outstanding with an aggregate principal balance of $6.9 billion and $6.7 billion, respectively. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions, and other customary terms. The Company believes it was in compliance with these covenants at September 30, 2025.
25

Table of Contents
The following table summarizes the Company’s senior unsecured note issuances for the nine months ended September 30, 2025 (dollars in thousands):

Issue Date |  | Amount |  | Coupon Rate(1) |  | Maturity Year
February 14, 2025 |  | $ | 500,000 |  |  | 5.38 | % |  | 2035
August 14, 2025 |  | 500,000 |  |  | 4.75 | % |  | 2033

_______________________________________
(1)The effective interest rate, which includes amortization of debt discounts and debt issuance costs, is 5.56% for the senior unsecured notes issued in February 2025 and 5.02% for the senior unsecured notes issued in August 2025.
The following table summarizes the Company’s senior unsecured note repayments during the nine months ended September 30, 2025 (dollars in thousands):

Repayment Date |  | Amount |  | Coupon Rate(1) |  | Maturity Year
February 3, 2025 |  | $ | 348,194 |  |  | 3.40 | % |  | 2025
June 2, 2025 |  | 451,806 |  |  | 4.00 | % |  | 2025

_______________________________________
(1)The effective interest rate, which includes amortization of debt discounts and debt issuance costs, was 3.58% for the senior unsecured notes repaid in February 2025 and 4.19% for the senior unsecured notes repaid in June 2025.
During the year ended December 31, 2024, there were no issuances, repurchases, or redemptions of senior unsecured notes; however, as described above, concurrently with the consummation of the Merger, the Company assumed $1.25 billion aggregate principal of senior unsecured notes.
Mortgage Debt
At September 30, 2025 and December 31, 2024, the Company had $350 million and $356 million, respectively, in aggregate principal of mortgage debt outstanding. At September 30, 2025, this mortgage debt was secured by 18 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of $752 million. At December 31, 2024, this mortgage debt was secured by 19 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of $770 million.
Mortgage debt generally requires monthly principal and interest payments, is collateralized by real estate assets, and is non-recourse. Mortgage debt typically requires maintenance of the assets in good condition, includes conditions to obtain lender consent to enter into or terminate material leases, requires insurance on the assets, requires payment of real estate taxes, restricts transfer of the encumbered assets and repayment of the loan, and prohibits additional liens. Some of the mortgage debt may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.
During each of the three months ended September 30, 2025 and 2024, the Company made aggregate principal repayments of mortgage debt of $1 million. During the nine months ended September 30, 2025 and 2024, the Company made aggregate principal repayments of mortgage debt of $6 million and $3 million, respectively. Included in the $6 million of aggregate principal payments of mortgage debt for the nine months ended September 30, 2025 was a $4 million full principal repayment of mortgage debt secured by one outpatient medical building that matured in March 2025.
The Company has $142 million of mortgage debt secured by a portfolio of 13 outpatient medical buildings that matures in 2026. In April 2022, the Company terminated its existing interest rate cap instruments associated with this variable rate mortgage debt and entered into two interest rate swap instruments that are designated as cash flow hedges and mature in May 2026. In February 2023, the agreements associated with this variable rate mortgage debt were amended to change the interest rate benchmarks from LIBOR to SOFR, effective March 2023. Concurrently, the Company modified the related interest rate swap instruments to reflect the change in the interest rate benchmarks from LIBOR to SOFR (see Note 18). The variable rate mortgage debt associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instrument.
26

Table of Contents
Debt Maturities
The following table summarizes the Company’s stated debt maturities and scheduled principal repayments at September 30, 2025 (dollars in thousands):

|  |  |  |  |  |  |  | Senior Unsecured Notes(3) |  | Mortgage Debt(4) |  |
Year |  | Bank Line of Credit(1) |  | Commercial Paper(1)(2) |  | Term Loans |  | Amount |  | Interest Rate(5) |  | Amount |  | Interest Rate(5) |  | Total
2025 |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | — | % |  | $ | 940 |  |  | 3.91 | % |  | $ | 940 |
2026 |  | — |  |  | — |  |  | — |  |  | 650,000 |  |  | 3.40 | % |  | 344,999 |  |  | 4.99 | % |  | 994,999 |
2027 |  | — |  |  | — |  |  | 500,000 |  |  | 850,000 |  |  | 3.23 | % |  | 842 |  |  | 5.11 | % |  | 1,350,842 |
2028 |  | — |  |  | — |  |  | 400,000 |  |  | 850,000 |  |  | 3.53 | % |  | 2,775 |  |  | 4.51 | % |  | 1,252,775 |
2029 |  | — |  |  | 368,125 |  |  | 750,000 |  |  | 650,000 |  |  | 3.65 | % |  | — |  |  | — | % |  | 1,768,125 |
Thereafter |  | — |  |  | — |  |  | — |  |  | 3,900,000 |  |  | 4.71 | % |  | — |  |  | — | % |  | 3,900,000 |
|  | — |  |  | 368,125 |  |  | 1,650,000 |  |  | 6,900,000 |  |  |  |  | 349,556 |  |  |  |  | 9,267,681 |
Premiums, (discounts), and debt issuance costs, net |  | — |  |  | — |  |  | (3,088) |  |  | (133,650) |  |  |  |  | 618 |  |  |  |  | (136,120) |
|  | $ | — |  |  | $ | 368,125 |  |  | $ | 1,646,912 |  |  | $ | 6,766,350 |  |  |  |  | $ | 350,174 |  |  |  |  | $ | 9,131,561 |

_______________________________________
(1)As of September 30, 2025, total unamortized debt issuance costs for the Revolving Facility and Commercial Paper Program were $15 million, which are recorded in other assets, net on the Consolidated Balance Sheets.
(2)Commercial Paper Program borrowings are backstopped by the availability under the Revolving Facility. As such, the Company calculates the weighted average remaining term of its Commercial Paper Program borrowings using the maturity date of the Revolving Facility.
(3)Effective interest rates on the senior unsecured notes range from 1.54% to 6.87% with a weighted average effective interest rate of 4.16% and a weighted average maturity of approximately 5 years.
(4)Effective interest rates on the mortgage debt range from 3.43% to 7.03% with a weighted average effective interest rate of 4.99% and a weighted average maturity of approximately 1 year. These interest rates include the impact of designated interest rate swap instruments, which effectively fix the interest rate on certain variable rate debt.
(5)Represents the weighted-average effective interest rate as of the end of the applicable period, including amortization of debt premiums (discounts) and debt issuance costs.
Additionally, as of September 30, 2025, the Company had 16 outstanding letter of credit obligations totaling $16 million.
NOTE 11. Commitments and Contingencies

Legal Proceedings
From time to time, the Company is a party to legal proceedings, lawsuits and other claims that arise in the ordinary course of the Company’s business. The Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company’s financial condition, results of operations, or cash flows. The Company’s policy is to expense legal costs as they are incurred.
DownREITs and Other Partnerships
In connection with the formation of certain limited liability companies (“DownREITs”), members may contribute appreciated real estate to a DownREIT in exchange for DownREIT units. These contributions are generally tax-deferred, so that the pre-contribution gain related to the property is not taxed to the member. However, if a contributed property is later sold by the DownREIT, the unamortized pre-contribution gain that exists at the date of sale is specifically allocated and taxed to the contributing members. In many of the DownREITs, the Company has entered into indemnification agreements with those members who contributed appreciated property into the DownREIT. Under these indemnification agreements, if any of the appreciated real estate contributed by the members is sold by the DownREIT in a taxable transaction within a specified number of years, the Company will reimburse the affected members for the federal and state income taxes associated with the pre-contribution gain that is specially allocated to the affected member under the Internal Revenue Code (“make-whole payments”). These make-whole payments include a tax gross-up provision. As of September 30, 2025, the Company had indemnification agreements on a total of 28 properties within its DownREITs.
Additionally, the Company owns a 49% interest in the Lab JV (see Note 8). If the property in the joint venture is sold in a taxable transaction, the Company is generally obligated to indemnify its joint venture partner for its federal and state income taxes associated with the gain that existed at the time of the contribution to the joint venture.
27

Table of Contents
NOTE 12. Equity and Redeemable Noncontrolling Interests

Dividends
On October 6, 2025, the Company’s Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for each of October, November, and December 2025, payable on October 30, 2025, November 26, 2025, and December 30, 2025, respectively, to stockholders of record as of the close of business on October 17, 2025, November 14, 2025, and December 19, 2025, respectively.
During the three months ended September 30, 2025 and 2024, the Company declared and paid common stock cash dividends of $0.305 and $0.300 per share, respectively. During the nine months ended September 30, 2025 and 2024, the Company declared and paid common stock cash dividends of $0.915 and $0.900 per share, respectively.
Issuance of Common Stock in Connection with the Merger
Pursuant to the terms set forth in the Merger Agreement, on the Closing Date, each outstanding share of Physicians Realty Trust (other than Physicians Realty Trust common shares that were canceled in accordance with the Merger Agreement) automatically converted into the right to receive 0.674 shares of the Company’s common stock. Based on the number of outstanding Physicians Realty Trust common shares as of the Closing Date, the Company issued 162 million shares of common stock. Refer to Note 3 for additional information regarding the Merger.
At-The-Market Equity Offering Program
In February 2023, the Company terminated its previous at-the-market equity offering program and established a new at-the-market equity offering program (the “ATM Program”). The ATM Program was amended in: (i) March 2024 to contemplate the sale of the remaining shares of common stock pursuant to the Company’s Registration Statement on Form S-3 filed with the SEC on February 8, 2024 and (ii) each of May 2024 and February 2025 to add certain banks as sales agents, a forward seller, and a forward purchaser under the ATM Program. The ATM Program allows for the sale of shares of common stock having an aggregate gross sales price of up to $1.5 billion (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement (each, an “ATM forward contract”). The use of ATM forward contracts allows the Company to lock in a share price on the sale of shares at the time the ATM forward contract becomes effective, but defer receiving the proceeds from the sale of shares until a later date.
ATM forward contracts generally have a one- to two-year term. At any time during the term, the Company may settle a forward sale by delivery of physical shares of common stock to the forward seller or, at the Company’s election, in cash or net shares. The forward sale price the Company expects to receive upon settlement of outstanding ATM forward contracts will be the initial forward price established upon the effective date, subject to adjustments for: (i) accrued interest, (ii) the forward purchasers’ stock borrowing costs, and (iii) certain fixed price reductions during the term of the ATM forward contract.
At September 30, 2025, $1.5 billion of the Company’s common stock remained available for sale under the ATM Program.
ATM Forward Contracts
During each of the three and nine months ended September 30, 2025 and 2024, the Company did not utilize the forward provisions under the ATM Program.
ATM Direct Issuances
During each of the three and nine months ended September 30, 2025 and 2024, there were no direct issuances of shares of common stock under the ATM Program.
Share Repurchase Programs
On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $500 million (the “2022 Share Repurchase Program”). Purchases of common stock under the 2022 Share Repurchase Program could be exercised at the Company’s discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. Under Maryland General Corporation Law, outstanding shares of common stock acquired by a corporation become authorized but unissued shares, which may be re-issued. During the three months ended September 30, 2024, the Company repurchased 1.0 million shares of its common stock under the 2022 Share Repurchase Program at a weighted average price of $19.42 per share for a total of $20 million. During the nine months ended September 30, 2024, the Company repurchased 10.5 million shares of its common stock under the 2022 Share Repurchase Program at a weighted average price of $17.98 per share for a total of $188 million.
28

Table of Contents
On July 24, 2024, the Company’s Board of Directors approved a new share repurchase program (the “2024 Share Repurchase Program”) to supersede and replace the 2022 Share Repurchase Program. Upon adoption of the 2024 Share Repurchase Program, no further share repurchases may be made pursuant to the 2022 Share Repurchase Program. Under the 2024 Share Repurchase Program, the Company may acquire shares of its common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), up to an aggregate purchase price of $500 million. Purchases of common stock under the 2024 Share Repurchase Program may be exercised at the Company’s discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The 2024 Share Repurchase Program expires in July 2026 and may be suspended or terminated at any time without prior notice. During the three months ended September 30, 2025, there were no repurchases of common stock under the 2024 Share Repurchase Program. During the nine months ended September 30, 2025, the Company repurchased 5.09 million shares of its common stock under the 2024 Share Repurchase Program at a weighted average price of $18.50 per share for a total of $94 million. At September 30, 2025, $406 million remained available for the repurchase of the Company’s common stock under the 2024 Share Repurchase Program.
Accumulated Other Comprehensive Income (Loss)
The following table summarizes the Company’s accumulated other comprehensive income (loss) (in thousands):

|  | September 30, 2025 |  | December 31, 2024
Unrealized gains (losses) on derivatives, net |  | $ | (6,298) |  |  | $ | 30,707 |
Supplemental Executive Retirement Plan minimum liability |  | (1,677) |  |  | (1,889) |
Total accumulated other comprehensive income (loss) |  | $ | (7,975) |  |  | $ | 28,818 |

The Company has a defined benefit pension plan, known as the Supplemental Executive Retirement Plan, with one plan participant, a former Chief Executive Officer (“CEO”) of the Company who departed in 2003. Changes to the Supplemental Executive Retirement Plan minimum liability are reflected in other comprehensive income (loss).
Noncontrolling Interests
Redeemable Noncontrolling Interests
Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. Certain of the Company’s noncontrolling interest holders have the ability to put their equity interests to the Company upon specified events or after the passage of a predetermined period of time (each, a “Put Option”). Each Put Option is payable in cash and subject to changes in redemption value, which is generally based on the underlying property’s fair value. Accordingly, the Company records redeemable noncontrolling interests outside of permanent equity and presents the redeemable noncontrolling interests at the greater of their carrying amount or redemption value at the end of each reporting period. In addition to the rights of the redeemable noncontrolling interest holders, the Company has the ability to buy out the interests of certain noncontrolling interest holders. The values of the redeemable noncontrolling interests are subject to change based on the assessment of redemption value at each redemption date.
During the nine months ended September 30, 2025, the Company entered into two outpatient medical development joint ventures in which the noncontrolling interest holders have a Put Option.
As of September 30, 2025, the estimated redemption value of the redeemable noncontrolling interests with currently exercisable Put Options is $15 million. The estimated redemption value of the redeemable noncontrolling interests that will become exercisable upon completion of each of the related development projects is $13 million.
In April 2024, the Company exercised its option to buy out four redeemable noncontrolling interests that met the criteria for redemption. Accordingly, during the three months ended June 30, 2024, the Company made aggregate cash payments for the total redemption value of $53 million to the related noncontrolling interest holders and acquired the redeemable noncontrolling interests associated with the entities.
29

Table of Contents
Healthpeak OP
During each of the nine months ended September 30, 2025 and 2024, certain employees of the Company (“OP Unitholders”) were issued approximately 2 million non-managing member units in Healthpeak OP (“OP Units”), all of which were profits interests in Healthpeak OP. When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their OP Units for cash or shares of the Company’s common stock, at the Company’s option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of the Company’s common stock or cash equal to the fair value of a share of common stock at the time of redemption. The Company classifies the OP Units in permanent equity because it may elect, in its sole discretion, to issue shares of its common stock to OP Unitholders who choose to redeem their OP Units rather than using cash. As of September 30, 2025, there were approximately 4 million OP Units outstanding and 265 thousand had met the criteria for redemption. As of December 31, 2024, there were approximately 3 million OP Units outstanding and 76 thousand had met the criteria for redemption.
DownREITs
The non-managing member units of the Company’s DownREITs are exchangeable for an amount of cash approximating the then-current market value of shares of the Company’s common stock or, at the Company’s option, shares of the Company’s common stock (subject to certain adjustments, such as stock splits and reclassifications). Upon exchange of DownREIT units for the Company’s common stock, the carrying amount of the DownREIT units is reclassified to stockholders’ equity. At each of September 30, 2025 and December 31, 2024, there were approximately 11 million DownREIT units (13 million and 14 million shares of Healthpeak common stock are issuable upon conversion, respectively) outstanding in eight DownREIT LLCs, for all of which the Company holds a controlling interest and/or acts as the managing member. At September 30, 2025 and December 31, 2024, the carrying value of the 11 million DownREIT units was $307 million and $310 million, respectively.
NOTE 13. Earnings Per Common Share

Basic income (loss) per common share (“EPS”) is computed based on the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed based on the weighted average number of common shares outstanding plus the impact of forward equity sales agreements using the treasury stock method, common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, OP Units, and unvested restricted stock units. Only those instruments having a dilutive impact on the Company’s basic income (loss) per share are included in diluted income (loss) per share during the periods presented.
Certain restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share.
The Company considers the potential dilution resulting from forward agreements under its ATM Program to the calculation of earnings per share. At inception, the agreements do not have an effect on the computation of basic EPS as no shares are delivered until settlement. However, the Company uses the treasury stock method to calculate the dilution, if any, resulting from the forward sales agreements during the period of time prior to settlement. Refer to Note 12 for a discussion of the sale of shares under and settlement of forward sales agreements, of which there were none during the three and nine months ended September 30, 2025 and 2024.
30

Table of Contents
The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Numerator - Basic |  |  |  |  |  |  |
Net income (loss) | $ | (109,848) |  |  | $ | 92,738 |  |  | $ | (20,765) |  |  | $ | 256,631 |
Noncontrolling interests’ share in earnings | (7,274) |  |  | (6,866) |  |  | (21,856) |  |  | (18,036) |
Net income (loss) attributable to Healthpeak Properties, Inc. | (117,122) |  |  | 85,872 |  |  | (42,621) |  |  | 238,595 |
Less: Participating securities’ share in earnings | (134) |  |  | (197) |  |  | (714) |  |  | (610) |
Net income (loss) applicable to common shares | $ | (117,256) |  |  | $ | 85,675 |  |  | $ | (43,335) |  |  | $ | 237,985 |
Numerator - Dilutive |  |  |  |  |  |  |
Net income (loss) applicable to common shares | $ | (117,256) |  |  | $ | 85,675 |  |  | $ | (43,335) |  |  | $ | 237,985 |
Add: distributions on dilutive convertible units and other | — |  |  | 47 |  |  | — |  |  | 72 |
Dilutive net income (loss) available to common shares | $ | (117,256) |  |  | $ | 85,722 |  |  | $ | (43,335) |  |  | $ | 238,057 |
Denominator |  |  |  |  |  |  |
Basic weighted average shares outstanding | 694,930 |  |  | 699,349 |  |  | 696,380 |  |  | 667,536 |
Dilutive potential common shares - equity awards(1) | — |  |  | 137 |  |  | — |  |  | 150 |
Dilutive potential common shares - OP Units(2) | — |  |  | 660 |  |  | — |  |  | 410 |
Diluted weighted average common shares | 694,930 |  |  | 700,146 |  |  | 696,380 |  |  | 668,096 |
Earnings (loss) per common share |  |  |  |  |  |  |
Basic | $ | (0.17) |  |  | $ | 0.12 |  |  | $ | (0.06) |  |  | $ | 0.36 |
Diluted | $ | (0.17) |  |  | $ | 0.12 |  |  | $ | (0.06) |  |  | $ | 0.36 |

_______________________________________
(1)For each of the three and nine months ended September 30, 2025, the 1 million outstanding equity awards (restricted stock units and stock options) were anti-dilutive. For each of the three and nine months ended September 30, 2024, represents the dilutive impact of 1 million outstanding equity awards (restricted stock units and stock options).
(2)For each of the three and nine months ended September 30, 2025, all 4 million outstanding OP Units were anti-dilutive. For each of the three and nine months ended September 30, 2024, represents the dilutive impact of 3 million outstanding OP Units.
For each of the three and nine months ended September 30, 2025, all 13 million shares issuable upon conversion of DownREIT units were not included because they were anti-dilutive. For each of the three and nine months ended September 30, 2024, all 14 million shares issuable upon conversion of DownREIT units were not included because they were anti-dilutive.
31

Table of Contents
NOTE 14. Segment Disclosures

The Company’s operating segments, based on how its CODM, the President and Chief Executive Officer, evaluates the business and allocates resources, are as follows: (i) outpatient medical, (ii) lab, (iii) CCRC, (iv) an interest in an unconsolidated joint venture that owns 19 senior housing assets (the “SWF SH JV”), (v) loans receivable, and (vi) a preferred equity investment. The Company’s reportable segments, as determined in accordance with ASC 280, Segment Reporting, are as follows: (i) outpatient medical, (ii) lab, and (iii) CCRC. The SWF SH JV, loans receivable, and preferred equity investment are non-reportable segments that have been presented on a combined basis within the Notes to the Consolidated Financial Statements herein. The accounting policies of the segments are the same as those described in Note 2 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC, as updated by Note 2 herein.
The CODM evaluates performance based on property Adjusted NOI. Adjusted NOI is used to evaluate performance because it provides relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and presenting it on an unlevered basis. Adjusted NOI represents real estate revenues (inclusive of rental and related revenues, resident fees and services, and government grant income and exclusive of interest income), less property level operating expenses; Adjusted NOI excludes all other financial statement amounts included in net income (loss). Adjusted NOI eliminates the effects of straight-line rents, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense.
Adjusted NOI is calculated as Adjusted NOI from consolidated properties, plus the Company’s share of Adjusted NOI from unconsolidated joint ventures (calculated by applying the Company’s actual ownership percentage for the period), less noncontrolling interests’ share of Adjusted NOI from consolidated joint ventures (calculated by applying the Company’s actual ownership percentage for the period). Management utilizes its share of Adjusted NOI in assessing its performance as the Company has various joint ventures that contribute to its performance.
Segment assets consist of real estate assets, intangible assets, and right-of-use assets. Non-segment assets consist of assets in the Company’s other non-reportable segments and corporate non-segment assets. Corporate non-segment assets consist primarily of corporate assets, including cash and cash equivalents, restricted cash, accounts receivable, other assets, and real estate assets held for sale. Reportable segment asset information is not provided to the CODM as the CODM does not use segment asset information to evaluate the business and allocate resources.
32

Table of Contents
The following table summarizes financial information for the reportable segments for the three months ended September 30, 2025 (in thousands):

|  | Outpatient Medical |  | Lab |  | CCRC |  |  |  |  |  | Total
Total revenues |  | $ | 326,561 |  |  | $ | 213,325 |  |  | $ | 150,458 |  |  |  |  |  |  | $ | 690,344 |
Healthpeak’s share of unconsolidated joint venture total revenues |  | 7,327 |  |  | 6,834 |  |  | — |  |  |  |  |  |  | 14,161 |
Noncontrolling interests’ share of consolidated joint venture total revenues |  | (10,334) |  |  | — |  |  | — |  |  |  |  |  |  | (10,334) |
Operating expenses(1) |  | (113,660) |  |  | (64,352) |  |  | (113,910) |  |  |  |  |  |  | (291,922) |
Healthpeak’s share of unconsolidated joint venture operating expenses |  | (2,887) |  |  | (2,229) |  |  | — |  |  |  |  |  |  | (5,116) |
Noncontrolling interests’ share of consolidated joint venture operating expenses |  | 3,765 |  |  | — |  |  | — |  |  |  |  |  |  | 3,765 |
Adjustments to NOI(2) |  | (10,358) |  |  | (15,520) |  |  | — |  |  |  |  |  |  | (25,878) |
Adjusted NOI for reportable segments |  | $ | 200,414 |  |  | $ | 138,058 |  |  | $ | 36,548 |  |  |  |  |  |  | $ | 375,020 |
Plus: Adjustments to NOI(2) |  |  |  |  |  |  |  |  |  |  |  | 25,878 |
Interest income and other |  |  |  |  |  |  |  |  |  |  |  | 15,529 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  | (76,784) |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  | (262,317) |
General and administrative |  |  |  |  |  |  |  |  |  |  |  | (19,907) |
Transaction and merger-related costs |  |  |  |  |  |  |  |  |  |  |  | (2,420) |
Impairments and loan loss reserves, net |  |  |  |  |  |  |  |  |  |  |  | 54 |
Gain (loss) on sales of real estate, net |  |  |  |  |  |  |  |  |  |  |  | 11,500 |
Other income (expense), net |  |  |  |  |  |  |  |  |  |  |  | 1,160 |
Less: Healthpeak’s share of unconsolidated joint venture Adjusted NOI |  |  |  |  |  |  |  |  |  |  |  | (9,045) |
Plus: Noncontrolling interests’ share of consolidated joint venture Adjusted NOI |  |  |  |  |  |  |  |  |  |  |  | 6,569 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |  |  |  |  |  | $ | 65,237 |

_______________________________________
(1)See reconciliation of significant expense categories below.
(2)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.
The following table summarizes the Company’s significant expense categories by reportable segment for the three months ended September 30, 2025 (in thousands):

|  | Outpatient Medical |  | Lab |  | CCRC
Compensation and property management |  | $ | 15,451 |  |  | $ | 8,484 |  |  | $ | 71,809 |
Food |  | — |  |  | — |  |  | 6,855 |
Real estate taxes |  | 25,584 |  |  | 19,500 |  |  | 4,073 |
Repairs and maintenance |  | 17,848 |  |  | 8,966 |  |  | 5,461 |
Utilities |  | 21,614 |  |  | 14,855 |  |  | 6,278 |
Other segment items(1) |  | 33,163 |  |  | 12,547 |  |  | 19,434 |
Operating expenses |  | $ | 113,660 |  |  | $ | 64,352 |  |  | $ | 113,910 |

_______________________________________
(1)Other segment items for each segment include:
•Outpatient medical and lab – (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.
•CCRC – (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense.
33

Table of Contents
The following table summarizes financial information for the reportable segments for the three months ended September 30, 2024 (in thousands):

|  | Outpatient Medical |  | Lab |  | CCRC |  |  |  |  |  | Total |
Total revenues |  | $ | 317,659 |  |  | $ | 225,592 |  |  | $ | 142,845 |  |  |  |  |  |  | $ | 686,096 |  |
Healthpeak’s share of unconsolidated joint venture total revenues |  | 7,065 |  |  | 5,242 |  |  | — |  |  |  |  |  |  | 12,307 |  |
Noncontrolling interests’ share of consolidated joint venture total revenues |  | (9,734) |  |  | — |  |  | — |  |  |  |  |  |  | (9,734) |  |
Operating expenses(1) |  | (106,484) |  |  | (64,075) |  |  | (109,720) |  |  |  |  |  |  | (280,279) |  |
Healthpeak’s share of unconsolidated joint venture operating expenses |  | (2,832) |  |  | (1,811) |  |  | — |  |  |  |  |  |  | (4,643) |  |
Noncontrolling interests’ share of consolidated joint venture operating expenses |  | 2,851 |  |  | — |  |  | — |  |  |  |  |  |  | 2,851 |  |
Adjustments to NOI(2) |  | (11,020) |  |  | (16,900) |  |  | 95 |  |  |  |  |  |  | (27,825) |  |
Adjusted NOI for reportable segments |  | $ | 197,505 |  |  | $ | 148,048 |  |  | $ | 33,220 |  |  |  |  |  |  | $ | 378,773 |  |
Plus: Adjustments to NOI(2) |  |  |  |  |  |  |  |  |  |  |  | 27,825 |  |
Interest income and other |  |  |  |  |  |  |  |  |  |  |  | 14,301 |  |
Interest expense |  |  |  |  |  |  |  |  |  |  |  | (74,105) |  |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  | (280,019) |  |
General and administrative |  |  |  |  |  |  |  |  |  |  |  | (23,216) |  |
Transaction and merger-related costs |  |  |  |  |  |  |  |  |  |  |  | (7,134) |  |
Impairments and loan loss reserves, net |  |  |  |  |  |  |  |  |  |  |  | (441) |  |
Gain (loss) on sales of real estate, net |  |  |  |  |  |  |  |  |  |  |  | 62,325 |  |
Other income (expense), net |  |  |  |  |  |  |  |  |  |  |  | 982 |  |
Less: Healthpeak’s share of unconsolidated joint venture Adjusted NOI |  |  |  |  |  |  |  |  |  |  |  | (7,664) |  |
Plus: Noncontrolling interests’ share of consolidated joint venture Adjusted NOI |  |  |  |  |  |  |  |  |  |  |  | 6,883 |  |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |  |  |  |  |  | $ | 98,510 |  |

_______________________________________
(1)See reconciliation of significant expense categories below.
(2)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.
The following table summarizes the Company’s significant expense categories by reportable segment for the three months ended September 30, 2024 (in thousands):

|  | Outpatient Medical |  | Lab |  | CCRC
Compensation and property management |  | $ | 14,527 |  |  | $ | 7,835 |  |  | $ | 69,873 |
Food |  | — |  |  | — |  |  | 6,563 |
Real estate taxes |  | 23,861 |  |  | 19,830 |  |  | 3,989 |
Repairs and maintenance |  | 16,241 |  |  | 7,768 |  |  | 4,692 |
Utilities |  | 20,437 |  |  | 16,535 |  |  | 6,042 |
Other segment items(1) |  | 31,418 |  |  | 12,107 |  |  | 18,561 |
Operating expenses |  | $ | 106,484 |  |  | $ | 64,075 |  |  | $ | 109,720 |

_______________________________________
(1)Other segment items for each segment include:
•Outpatient medical and lab – (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.
•CCRC – (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense.
34

Table of Contents
The following table summarizes financial information for the reportable segments for the nine months ended September 30, 2025 (in thousands):

|  | Outpatient Medical |  | Lab |  | CCRC |  |  |  |  |  | Total
Total revenues |  | $ | 967,591 |  |  | $ | 640,123 |  |  | $ | 448,240 |  |  |  |  |  |  | $ | 2,055,954 |
Healthpeak’s share of unconsolidated joint venture total revenues |  | 21,769 |  |  | 16,992 |  |  | — |  |  |  |  |  |  | 38,761 |
Noncontrolling interests’ share of consolidated joint venture total revenues |  | (30,327) |  |  | — |  |  | — |  |  |  |  |  |  | (30,327) |
Operating expenses(1) |  | (324,216) |  |  | (181,412) |  |  | (335,618) |  |  |  |  |  |  | (841,246) |
Healthpeak’s share of unconsolidated joint venture operating expenses |  | (8,576) |  |  | (5,793) |  |  | — |  |  |  |  |  |  | (14,369) |
Noncontrolling interests’ share of consolidated joint venture operating expenses |  | 9,344 |  |  | — |  |  | — |  |  |  |  |  |  | 9,344 |
Adjustments to NOI(2) |  | (33,253) |  |  | (42,844) |  |  | (844) |  |  |  |  |  |  | (76,941) |
Adjusted NOI for reportable segments |  | $ | 602,332 |  |  | $ | 427,066 |  |  | $ | 111,778 |  |  |  |  |  |  | $ | 1,141,176 |
Plus: Adjustments to NOI(2) |  |  |  |  |  |  |  |  |  |  |  | 76,941 |
Interest income and other |  |  |  |  |  |  |  |  |  |  |  | 47,156 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  | (224,540) |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  | (796,779) |
General and administrative |  |  |  |  |  |  |  |  |  |  |  | (66,789) |
Transaction and merger-related costs |  |  |  |  |  |  |  |  |  |  |  | (18,169) |
Impairments and loan loss reserves, net |  |  |  |  |  |  |  |  |  |  |  | 117 |
Gain (loss) on sales of real estate, net |  |  |  |  |  |  |  |  |  |  |  | 13,136 |
Other income (expense), net |  |  |  |  |  |  |  |  |  |  |  | (9,658) |
Less: Healthpeak’s share of unconsolidated joint venture Adjusted NOI |  |  |  |  |  |  |  |  |  |  |  | (24,392) |
Plus: Noncontrolling interests’ share of consolidated joint venture Adjusted NOI |  |  |  |  |  |  |  |  |  |  |  | 20,983 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |  |  |  |  |  | $ | 159,182 |

_______________________________________
(1)See reconciliation of significant expense categories below.
(2)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.
The following table summarizes the Company’s significant expense categories by reportable segment for the nine months ended September 30, 2025 (in thousands):

|  | Outpatient Medical |  | Lab |  | CCRC
Compensation and property management |  | $ | 45,089 |  |  | $ | 25,071 |  |  | $ | 213,558 |
Food |  | — |  |  | — |  |  | 20,080 |
Real estate taxes |  | 74,963 |  |  | 57,510 |  |  | 12,905 |
Repairs and maintenance |  | 48,741 |  |  | 24,526 |  |  | 15,181 |
Utilities |  | 57,858 |  |  | 35,965 |  |  | 17,660 |
Other segment items(1) |  | 97,565 |  |  | 38,340 |  |  | 56,234 |
Operating expenses |  | $ | 324,216 |  |  | $ | 181,412 |  |  | $ | 335,618 |

_______________________________________
(1)Other segment items for each segment include:
•Outpatient medical and lab – (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.
•CCRC – (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense.
35

Table of Contents
The following table summarizes financial information for the reportable segments for the nine months ended September 30, 2024 (in thousands):

|  | Outpatient Medical |  | Lab |  | CCRC |  |  |  |  |  | Total
Total revenues |  | $ | 888,446 |  |  | $ | 663,619 |  |  | $ | 422,512 |  |  |  |  |  |  | $ | 1,974,577 |
Healthpeak’s share of unconsolidated joint venture total revenues |  | 16,707 |  |  | 14,404 |  |  | — |  |  |  |  |  |  | 31,111 |
Noncontrolling interests’ share of consolidated joint venture total revenues |  | (27,952) |  |  | (196) |  |  | — |  |  |  |  |  |  | (28,148) |
Operating expenses(1) |  | (299,455) |  |  | (177,571) |  |  | (320,809) |  |  |  |  |  |  | (797,835) |
Healthpeak’s share of unconsolidated joint venture operating expenses |  | (6,380) |  |  | (4,663) |  |  | — |  |  |  |  |  |  | (11,043) |
Noncontrolling interests’ share of consolidated joint venture operating expenses |  | 7,889 |  |  | 52 |  |  | — |  |  |  |  |  |  | 7,941 |
Adjustments to NOI(2) |  | (27,573) |  |  | (51,624) |  |  | (1,645) |  |  |  |  |  |  | (80,842) |
Adjusted NOI for reportable segments |  | $ | 551,682 |  |  | $ | 444,021 |  |  | $ | 100,058 |  |  |  |  |  |  | $ | 1,095,761 |
Plus: Adjustments to NOI(2) |  |  |  |  |  |  |  |  |  |  |  | 80,842 |
Interest income and other |  |  |  |  |  |  |  |  |  |  |  | 27,884 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  | (209,922) |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  | (782,736) |
General and administrative |  |  |  |  |  |  |  |  |  |  |  | (73,233) |
Transaction and merger-related costs |  |  |  |  |  |  |  |  |  |  |  | (122,113) |
Impairments and loan loss reserves, net |  |  |  |  |  |  |  |  |  |  |  | (11,346) |
Gain (loss) on sales of real estate, net |  |  |  |  |  |  |  |  |  |  |  | 187,624 |
Other income (expense), net |  |  |  |  |  |  |  |  |  |  |  | 83,502 |
Less: Healthpeak’s share of unconsolidated joint venture Adjusted NOI |  |  |  |  |  |  |  |  |  |  |  | (20,068) |
Plus: Noncontrolling interests’ share of consolidated joint venture Adjusted NOI |  |  |  |  |  |  |  |  |  |  |  | 20,207 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |  |  |  |  |  | $ | 276,402 |

_______________________________________
(1)See reconciliation of significant expense categories below.
(2)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.
The following table summarizes the Company’s significant expense categories by reportable segment for the nine months ended September 30, 2024 (in thousands):

|  | Outpatient Medical |  | Lab |  | CCRC
Compensation and property management |  | $ | 40,802 |  |  | $ | 24,257 |  |  | $ | 205,979 |
Food |  | — |  |  | — |  |  | 19,632 |
Real estate taxes |  | 71,795 |  |  | 58,534 |  |  | 12,567 |
Repairs and maintenance |  | 44,337 |  |  | 21,586 |  |  | 13,884 |
Utilities |  | 52,120 |  |  | 38,632 |  |  | 16,750 |
Other segment items(1) |  | 90,401 |  |  | 34,562 |  |  | 51,997 |
Operating expenses |  | $ | 299,455 |  |  | $ | 177,571 |  |  | $ | 320,809 |

_______________________________________
(1)Other segment items for each segment include:
•Outpatient medical and lab – (i) Cleaning expense, (ii) ground rent expense, (iii) insurance expense, (iv) roads and grounds expense, (v) security expense, and (vi) other administrative expense.
•CCRC – (i) Cleaning and supplies, (ii) insurance expense, (iii) marketing expense, and (iv) other administrative expense.
36

Table of Contents
The following table summarizes the Company’s revenues by reportable segment (in thousands):

|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
Segment |  | 2025 |  | 2024 |  | 2025 |  | 2024
Outpatient medical |  | $ | 326,561 |  |  | $ | 317,659 |  |  | $ | 967,591 |  |  | $ | 888,446 |
Lab |  | 213,325 |  |  | 225,592 |  |  | 640,123 |  |  | 663,619 |
CCRC |  | 150,458 |  |  | 142,845 |  |  | 448,240 |  |  | 422,512 |
Total revenues for reportable segments |  | 690,344 |  |  | 686,096 |  |  | 2,055,954 |  |  | 1,974,577 |
Interest income and other |  | 15,529 |  |  | 14,301 |  |  | 47,156 |  |  | 27,884 |
Total revenues |  | $ | 705,873 |  |  | $ | 700,397 |  |  | $ | 2,103,110 |  |  | $ | 2,002,461 |

NOTE 15. Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in thousands):

|  | Nine Months Ended September 30,
|  | 2025 |  | 2024
Supplemental cash flow information: |  |  |  |
Interest paid, net of capitalized interest |  | $ | 219,686 |  |  | $ | 204,858 |
Income taxes paid (refunded), net |  | 2,089 |  |  | 6,820 |
Capitalized interest |  | 63,541 |  |  | 48,446 |
Supplemental schedule of non-cash investing and financing activities: |  |  |  |
Accrued construction costs |  | 164,460 |  |  | 120,543 |
Increase in ROU asset in exchange for new lease liability related to operating leases |  | 7,049 |  |  | 15,406 |
Retained investment in connection with Callan Ridge JV (see Note 8) |  | — |  |  | 69,255 |
Non-cash assets and liabilities assumed in connection with the Merger (see Note 3) |  | — |  |  | 2,927,611 |
Seller financing provided on disposition of real estate assets (see Note 7) |  | — |  |  | 404,598 |

The following table summarizes cash, cash equivalents, and restricted cash (in thousands):

|  | Nine Months Ended September 30,
|  | 2025 |  | 2024 |  |  |  |  |  |  |  |
Beginning of period: |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 119,818 |  |  | $ | 117,635 |  |  |  |  |  |  |  |  |
Restricted cash |  | 64,487 |  |  | 51,388 |  |  |  |  |  |  |  |  |
Cash, cash equivalents, and restricted cash |  | $ | 184,305 |  |  | $ | 169,023 |  |  |  |  |  |  |  |  |
End of period: |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 91,038 |  |  | $ | 180,430 |  |  |  |  |  |  |  |  |
Restricted cash |  | 68,694 |  |  | 61,615 |  |  |  |  |  |  |  |  |
Cash, cash equivalents, and restricted cash |  | $ | 159,732 |  |  | $ | 242,045 |  |  |  |  |  |  |  |  |

Cash and Cash Equivalents
The Company maintains its cash and cash equivalents at financial institutions insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per institution. As of September 30, 2025 and December 31, 2024, the account balances at certain institutions exceeded the FDIC insurance coverage.
37

Table of Contents
NOTE 16. Variable Interest Entities

Operating Subsidiary
Healthpeak OP is the Company’s operating subsidiary and a limited liability company that has governing provisions that are the functional equivalent of a limited partnership. The Company holds a membership interest in Healthpeak OP, acts as the managing member of Healthpeak OP, and exercises full responsibility, discretion, and control over the day-to-day management of Healthpeak OP. Because the noncontrolling interests in Healthpeak OP do not have substantive liquidation rights, substantive kick-out rights without cause, or substantive participating rights, the Company has determined that Healthpeak OP is a VIE. The Company, as managing member, has the power to direct the core activities of Healthpeak OP that most significantly affect Healthpeak OP’s performance, and through its interest in Healthpeak OP, has both the right to receive benefits from and the obligation to absorb losses of Healthpeak OP. Accordingly, the Company is the primary beneficiary of Healthpeak OP and consolidates Healthpeak OP. As the Company conducts its business and holds its assets and liabilities through Healthpeak OP, the total consolidated assets and liabilities, income (losses), and cash flows of Healthpeak OP represent substantially all of the total consolidated assets and liabilities, including the consolidated and unconsolidated entities discussed in this Note 16, income (losses), and cash flows of the Company.
Unconsolidated Variable Interest Entities
The Company has investments in certain unconsolidated VIEs. The Company determined it is not the primary beneficiary of and therefore does not consolidate these VIEs because it does not have the ability to control the activities that most significantly impact their economic performance. Except for the Company’s equity interest in the unconsolidated joint ventures, as more fully discussed below, it has no formal involvement in these VIEs beyond its investments.
LLC Investment. The Company holds a limited partner ownership interest in an unconsolidated LLC (“LLC Investment”) that has been identified as a VIE. The Company’s involvement in the entity is limited to its equity investment as a limited partner and it does not have any substantive participating rights or kick-out rights over the general partner and given its rights and ownership percentage, the Company has virtually no influence or control. The assets and liabilities of the entity primarily consist of three hospitals as well as senior housing real estate. Any assets generated by the entity may only be used to settle its contractual obligations (primarily capital expenditures and debt service payments).
Other Equity Investments. The Company holds certain limited partner interests in funds that make venture capital investments in various early-stage technology solutions (“Other Equity Investments”). As of September 30, 2025, the Company had an aggregate commitment of $12 million related to its Other Equity Investments and as of September 30, 2025 and December 31, 2024, the Company’s total investments aggregated $3 million and $1 million, respectively. The Other Equity Investments have been identified as VIEs. The Company’s involvement in the entities is limited to its equity investment as a limited partner and it does not have any substantive participating rights or kick-out rights over the general partner and given its rights and ownership percentage, the Company has virtually no influence or control. The assets and liabilities of the entities primarily consist of its capital investments. All future investments will be funded with capital contributions from the Company and other limited partners in accordance with their respective commitments.
Needham Land Parcel JV. In December 2021, the Company acquired a 38% interest in a lab development joint venture in Needham, Massachusetts for $13 million. Current equity at risk is not sufficient to finance the joint venture’s activities. The assets and liabilities of the entity primarily consist of real estate and debt service obligations. Any assets generated by the entity may only be used to settle its contractual obligations (primarily development costs and debt service payments).
HQ Point Preferred Equity Investment. In February 2025, the Company made a preferred equity investment in a joint venture that holds a lab campus under development in San Diego, California. As of September 30, 2025, the Company had funded $45 million of its investment. Current equity at risk is not sufficient to finance the entity’s activities. The assets and liabilities of the entity primarily consist of real estate and debt service obligations. Any assets generated by the entity may only be used to settle its contractual obligations (primarily development costs and debt service payments).
Loans Receivable Investments. In March 2025, the Company entered into an agreement to provide aggregate financing of $41 million to fund the development of an outpatient medical building in Dallas, Texas. The borrower entity for these investments meets the criteria of a VIE in accordance with ASC 810, Consolidation, and the Company is not the primary beneficiary of the borrower.
38

Table of Contents
The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company’s involvement with these VIEs at September 30, 2025 was as follows (in thousands):

VIE Type |  | Asset Type |  | Maximum Loss Exposure and Carrying Amount(1)
LLC Investment and Other Equity Investments |  | Other assets, net |  | $ | 17,515 |
Needham Land Parcel JV and HQ Point Preferred Equity Investment |  | Investments in and advances to unconsolidated joint ventures |  | 59,308 |
Loans Receivable Investments |  | Loans receivable, net |  | 7,048 |

_______________________________________
(1)The Company’s maximum loss exposure represents the aggregate carrying amount of such investments.
As of September 30, 2025, the Company had not provided, and is not required to provide, financial support through a liquidity arrangement or otherwise, to its unconsolidated VIEs, including under circumstances in which it could be exposed to further losses (e.g., cash shortfalls).
Consolidated Variable Interest Entities
The Company’s consolidated total assets and total liabilities at September 30, 2025 and December 31, 2024 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to the Company.
Ventures V, LLC. The Company holds a 51% ownership interest in and is the managing member of a joint venture entity formed in October 2015 that owns and leases outpatient medical buildings (“Ventures V”). The Company classifies Ventures V as a VIE due to the non-managing member lacking substantive participation rights in the management of Ventures V or kick-out rights over the managing member. The Company consolidates Ventures V as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of Ventures V primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by Ventures V may only be used to settle its contractual obligations.
MSREI JV. The Company holds a 51% ownership interest in, and is the managing member of, a joint venture entity formed in August 2018 that owns and leases outpatient medical buildings (the “MSREI JV”). The MSREI JV is a VIE due to the non-managing member lacking substantive participation rights in the management of the joint venture or kick-out rights over the managing member. The Company consolidates the MSREI JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of the MSREI JV primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by the MSREI JV may only be used to settle its contractual obligations.
DownREITs. As of September 30, 2025 and December 31, 2024, the Company held a controlling ownership interest in and was the managing member of eight DownREITs. The Company classifies the DownREITs as VIEs due to the non-managing members lacking substantive participation rights in the management of the DownREITs or kick-out rights over the managing member. The Company consolidates the DownREITs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the DownREITs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of capital expenditures for the properties, debt service payments, and with respect to DOC DR OP Sub, certain guarantees. Assets generated by the DownREITs (primarily from tenant rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).
Other Consolidated Real Estate Partnerships. The Company holds a controlling ownership interest in and is the general partner (or managing member) of multiple partnerships that own and lease real estate assets (the “Partnerships”). The Company classifies the Partnerships as VIEs due to the limited partners (non-managing members) lacking substantive participation rights in the management of the Partnerships or kick-out rights over the general partner (managing member). The Company consolidates the Partnerships as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Partnerships primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Partnerships (primarily from tenant rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).
39

Table of Contents
Total assets and total liabilities include VIE assets and liabilities, excluding those of Healthpeak OP, as follows (in thousands):

| September 30, 2025 |  | December 31, 2024 |
Assets |  |  |  |
Buildings and improvements | $ | 4,707,134 |  |  | $ | 4,669,914 |  |
Development costs and construction in progress | 135,076 |  |  | 92,710 |  |
Land and improvements | 474,058 |  |  | 472,232 |  |
Accumulated depreciation and amortization | (895,705) |  |  | (761,759) |  |
Net real estate | 4,420,563 |  |  | 4,473,097 |  |
Loans receivable, net | 566,552 |  |  | 550,829 |  |
Investments in and advances to unconsolidated joint ventures | 25,481 |  |  | 39,946 |  |
Accounts receivable, net | 23,273 |  |  | 17,357 |  |
Cash and cash equivalents | 43,806 |  |  | 32,421 |  |
Restricted cash | 2,885 |  |  | 1,029 |  |
Intangible assets, net | 490,005 |  |  | 629,802 |  |
Assets held for sale, net(1) | 35,244 |  |  | — |  |
Right-of-use asset, net | 269,797 |  |  | 270,918 |  |
Other assets, net | 180,651 |  |  | 173,435 |  |
Total assets | $ | 6,058,257 |  |  | $ | 6,188,834 |  |
Liabilities |  |  |  |
Term loans | $ | 401,502 |  |  | $ | 401,895 |  |
Senior unsecured notes | 1,164,248 |  |  | 1,151,801 |  |
Mortgage debt | 245,691 |  |  | 247,776 |  |
Intangible liabilities, net | 80,210 |  |  | 95,315 |  |
Liabilities related to assets held for sale, net(1) | 11,798 |  |  | — |  |
Lease liability | 195,277 |  |  | 193,421 |  |
Accounts payable, accrued liabilities, and other liabilities | 142,859 |  |  | 125,688 |  |
Deferred revenue | 61,217 |  |  | 65,358 |  |
Total liabilities | $ | 2,302,802 |  |  | $ | 2,281,254 |  |

_______________________________________
(1)Relates to four assets classified as held for sale as of September 30, 2025. Assets held for sale, net, primarily includes: (i) net real estate of $27 million and (ii) right-of-use assets of $7 million. Liabilities related to assets held for sale, net, primarily includes: (i) lease liabilities of $9 million and (ii) deferred revenue of $3 million.
40

Table of Contents
NOTE 17. Fair Value Measurements

The table below summarizes the carrying amounts and fair values of the Company’s financial instruments either recorded or disclosed on a recurring basis (in thousands):

| September 30, 2025(3) |  | December 31, 2024(3)
| Carrying Value |  | Fair Value |  | Carrying Value |  | Fair Value
Loans receivable, net(2) | $ | 673,502 |  |  | $ | 688,697 |  |  | $ | 717,190 |  |  | $ | 729,637 |
Interest rate swap assets(2) | 7,742 |  |  | 7,742 |  |  | 35,120 |  |  | 35,120 |
Bank line of credit and commercial paper(2) | 368,125 |  |  | 368,125 |  |  | 150,000 |  |  | 150,000 |
Term loans(2) | 1,646,912 |  |  | 1,646,912 |  |  | 1,646,043 |  |  | 1,646,043 |
Senior unsecured notes(1) | 6,766,350 |  |  | 6,781,049 |  |  | 6,563,256 |  |  | 6,373,528 |
Mortgage debt(2) | 350,174 |  |  | 348,418 |  |  | 356,750 |  |  | 350,292 |
Interest rate swap liabilities(2) | 10,118 |  |  | 10,118 |  |  | — |  |  | — |

_______________________________________
(1)Level 1: Fair value is calculated based on quoted prices in active markets.
(2)Level 2: For loans receivable, net, interest rate swap instruments, and mortgage debt, fair value is based on standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit, commercial paper, and term loans, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating.
(3)During the nine months ended September 30, 2025 and year ended December 31, 2024, there were no material transfers of financial assets or liabilities within the fair value hierarchy.
NOTE 18. Derivative Financial Instruments

The Company uses derivative instruments to mitigate the effects of interest rate fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. Utilizing derivative instruments allows the Company to manage the risk of fluctuations in interest rates and their related potential impact on future earnings and cash flows. The Company does not use derivative instruments for speculative or trading purposes. At September 30, 2025, a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by up to $43 million.
In April 2022, the Company entered into two interest rate swap instruments that are designated as cash flow hedges and mature in May 2026 on $142 million of variable rate mortgage debt secured by a portfolio of outpatient medical buildings (see Note 10). In February 2023, the Company modified these two interest rate swap instruments to reflect the change in the related variable rate mortgage debt’s interest rate benchmarks from LIBOR to SOFR (see Note 10).
In August 2022, the Company entered into two forward-starting interest rate swap instruments on the $500 million aggregate principal amount of the 2027 Term Loans (see Note 10). The interest rate swap instruments are designated as cash flow hedges.
In January 2024, the Company entered into forward-starting interest rate swap instruments on the $750 million aggregate principal amount of the 2029 Term Loan (see Note 10). The interest rate swap instruments are designated as cash flow hedges.
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, the Company acquired: (i) three interest rate swap instruments on the $400 million aggregate principal amount of the 2028 Term Loan that are designated as cash flow hedges and (ii) one interest rate swap instrument on $36 million of variable rate mortgage debt that was designated as a cash flow hedge (see Note 10), prior to its maturity in October 2024.
41

Table of Contents
The following table summarizes the Company’s interest rate swap instruments (in thousands):

|  |  |  |  |  | Fair Value(2) |  |  |  |  |  |
Date Entered(1) | Maturity Date | Hedge Designation | Notional Amount | Pay Rate | Receive Rate | September 30, 2025 |  | December 31, 2024 |  |  |  |  |  |
Interest rate swap assets: |  |  |  |  |  |  |  |  |  |  |  |  |
April 2022 | May 2026 | Cash flow | $ | 51,100 |  | 4.99 % | USD-SOFR w/ -5 Day Lookback + 2.50% | $ | 382 |  |  | $ | 1,050 |  |  |  |  |  |  |
April 2022 | May 2026 | Cash flow | 91,000 |  | 4.54 % | USD-SOFR w/ -5 Day Lookback + 2.05% | 680 |  |  | 1,870 |  |  |  |  |  |  |
August 2022 | February 2027 | Cash flow | 250,000 |  | 2.60 % | 1 mo. USD-SOFR CME Term | 2,913 |  |  | 7,224 |  |  |  |  |  |  |
August 2022 | August 2027 | Cash flow | 250,000 |  | 2.54 % | 1 mo. USD-SOFR CME Term | 3,767 |  |  | 9,122 |  |  |  |  |  |  |
May 2023(3)(4) | May 2028 | Cash flow | 400,000 |  | 3.59 % | USD-SOFR w/ -5 Day Lookback | — |  |  | 4,887 |  |  |  |  |  |  |
January 2024(5) | February 2029 | Cash flow | 750,000 |  | 3.59 % | USD-SOFR w/ -5 Day Lookback | — |  |  | 10,967 |  |  |  |  |  |  |
Total interest rate swap assets | $ | 7,742 |  |  | $ | 35,120 |  |  |  |  |  |  |
Interest rate swap liabilities: |  |  |  |  |  |  |  |  |
May 2023(3)(4) | May 2028 | Cash flow | $ | 400,000 |  | 3.59 % | USD-SOFR w/ -5 Day Lookback | $ | (2,961) |  |  | $ | — |  |  |  |  |  |  |
January 2024(5) | February 2029 | Cash flow | 750,000 |  | 3.59 % | USD-SOFR w/ -5 Day Lookback | (7,157) |  |  | — |  |  |  |  |  |  |
Total interest rate swap liabilities |  |  |  |  | $ | (10,118) |  |  | $ | — |  |  |  |  |  |  |

_____________________________
(1)Represents interest rate swap instruments that hedge fluctuations in interest payments on variable rate debt by converting the interest rates to fixed interest rates. The changes in fair value of designated derivatives that qualify as cash flow hedges are recorded in accumulated other comprehensive income (loss) on the Consolidated Balance Sheets.
(2)Derivative assets are recorded at fair value in other assets, net and derivative liabilities are recorded at fair value in accounts payable, accrued liabilities, and other liabilities on the Consolidated Balance Sheets.
(3)Includes interest rate swap instruments acquired as part of the Merger (see Note 3). These interest rate swap instruments were redesignated as cash flow hedges on the Closing Date. As a result of the Merger, the aggregate fair value of these interest rate swap instruments was determined to be $7 million on March 1, 2024, which was recognized within other assets, net on the Consolidated Balance Sheets on the Closing Date. The aggregate fair value as of the Closing Date is being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related interest rate swap instruments. During the three months ended September 30, 2025 and 2024, the Company recognized $0.4 million and $1 million, respectively, of related amortization into interest expense. During the nine months ended September 30, 2025 and 2024, the Company recognized $1 million and $2 million, respectively, of related amortization into interest expense.
(4)Includes two interest rate swap instruments each with notional amounts of $110 million and one interest rate swap instrument with a notional amount of $180 million.
(5)Includes the following: (i) two interest rate swap instruments each with a pay rate of 3.56% and $50 million notional amount; (ii) three interest rate swap instruments each with a pay rate of 3.57% and $50 million notional amount; (iii) one interest rate swap instrument with a pay rate of 3.58% and $100 million notional amount; (iv) five interest rate swap instruments each with a pay rate of 3.60% and $50 million notional amount; and (v) three interest rate swap instruments each with a pay rate of 3.61% and $50 million notional amount.
NOTE 19. Accounts Payable, Accrued Liabilities, and Other Liabilities

The following table summarizes the Company’s accounts payable, accrued liabilities, and other liabilities (in thousands):

| September 30, 2025 |  | December 31, 2024
Refundable entrance fees | $ | 223,339 |  |  | $ | 236,563 |
Accrued construction costs | 164,460 |  |  | 136,767 |
Accrued interest | 57,186 |  |  | 76,040 |
Other accounts payable and accrued liabilities(1) | 301,244 |  |  | 275,972 |
Accounts payable, accrued liabilities, and other liabilities | $ | 746,229 |  |  | $ | 725,342 |

_______________________________________
(1)As of September 30, 2025 and December 31, 2024, includes $0.2 million and $4 million, respectively, of severance-related obligations associated with the departure of a former CEO in October 2022 that had not yet been paid.
42

Table of Contents
NOTE 20. Deferred Revenue

The following table summarizes the Company’s deferred revenue, excluding deferred revenue related to assets classified as held for sale (in thousands):

| September 30, 2025 |  | December 31, 2024
Non-refundable entrance fees(1) | $ | 652,173 |  |  | $ | 615,723 |
Other deferred revenue(2) | 317,904 |  |  | 324,413 |
Deferred revenue | $ | 970,077 |  |  | $ | 940,136 |

_______________________________________
(1)During the three and nine months ended September 30, 2025, the Company collected non-refundable entrance fees of $37 million and $108 million, respectively, and recognized amortization of $24 million and $72 million, respectively. During the three and nine months ended September 30, 2024, the Company collected non-refundable entrance fees of $34 million and $96 million, respectively, and recognized amortization of $23 million and $66 million, respectively. The amortization of non-refundable entrance fees is included within resident fees and services on the Consolidated Statements of Operations.
(2)Other deferred revenue is primarily comprised of prepaid rent, deferred rent, and tenant-funded tenant improvements owned by the Company. During the three and nine months ended September 30, 2025, the Company recognized amortization related to other deferred revenue of $13 million and $37 million, respectively. During the three and nine months ended September 30, 2024, the Company recognized amortization related to other deferred revenue of $13 million and $40 million, respectively. The amortization of other deferred revenue is included in rental and related revenues on the Consolidated Statements of Operations.
43

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
All references in this report to “Healthpeak,” the “Company,” “we,” “us,” or “our” mean Healthpeak Properties, Inc., together with its consolidated subsidiaries. Unless the context suggests otherwise, references to “Healthpeak Properties, Inc.” mean the parent company without its subsidiaries.
Cautionary Language Regarding Forward-Looking Statements
Statements in this Quarterly Report on Form 10-Q that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include, among other things, statements regarding our and our officers’ intent, belief or expectation as identified by the use of words such as “may,” “will,” “project,” “expect,” “believe,” “intend,” “anticipate,” “seek,” “target,” “forecast,” “plan,” “potential,” “estimate,” “could,” “would,” “should” and other comparable and derivative terms or the negatives thereof. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could cause actual results, including our future financial condition and results of operations, to differ materially from those expressed or implied by any forward-looking statements. You are urged to carefully review the disclosures we make concerning risks and uncertainties that may affect our business and future financial performance.
Forward-looking statements are based on certain assumptions and analysis made in light of our experience and perception of historical trends, current conditions and expected future developments as well as other factors that we believe are appropriate under the circumstances. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this Quarterly Report on Form 10-Q, and you should not place undue reliance on these forward-looking statements, which speak only as of the date of this report.
As more fully set forth under Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, principal risks and uncertainties that may cause our actual results to differ materially from the expectations contained in the forward-looking statements include, among other things:
•macroeconomic trends that may increase construction, labor, and other operating costs;
•changes within the life science industry, and significant regulation, funding requirements, and uncertainty faced by our lab tenants;
•factors adversely affecting our tenants’, operators’, or borrowers’ ability to meet their financial and other contractual obligations to us;
•the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers;
•our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in that specific sector than if we invested across multiple sectors;
•the illiquidity of real estate investments;
•our ability to identify and secure new or replacement tenants and operators;
•our property development, redevelopment, and tenant improvement risks, which can render a project less profitable or unprofitable and delay or prevent its undertaking or completion;
•the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable;
•our ability to develop, maintain, or expand hospital and health system client relationships;
•operational risks associated with our senior housing properties managed by third parties, including our properties operated through structures permitted by the Housing and Economic Recovery Act of 2008, which includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as “RIDEA”);
•economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments;
•uninsured or underinsured losses, which could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated expenses;
•our use of joint ventures may limit our returns on and our flexibility with jointly owned investments;
•our use of rent escalators or contingent rent provisions in our leases;
•competition for suitable healthcare properties to grow our investment portfolio;
•our ability to exercise rights on collateral securing our real estate-related loans;
•any requirement that we recognize reserves, allowances, credit losses, or impairment charges;
44

Table of Contents
•investment of substantial resources and time in transactions that are not consummated;
•our ability to successfully integrate or operate acquisitions and/or internalize property management;
•the potential impact of unfavorable resolution of litigation or disputes and resulting rising liability and insurance costs;
•environmental compliance costs and liabilities associated with our real estate investments;
•environmental, social, and governance (“corporate impact”) and sustainability commitments and requirements, as well as stakeholder expectations;
•epidemics, pandemics, or other infectious diseases, including the coronavirus disease (“Covid”), and health and safety measures intended to reduce their spread;
•human capital risks, including the loss or limited availability of our key personnel;
•our reliance on information technology and any material failure, inadequacy, interruption, or security failure of that technology;
•the use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors;
•volatility, disruption, or uncertainty in the financial markets;
•increased borrowing costs, which could impact our ability to refinance existing debt, sell properties, and conduct investment activities;
•cash available for distribution to stockholders and our ability to make dividend distributions at expected levels;
•the availability of external capital on acceptable terms or at all;
•an increase in our level of indebtedness;
•covenants in our debt instruments, which may limit our operational flexibility, and breaches of these covenants;
•volatility in the market price and trading volume of our common stock;
•adverse changes in our credit ratings;
•the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements;
•required regulatory approvals to transfer our senior housing properties;
•compliance with the Americans with Disabilities Act and fire, safety, and other regulations;
•laws or regulations prohibiting eviction of our tenants;
•the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid, and legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services;
•our participation in the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) Provider Relief Fund and other Covid-related stimulus and relief programs;
•changes in federal, state, or local laws or regulations that may limit our opportunities to participate in the ownership of, or investment in, healthcare real estate;
•our ability to successfully integrate our operations with Physicians Realty Trust and realize the anticipated synergies of our merger with Physicians Realty Trust (the “Merger”) and benefits of property management internalization;
•our ability to maintain our qualification as a real estate investment trust (“REIT”);
•our taxable REIT subsidiaries being subject to corporate level tax;
•tax imposed on any net income from “prohibited transactions”;
•changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions;
•calculating non-REIT tax earnings and profits distributions;
•tax protection agreements that may limit our ability to dispose of certain properties and may require us to maintain certain debt levels;
•ownership limits in our charter that restrict ownership in our stock, and provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders;
•conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP, LLC (“Healthpeak OP”) common units;
•provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; and
•our status as a holding company of Healthpeak OP.
45

Table of Contents
Important Information Regarding Our Disclosure to Investors
We may use our website (www.healthpeak.com) and our LinkedIn account (https://www.linkedin.com/company/healthpeak) to communicate with our investors and disclose company information. The information disclosed through those channels may be considered to be material, so investors should monitor them in addition to our press releases, U.S. Securities and Exchange Commission (“SEC”) filings, and public conference calls and webcasts. The contents of our website or social media channels referenced herein are not incorporated by reference into this Quarterly Report on Form 10-Q.
Overview
The information set forth in this Item 2 is intended to provide readers with an understanding of our financial condition, changes in financial condition and results of operations. We will discuss and provide our analysis in the following order:
•Executive Summary
•Market Trends and Uncertainties
•Company Highlights
•Dividends
•Results of Operations
•Liquidity and Capital Resources
•Non-GAAP Financial Measures Reconciliations
•Critical Accounting Estimates
Executive Summary
Healthpeak Properties, Inc. is a Standard & Poor’s (“S&P”) 500 company that owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States (“U.S.”). Our company was originally founded in 1985. We are organized as an umbrella partnership REIT (“UPREIT”). We hold substantially all of our assets and conduct our operations through our operating subsidiary, Healthpeak OP, a consolidated subsidiary of which we are the managing member. We are a Maryland corporation and qualify as a self-administered REIT. We are headquartered in Denver, Colorado, with additional corporate offices in California, Tennessee, Wisconsin, and Massachusetts and property management offices in several locations throughout the U.S.
We have a diversified portfolio of high-quality healthcare properties across three core asset classes of outpatient medical, lab, and continuing care retirement community (“CCRC”) real estate. Under the outpatient medical and lab segments, we own, operate, and develop outpatient medical buildings, hospitals, and lab buildings. Under the CCRC segment, our properties are operated through RIDEA structures. We have other non-reportable segments that are comprised primarily of: (i) an interest in an unconsolidated joint venture that owns 19 senior housing assets (our “SWF SH JV”), (ii) loans receivable, and (iii) a preferred equity investment. These non-reportable segments have been p resented on a combined basis herein.
At September 30, 2025, our portfolio of investments, including properties in certain of our unconsolidated joint ventures, consisted of interests in 703 properties: (i) Outpatient medical – 530 properties; (ii) Lab – 139 properties; (iii) CCRC – 15 properties; and (iv) Other non-reportable – 19 properties. The following table summarizes information for our reportable segments for the three months ended September 30, 2025 (dollars in thousands):

Segment |  |  |  | Adjusted NOI by Reportable Segment(1) |  |  |  |
Outpatient medical |  |  |  | $ | 200,414 |  |  |  |  |
Lab |  |  |  | 138,058 |  |  |  |  |
CCRC |  |  |  | 36,548 |  |  |  |  |

_______________________________________
(1)Our Adjusted NOI for our reportable segments, which we also refer to as Total Portfolio Adjusted NOI for our reportable segments, includes results of operations from disposed properties through the disposition date. See Note 14 to the Consolidated Financial Statements for a reconciliation of Adjusted NOI by reportable segment to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. See our Segment Analysis below for additional information.
For a description of our significant activities during 2025, see “Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Company Highlights” in this report.
46

Table of Contents
Business Strategy
Our strategy is to own, operate, and develop high-quality real estate focused on healthcare discovery and delivery. We manage our real estate portfolio for the long-term to maximize risk-adjusted returns and support the growth of our dividends. Our strategy consists of four core elements:
(i)Our real estate: Our portfolio consists of high-quality properties in desirable locations. Our portfolio is focused on outpatient medical and lab buildings, favorable sectors that benefit from the universal desire for improved health. We have built scale and fostered deep industry relationships, two unique factors that provide us with a competitive advantage.
(ii)Our financials: We maintain a strong investment-grade balance sheet with ample liquidity as well as long-term fixed-rate debt financing with staggered maturities to reduce our exposure to interest rate volatility and refinancing risk.
(iii)Our partnerships: We work with leading pharmaceutical, biotechnology, and medical device companies, as well as healthcare delivery systems, specialty physician groups, and other healthcare service providers, to meet their real estate needs. We provide high-quality property management services to encourage tenants to renew, expand, and relocate into our properties, which drives increased occupancy, rental rates, and property values.
(iv)Our platform: We have a people-first culture that we believe attracts, develops, and retains top talent. We continually strive to create and maintain an industry-leading platform, with systems and tools that allow us to effectively and efficiently manage our assets and investment activity.
Market Trends and Uncertainties
Our operating results have been and will continue to be impacted by global and national economic and market conditions generally and by the local economic conditions where our properties are located.
Higher interest rates and uncertainty in public and private equity and fixed income markets have led to increased costs and limitations on the availability of capital. In addition, higher interest rates have and could continue to adversely impact our borrowing costs, the fair value of our fixed rate instruments, transaction volume, and real estate values generally, including our real estate. We have also been affected by increased costs relating to tenant improvements and construction, which, together with higher costs of capital and tariff actions (or potential tariff actions), have adversely affected, and in the future may adversely affect, construction starts and the expected yields on our capital projects, including our developments and redevelopments.
We continuously monitor the effects of domestic and global events on our operations and financial position, and on the operations and financial position of our tenants, operators, and borrowers, to enable us to remain responsive and adaptable to the dynamic changes in our operating environment. These events include, but are not limited to, the following, any of which could negatively impact our business: inflation; recession; interest rates; challenges in the financial markets; availability of private capital and funding in the life science industry; and actions by the U.S. political administration and regulatory agencies that affect healthcare policy, life science research and innovation, labor supply, procurement and construction costs, and general economic conditions (such as budget reconciliation actions, tariff actions, changes in healthcare regulation, decreases in government funding and staffing, and immigration reform).
To the extent our tenants and/or operators have experienced, or will experience, increased costs, liquidity constraints, and financing difficulties due to the foregoing macroeconomic and market conditions, they may be unable or unwilling to make payments or perform their obligations when due.
See Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 for additional discussion of the risks posed by macroeconomic conditions, as well as the uncertainties we and our tenants, operators, and borrowers may face as a result.
Company Highlights
Real Estate Transactions
•In February 2025, we acquired: (i) a lab land parcel in Cambridge, Massachusetts for $20 million and (ii) a portfolio of three outpatient medical buildings in New York for $17 million.
•During the three months ended June 30, 2025, we sold one outpatient medical land parcel for $4 million.
•In September 2025, we acquired a condominium interest in eight suites within an outpatient medical building in Atlanta, Georgia for $6 million.
•During the three months ended September 30, 2025, we sold two outpatient medical buildings for $27 million.
47

Table of Contents
Development and Redevelopment Activities
•During the nine months ended September 30, 2025, the following projects were placed in service: (i) a portion of two outpatient medical development projects with total project costs of $32 million, (ii) two lab development buildings held in our unconsolidated Callan Ridge JV of which our share of total project costs was $63 million, (iii) one outpatient medical development project with total project costs of $38 million, (iv) a portion of one lab development project with total project costs of $36 million, (v) two lab redevelopment buildings held in our unconsolidated South San Francisco JVs of which our share of total project costs was $26 million, (vi) one outpatient medical redevelopment project with total project costs of $12 million, and (vii) two lab redevelopment projects with total project costs of $7 million.
Financing Activities
•In February 2025, we repaid $348 million aggregate principal amount of 3.40% senior unsecured notes at maturity.
•In February 2025, we issued $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035.
•In June 2025, we repaid $452 million aggregate principal amount of 4.00% senior unsecured notes at maturity.
•In August 2025, we issued $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033.
•During the nine months ended September 30, 2025, we repurchased 5.09 million shares of our common stock under the 2024 Share Repurchase Program (as defined below) at a weighted average price of $18.50 per share for a total of $94 million.
Other Activities
•In February 2025, we made a preferred equity investment in a joint venture that holds a lab campus under development in San Diego, California (the “HQ Point Preferred Equity Investment”). This investment is entitled to a preferred return, and we have committed to fund up to a total investment of $50 million. As of September 30, 2025, we have funded $45 million of our total commitment.
•During the nine months ended September 30, 2025, we (i) entered into secured loans with an aggregate principal balance of $120 million, $36 million of which was funded upon closing of the loans, and (ii) entered into and funded one $4 million mezzanine loan to one of our unconsolidated joint ventures.
•During the nine months ended September 30, 2025, we entered into two outpatient medical development joint ventures.
•During the nine months ended September 30, 2025, we received full repayment of: (i) two seller financing loans receivable secured by senior housing assets with an aggregate principal balance of $106 million and (ii) the $15 million outstanding balance of one secured loan.
Dividends
The following table summarizes our common stock cash dividends declared in 2025:

Declaration Date |  | Record Date |  | Amount Per Share(1) |  | Dividend Payment Date
February 3 |  | February 14 |  | $ | 0.30500 |  |  | February 26
April 4 |  | April 18 |  | 0.10167 |  |  | April 30
April 4 |  | May 19 |  | 0.10167 |  |  | May 30
April 4 |  | June 16 |  | 0.10167 |  |  | June 27
July 7 |  | July 18 |  | 0.10167 |  |  | July 31
July 7 |  | August 18 |  | 0.10167 |  |  | August 29
July 7 |  | September 19 |  | 0.10167 |  |  | September 30
October 6 |  | October 17 |  | 0.10167 |  |  | October 30
October 6 |  | November 14 |  | 0.10167 |  |  | November 26
October 6 |  | December 19 |  | 0.10167 |  |  | December 30

_______________________________________
(1)Our Board of Directors declares our common stock cash dividends on a quarterly basis. Commencing in April 2025, our Board of Directors transitioned from paying the common stock cash dividend on a quarterly basis to a monthly basis.
48

Table of Contents
Results of Operations
We evaluate our business and allocate resources among our operating segments: (i) outpatient medical, (ii) lab, (iii) CCRC, (iv) an interest in our unconsolidated SWF SH JV, (v) loans receivable, and (vi) a preferred equity investment. The Company’s reportable segments, as determined in accordance with ASC 280, Segment Reporting, are as follows: (i) outpatient medical, (ii) lab, and (iii) CCRC. Under the outpatient medical and lab segments, we own, operate, and develop outpatient medical buildings, hospitals, and lab buildings. Our CCRCs are operated through RIDEA structures. The SWF SH JV, loans receivable, and preferred equity investment are non-reportable segments that have been presented on a combined basis herein. We evaluate performance based upon property adjusted net operating income (“Adjusted NOI” or “Cash NOI”) in each segment. The accounting policies of the segments are the same as those described in the summary of significant accounting policies in Note 2 to the Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”), as updated by Note 2 to the Consolidated Financial Statements herein.
Non-GAAP Financial Measures
Adjusted NOI
Adjusted NOI is a non-U.S. generally accepted accounting principles (“GAAP”) supplemental financial measure used to evaluate the operating performance of real estate. Adjusted NOI represents real estate revenues (inclusive of rental and related revenues, resident fees and services, and government grant income and exclusive of interest income), less property level operating expenses; Adjusted NOI excludes all other financial statement amounts included in net income (loss) as presented in Note 14 to the Consolidated Financial Statements. Adjusted NOI eliminates the effects of straight-line rents, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense. Adjusted NOI is calculated as Adjusted NOI from consolidated properties, plus our share of Adjusted NOI from unconsolidated joint ventures (calculated by applying our actual ownership percentage for the period), less noncontrolling interests’ share of Adjusted NOI from consolidated joint ventures (calculated by applying our actual ownership percentage for the period). We utilize our share of Adjusted NOI in assessing our performance as we have various joint ventures that contribute to our performance. Our share of Adjusted NOI should not be considered a substitute for, and should only be considered together with and as a supplement to, our financial information presented in accordance with GAAP.
Adjusted NOI is oftentimes referred to as “Cash NOI.” Management believes Adjusted NOI is an important supplemental measure because it provides relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and presents them on an unlevered basis. We use Adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and to evaluate our Merger-Combined Same-Store (“Merger-Combined SS”) performance, as described below. We believe that net income (loss) is the most directly comparable GAAP measure to Adjusted NOI. Adjusted NOI should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items. Further, our definition of Adjusted NOI may not be comparable to the definitions used by other REITs or real estate companies, as they may use different methodologies for calculating Adjusted NOI.
As described in Note 14 to the Consolidated Financial Statements, our chief operating decision maker (“CODM”) evaluates the performance of our operating segments based on Adjusted NOI. Our operating segments are aggregated into reportable segments for which we disclose Total Portfolio Adjusted NOI for our reportable segments. For further information, including information reconciling our Adjusted NOI for reportable segments to our income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures, refer to Note 14 to the Consolidated Financial Statements.
Operating expenses generally relate to leased outpatient medical and lab buildings, as well as CCRC facilities. We generally recover all or a portion of our leased outpatient medical and lab property expenses through tenant recoveries, which are recognized within rental and related revenues.
Merger-Combined Same-Store Adjusted NOI
Merger-Combined Same-Store Adjusted NOI includes legacy Physicians Realty Trust properties that met the same-store criteria as if they were owned by the Company for the full analysis period. This information allows our investors, analysts, and us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties, excluding properties within the other non-reportable segments. We include properties from our consolidated portfolio, as well as properties owned by our unconsolidated joint ventures in Adjusted NOI (see Adjusted NOI definition above for further discussion regarding our use of pro-rata share information and its limitations). Merger-Combined Same-Store Adjusted NOI excludes government grant income under the CARES Act, amortization of deferred revenue from tenant-funded improvements, and certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis.
49

Table of Contents
Properties are included in Merger-Combined Same-Store once they are fully operating for the entirety of the comparative periods presented. A property is removed from Merger-Combined Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event that significantly impacts operations, or a significant tenant relocates from a Merger-Combined Same-Store property to a Merger-Combined non Same-Store property and that change results in a corresponding increase in revenue. We do not report Merger-Combined Same-Store metrics for our other non-reportable segments.
Management believes that continued reporting of the same-store portfolio for only pre-merger Healthpeak Properties, Inc. offers minimal value to investors who are seeking to understand the operating performance and growth potential of the Combined Company. The Company was provided access to the underlying financial statements of legacy Physicians Realty Trust and other detailed information about each property, such as the acquisition date. Based on this available information, the Company was able to consistently apply its same-store definition across the combined portfolio. As a result of the Merger, approximately 97% of the combined portfolio is represented in the Merger-Combined Same-Store presentation for the outpatient medical segment for each of the three and nine months ended September 30, 2025.
For a reconciliation of Merger-Combined Same-Store to total portfolio Adjusted NOI and other relevant disclosures by segment, refer to our Segment Analysis below.
Nareit FFO. Funds from Operations (“FFO”), as defined by the National Association of Real Estate Investment Trusts (“Nareit”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate or land held for development, plus real estate-related depreciation and amortization, and adjustments to compute our share of Nareit FFO from joint ventures. Adjustments for joint ventures are calculated to reflect our pro rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of Nareit FFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. For consolidated joint ventures in which we do not own 100%, we reflect our share of the equity by adjusting our Nareit FFO to remove the third-party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. Our pro rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our actual ownership percentage for the period. We do not control the unconsolidated joint ventures, and the pro rata presentations of reconciling items included in Nareit FFO do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.
The presentation of pro rata information has limitations, which include, but are not limited to, the following: (i) the amounts shown on the individual line items were derived by applying our overall economic ownership interest percentage determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro rata financial information as a supplement.
We believe Nareit FFO applicable to common shares and diluted Nareit FFO applicable to common shares are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term Nareit FFO was designed by the REIT industry to address this issue.
Nareit FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income (loss). We compute Nareit FFO in accordance with the current Nareit definition; however, other REITs may report Nareit FFO differently or have a different interpretation of the current Nareit definition from ours. For a reconciliation of net income (loss) to Nareit FFO and other relevant disclosures, refer to “Non-GAAP Financial Measures Reconciliations” below.
FFO as Adjusted. In addition, we present Nareit FFO on an adjusted basis before the impact of non-comparable items including, but not limited to, transaction and merger-related items, other impairments (recoveries) and other losses (gains), restructuring and severance-related charges, prepayment costs (benefits) associated with early retirement or payment of debt, litigation costs (recoveries), casualty-related charges (recoveries), deferred tax asset valuation allowances, and changes in tax legislation (“FFO as Adjusted”). These adjustments are net of tax, when applicable, and are reflective of our share of our joint ventures. Adjustments for joint ventures are calculated to reflect our pro rata share of both our consolidated and unconsolidated
50

Table of Contents
joint ventures. We reflect our share of FFO as Adjusted for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our FFO as Adjusted to remove the third-party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. See “Nareit FFO” above for further disclosures regarding our use of pro rata share information and its limitations. Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Other impairments (recoveries) and other losses (gains) include interest income associated with early and partial repayments of loans receivable and other losses or gains associated with non-depreciable assets including goodwill, undeveloped land parcels, and loans receivable. Management believes that FFO as Adjusted provides a meaningful supplemental measurement of our FFO run-rate and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. At the same time that Nareit created and defined its FFO measure for the REIT industry, it also recognized that “management of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.” We believe stockholders, potential investors, and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes certain other adjustments to net income (loss), in addition to adjustments made to arrive at the Nareit defined measure of FFO. FFO as Adjusted is used by management in analyzing our business and the performance of our properties and we believe it is important that stockholders, potential investors, and financial analysts understand this measure used by management. We use FFO as Adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of our management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess our performance as compared with similar real estate companies and the industry in general, and (v) evaluate how a specific potential investment will impact our future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO measure, and accordingly, our FFO as Adjusted may not be comparable to those reported by other REITs. For a reconciliation of net income (loss) to FFO as Adjusted and other relevant disclosure, refer to “Non-GAAP Financial Measures Reconciliations” below.
Adjusted FFO (“AFFO”). AFFO is defined as FFO as Adjusted after excluding the impact of the following: (i) stock-based compensation amortization expense, (ii) amortization of deferred financing costs and debt discounts (premiums), (iii) straight-line rents, (iv) deferred income taxes, (v) amortization of above (below) market lease intangibles, net, (vi) non-refundable entrance fees collected in excess of (less than) the related amortization, and (vii) other AFFO adjustments, which include: (a) lease incentive amortization (reduction of straight-line rents), (b) actuarial reserves for insurance claims that have been incurred but not reported, and (c) amortization of deferred revenues, excluding amounts amortized into rental income that are associated with tenant funded improvements owned/recognized by us and up-front cash payments made by tenants to reduce their contractual rents. Also, AFFO is computed after deducting recurring capital expenditures, including second generation leasing costs and second generation tenant and capital improvements (“AFFO capital expenditures”). All adjustments are reflective of our pro rata share of both our consolidated and unconsolidated joint ventures (reported in “other AFFO adjustments”). We reflect our share of AFFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our AFFO to remove the third-party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. See “Nareit FFO” above for further disclosures regarding our use of pro rata share information and its limitations. We believe AFFO is an alternative run-rate performance measure that improves the understanding of our operating results among investors and makes comparisons with: (i) expected results, (ii) results of previous periods, and (iii) results among REITs more meaningful. AFFO does not represent cash generated from operating activities determined in accordance with GAAP and is not indicative of cash available to fund cash needs as it excludes the following items which generally flow through our cash flows from operating activities: (i) adjustments for changes in working capital or the actual timing of the payment of income or expense items that are accrued in the period, (ii) transaction-related costs, (iii) litigation settlement expenses, and (iv) restructuring and severance-related charges. Furthermore, AFFO is adjusted for recurring capital expenditures, which are generally not considered when determining cash flows from operations or liquidity. Other REITs or real estate companies may use different methodologies for calculating AFFO, and accordingly, our AFFO may not be comparable to those reported by other REITs. Management believes AFFO provides a meaningful supplemental measure of our performance and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT, and by presenting AFFO, we are assisting these parties in their evaluation. AFFO is a non-GAAP supplemental financial measure and should not be considered as an alternative to net income (loss) determined in accordance with GAAP and should only be considered together with and as a supplement to our financial information prepared in accordance with GAAP. For a reconciliation of net income (loss) to AFFO and other relevant disclosures, refer to “Non-GAAP Financial Measures Reconciliations” below.
51

Table of Contents
Comparison of the Three and Nine Months Ended September 30, 2025 to the Three and Nine Months Ended September 30, 2024
Overview

The following table summarizes results for the three months ended September 30, 2025 and 2024(1) (in thousands):

| Three Months Ended September 30,
| 2025 |  | 2024 |  | Change
Net income (loss) applicable to common shares | $ | (117,256) |  |  | $ | 85,675 |  |  | $ | (202,931) |
Nareit FFO | 318,155 |  |  | 311,247 |  |  | 6,908 |
FFO as Adjusted | 318,750 |  |  | 316,205 |  |  | 2,545 |
AFFO | 291,974 |  |  | 295,979 |  |  | (4,005) |

_______________________________________
(1)For the reconciliation of non-GAAP financial measures, see “Non-GAAP Financial Measures Reconciliations” below.
Net income (loss) applicable to common shares decreased primarily as a result of the following:
•other-than-temporary impairment charges on two lab unconsolidated joint ventures in 2025;
•a decrease in gain on sales of real estate related to fewer real estate dispositions in 2025;
•a decrease in Adjusted NOI generated from our outpatient medical and lab segments related to: (i) dispositions of real estate in 2024 and 2025 and (ii) assets placed into development and redevelopment in 2024 and 2025, partially offset by: (i) development and redevelopment projects placed in service during 2024 and 2025 and (ii) new leasing activity during 2024 and 2025 (including the impact to straight-line rents); and
•an increase in interest expense related to: (i) the issuance of $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035, which closed in February 2025, (ii) the issuance of $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033, which closed in August 2025, and (iii) higher borrowings under the commercial paper program.
The decrease in net income (loss) applicable to common shares was partially offset by:
•a decrease in depreciation related to dispositions of real estate in 2024 and 2025;
•a decrease in transaction and merger-related costs incurred in connection with the Merger;
•a decrease in general and administrative expenses due to: (i) lower compensation expense and (ii) merger-related synergies;
•an increase in income tax benefit related to the other-than-temporary impairment charge on the Needham Land Parcel JV;
•an increase in Adjusted NOI generated from our CCRC segment related to: (i) increased rates for resident fees and (ii) higher occupancy; and
•an increase in interest income related to: (i) secured loans funded in 2024 and 2025 and (ii) seller financing provided in connection with the disposition of two outpatient medical buildings in November 2024, partially offset by principal repayments on loans receivable in 2024 and 2025.
Nareit FFO increased primarily as a result of the aforementioned events impacting net income (loss) applicable to common shares, except for the following, which are excluded from Nareit FFO:
•other-than-temporary impairment charges;
•gain on sales of real estate; and
•depreciation and amortization expense.
FFO as Adjusted increased primarily as a result of the aforementioned events impacting Nareit FFO, except for transaction and merger-related items, which are excluded from FFO as Adjusted.
AFFO decreased primarily as a result of the aforementioned events impacting FFO as Adjusted, except for the impact of straight-line rents, which are excluded from AFFO, and higher AFFO capital expenditures during the period. The decrease to AFFO was partially offset by higher cash collections of non-refundable entrance fees in excess of amortization at our CCRCs.
52

Table of Contents
The following table summarizes results for the nine months ended September 30, 2025 and 2024(1) (in thousands):

| Nine Months Ended September 30,
| 2025 |  | 2024 |  | Change
Net income (loss) applicable to common shares | $ | (43,335) |  |  | $ | 237,985 |  |  | $ | (281,320) |
Nareit FFO | 940,418 |  |  | 785,876 |  |  | 154,542 |
FFO as Adjusted | 965,087 |  |  | 907,128 |  |  | 57,959 |
AFFO | 903,977 |  |  | 833,281 |  |  | 70,696 |

_______________________________________
(1)For the reconciliation of non-GAAP financial measures, see “Non-GAAP Financial Measures Reconciliations” below.
Net income (loss) applicable to common shares decreased primarily as a result of the following:
•other-than-temporary impairment charges on two lab unconsolidated joint ventures in 2025;
•a decrease in gain on sales of real estate related to fewer real estate dispositions in 2025;
•a decrease in gain upon change of control related to the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January 2024;
•an increase in interest expense related to: (i) debt assumed as part of the Merger, including $1.25 billion aggregate principal amount of senior unsecured notes, $400 million aggregate principal amount of the 2028 Term Loan, and $128 million aggregate principal amount of mortgage debt, (ii) borrowings under the 2029 Term Loan, which closed in March 2024, (iii) the issuance of $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035, which closed in February 2025, (iv) the issuance of $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033, which closed in August 2025, and (v) higher borrowings under the commercial paper program;
•an increase in depreciation related to: (i) assets acquired as part of the Merger and (ii) development and redevelopment projects placed in service during 2024 and 2025; and
•casualty-related losses recognized in 2025.
The decrease in net income (loss) applicable to common shares was partially offset by:
•a decrease in transaction and merger-related costs incurred in connection with the Merger;
•an increase in Adjusted NOI generated from our outpatient medical and lab segments related to: (i) assets acquired as part of the Merger, (ii) development and redevelopment projects placed in service during 2024 and 2025, and (iii) new leasing activity during 2024 and 2025 (including the impact to straight-line rents), partially offset by: (i) dispositions of real estate in 2024 and (ii) assets placed into development and redevelopment in 2024 and 2025;
•an increase in interest income related to: (i) seller financing provided in connection with the disposition of 61 outpatient medical buildings in 2024, (ii) loans receivable acquired as part of the Merger, and (iii) other secured loans funded in 2024 and 2025;
•a decrease in income tax expense related to: (i) income tax expense incurred in connection with the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January 2024, (ii) the tax benefit from casualty-related losses recognized in 2025, and (iii) the tax benefit related to the other-than-temporary impairment charge on the Needham Land Parcel JV;
•a decrease in loan loss reserves under the current expected credit losses model related to: (i) reserves recognized in 2024 on loans receivable acquired as part of the Merger, (ii) changes in operating performance and fair values of the underlying collateral of the Company’s loans receivable, and (iii) recoveries related to loans repaid during the nine months ended September 30, 2025;
•an increase in Adjusted NOI generated from our CCRC segment related to: (i) increased rates for resident fees and (ii) higher occupancy;
•a decrease in interest expense related to: (i) the repayment of $348 million aggregate principal amount of 3.40% senior unsecured notes in February 2025 and (ii) the repayment of $452 million aggregate principal amount of 4.00% senior unsecured notes in June 2025;
•a decrease in general and administrative expenses due to: (i) lower compensation expense and (ii) merger-related synergies.
53

Table of Contents
Nareit FFO increased primarily as a result of the aforementioned events impacting net income (loss) applicable to common shares, except for the following, which are excluded from Nareit FFO:
•other-than-temporary impairment charges;
•gain on sales of real estate;
•taxes associated with real estate dispositions;
•gain upon change of control; and
•depreciation and amortization expense.
FFO as Adjusted increased primarily as a result of the aforementioned events impacting Nareit FFO, except for the following, which are excluded from FFO as Adjusted:
•transaction and merger-related items;
•loan loss reserves (recoveries); and
•casualty-related charges.
AFFO increased primarily as a result of the aforementioned events impacting FFO as Adjusted, except for the impact of: (i) amortization of below market lease intangibles, (ii) amortization of deferred financing costs and debt discounts (premiums) on amounts recognized in connection with the Merger, (iii) deferred income taxes, and (iv) straight-line rents, which are excluded from AFFO. AFFO further increased as a result of higher cash collections of non-refundable entrance fees in excess of amortization at our CCRCs.
Segment Analysis
The following tables provide selected operating information for our Merger-Combined Same-Store and total property portfolio for each of our reportable segments. For the three months ended September 30, 2025, our Merger-Combined Same-Store consists of 631 properties representing properties fully operating on or prior to July 1, 2024 and that remained in operation through September 30, 2025. For the nine months ended September 30, 2025, our Merger-Combined Same-Store consists of 628 properties representing properties fully operating on or prior to January 1, 2024 and that remained in operation through September 30, 2025. Legacy Physicians Realty Trust properties that met the definition of Merger-Combined Same-Store are included in both periods presented as if they were owned by the Company for the full analysis period. See “Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures” for additional information. Our total property portfolio consisted of 703 and 700 properties at September 30, 2025 and 2024, respectively.
54

Table of Contents
Outpatient Medical

The following table summarizes results at and for the three months ended September 30, 2025 and 2024 (dollars and square feet in thousands, except per square foot data):

| Merger-Combined SS |  | Total Portfolio(1)
| Three Months Ended September 30, |  | Three Months Ended September 30,
| 2025 |  | 2024 |  | Change |  | 2025 |  | 2024 |  | Change
Rental and related revenues | $ | 315,473 |  |  | $ | 304,315 |  |  | $ | 11,158 |  |  | $ | 326,561 |  |  | $ | 317,659 |  |  | $ | 8,902 |
Healthpeak’s share of unconsolidated joint venture total revenues | 6,970 |  |  | 6,883 |  |  | 87 |  |  | 7,327 |  |  | 7,065 |  |  | 262 |
Noncontrolling interests’ share of consolidated joint venture total revenues | (10,129) |  |  | (9,553) |  |  | (576) |  |  | (10,334) |  |  | (9,734) |  |  | (600) |
Operating expenses | (107,921) |  |  | (99,414) |  |  | (8,507) |  |  | (113,660) |  |  | (106,484) |  |  | (7,176) |
Healthpeak’s share of unconsolidated joint venture operating expenses | (2,750) |  |  | (2,761) |  |  | 11 |  |  | (2,887) |  |  | (2,832) |  |  | (55) |
Noncontrolling interests’ share of consolidated joint venture operating expenses | 3,765 |  |  | 2,851 |  |  | 914 |  |  | 3,765 |  |  | 2,851 |  |  | 914 |
Adjustments to NOI(2) | (10,002) |  |  | (10,738) |  |  | 736 |  |  | (10,358) |  |  | (11,020) |  |  | 662 |
Adjusted NOI | $ | 195,406 |  |  | $ | 191,583 |  |  | $ | 3,823 |  |  | 200,414 |  |  | 197,505 |  |  | 2,909 |
Less: Merger-Combined Non-SS Adjusted NOI |  |  |  |  |  |  | (5,008) |  |  | (5,922) |  |  | 914 |
Merger-Combined SS Adjusted NOI |  |  |  |  |  |  | $ | 195,406 |  |  | $ | 191,583 |  |  | $ | 3,823 |
Adjusted NOI % change |  |  |  |  | 2.0% |  |  |  |  |  |
Property count(3) | 514 |  | 514 |  |  |  | 530 |  | 527 |  |
End of period occupancy(4) | 91.4% |  | 92.5% |  |  |  | 91.3% |  | 92.2% |  |
Average occupancy(4) | 91.5% |  | 92.5% |  |  |  | 91.2% |  | 92.2% |  |
Average occupied square feet | 33,186 |  | 33,667 |  |  |  | 33,878 |  | 34,956 |  |
Average annual total revenues per occupied square foot(5) | $ | 38 |  | $ | 36 |  |  |  | $ | 39 |  | $ | 36 |  |
Average annual base rent per occupied square foot(6) | $ | 28 |  | $ | 25 |  |  |  | $ | 29 |  | $ | 28 |  |

___________________________________
(1)Total Portfolio includes results of operations from disposed properties through the disposition date.
(2)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our reportable segments. See Note 14 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI.
(3)From our third quarter 2024 presentation of Merger-Combined Same-Store, we added: (i) three stabilized redevelopments placed in service, (ii) three stabilized acquisitions, (iii) and one stabilized development placed in service, and we removed: (i) five assets that were sold and (ii) one building that was placed into redevelopment.
(4)Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(5)Average annual total revenues does not include non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
(6)Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
Merger-Combined Same-Store Adjusted NOI increased primarily as a result of the following:
•mark-to-market lease renewals;
•annual rent escalations; and
•increased percentage-based rents; partially offset by
•higher operating expenses, net of savings from our internalization of property management.
Total Portfolio Adjusted NOI increased as a result of the aforementioned impacts to Merger-Combined Same-Store and the following Merger-Combined Non-Same-Store impacts:
•Adjusted NOI from the outpatient medical buildings acquired as part of the Merger in 2024;
•increased Adjusted NOI from outpatient medical buildings acquired in 2025; and
•increased occupancy in former redevelopment and development properties that have been placed into service; partially offset by
•decreased Adjusted NOI from our 2024 and 2025 dispositions.
55

Table of Contents
The following table summarizes results at and for the nine months ended September 30, 2025 and 2024 (dollars and square feet in thousands, except per square foot data):

| Merger-Combined SS(1) |  | Total Portfolio(2)
| Nine Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | Change |  | 2025 |  | 2024 |  | Change
Rental and related revenues | $ | 932,264 |  |  | $ | 894,342 |  |  | $ | 37,922 |  |  | $ | 967,591 |  |  | $ | 888,446 |  |  | $ | 79,145 |
Healthpeak’s share of unconsolidated joint venture total revenues | 21,073 |  |  | 20,221 |  |  | 852 |  |  | 21,769 |  |  | 16,707 |  |  | 5,062 |
Noncontrolling interests’ share of consolidated joint venture total revenues | (28,121) |  |  | (27,103) |  |  | (1,018) |  |  | (30,327) |  |  | (27,952) |  |  | (2,375) |
Operating expenses | (306,044) |  |  | (294,525) |  |  | (11,519) |  |  | (324,216) |  |  | (299,455) |  |  | (24,761) |
Healthpeak’s share of unconsolidated joint venture operating expenses | (8,296) |  |  | (7,627) |  |  | (669) |  |  | (8,576) |  |  | (6,380) |  |  | (2,196) |
Noncontrolling interests’ share of consolidated joint venture operating expenses | 8,662 |  |  | 7,616 |  |  | 1,046 |  |  | 9,344 |  |  | 7,889 |  |  | 1,455 |
Adjustments to NOI(3) | (32,355) |  |  | (26,154) |  |  | (6,201) |  |  | (33,253) |  |  | (27,573) |  |  | (5,680) |
Adjusted NOI | $ | 587,183 |  |  | $ | 566,770 |  |  | $ | 20,413 |  |  | 602,332 |  |  | 551,682 |  |  | 50,650 |
Pre-Merger legacy Physicians Realty Trust Adjusted NOI(4) |  |  |  |  |  |  | — |  |  | 61,398 |  |  | (61,398) |
Less: Merger-Combined Non-SS Adjusted NOI |  |  |  |  |  |  | (15,149) |  |  | (46,310) |  |  | 31,161 |
Merger-Combined SS Adjusted NOI |  |  |  |  |  |  | $ | 587,183 |  |  | $ | 566,770 |  |  | $ | 20,413 |
Adjusted NOI % change |  |  |  |  | 3.6% |  |  |  |  |  |
Property count(5) | 513 |  | 513 |  |  |  | 530 |  | 527 |  |
End of period occupancy(6) | 91.4% |  | 92.4% |  |  |  | 91.3% |  | 92.2% |  |
Average occupancy(6) | 92.0% |  | 92.6% |  |  |  | 91.6% |  | 92.1% |  |
Average occupied square feet | 33,324 |  | 33,593 |  |  |  | 33,989 |  | 36,209 |  |
Average annual total revenues per occupied square foot(7) | $ | 37 |  | $ | 36 |  |  |  | $ | 38 |  | $ | 36 |  |
Average annual base rent per occupied square foot(8) | $ | 28 |  | $ | 28 |  |  |  | $ | 29 |  | $ | 29 |  |

_______________________________________
(1)Merger-Combined Same-Store includes legacy Physicians Realty Trust properties that met the definition of Merger-Combined Same-Store as if they were owned by the Company for the full analysis period. Refer to “Non-GAAP Financial Measures” above for the definition of Merger-Combined Same-Store.
(2)Total Portfolio includes results of operations from disposed properties through the disposition date. 2024 Total Portfolio includes results of operations for legacy Healthpeak prior to the Closing Date and results of operations for the Combined Company after the Closing Date.
(3)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our reportable segments. See Note 14 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI.
(4)Represents Adjusted NOI for legacy Physicians Realty Trust properties prior to the Closing Date.
(5)From our third quarter 2024 presentation of Same-Store, we added: (i) five stabilized acquisitions and (ii) four stabilized redevelopments placed in service, and we removed: (i) five assets that were sold and (ii) one building that was placed into redevelopment.
(6)Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(7)Average annual total revenues does not include non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
(8)Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
Merger-Combined Same-Store Adjusted NOI increased primarily as a result of the following:
•mark-to-market lease renewals;
•annual rent escalations; and
•increased percentage-based rents; partially offset by
•higher operating expenses, net of savings from our internalization of property management.
Total Portfolio Adjusted NOI increased primarily as a result of the aforementioned impacts to Merger-Combined Same-Store and the following Merger-Combined Non-Same-Store impacts:
•Adjusted NOI from the outpatient medical buildings acquired as part of the Merger in 2024;
•increased Adjusted NOI from outpatient medical buildings acquired in 2025;
•increased occupancy in former redevelopment and development properties that have been placed into service; partially offset by
•decreased Adjusted NOI from our 2024 and 2025 dispositions.
56

Table of Contents
Lab

The following table summarizes results at and for the three months ended September 30, 2025 and 2024 (dollars and square feet in thousands, except per square foot data):

| Merger-Combined SS |  | Total Portfolio(1)
| Three Months Ended September 30, |  | Three Months Ended September 30,
| 2025 |  | 2024 |  | Change |  | 2025 |  | 2024 |  | Change
Rental and related revenues | $ | 178,162 |  |  | $ | 181,087 |  |  | $ | (2,925) |  |  | $ | 213,325 |  |  | $ | 225,592 |  |  | $ | (12,267)
Healthpeak’s share of unconsolidated joint venture total revenues | 2,282 |  |  | 2,083 |  |  | 199 |  |  | 6,834 |  |  | 5,242 |  |  | 1,592
Operating expenses | (51,086) |  |  | (51,829) |  |  | 743 |  |  | (64,352) |  |  | (64,075) |  |  | (277)
Healthpeak’s share of unconsolidated joint venture operating expenses | (762) |  |  | (754) |  |  | (8) |  |  | (2,229) |  |  | (1,811) |  |  | (418)
Adjustments to NOI(2) | (12,499) |  |  | (10,646) |  |  | (1,853) |  |  | (15,520) |  |  | (16,900) |  |  | 1,380
Adjusted NOI | $ | 116,097 |  | $ | 119,941 |  | $ | (3,844) |  | 138,058 |  |  | 148,048 |  |  | (9,990)
Less: Merger-Combined Non-SS Adjusted NOI |  |  |  |  |  |  | (21,961) |  |  | (28,107) |  |  | 6,146
Merger-Combined SS Adjusted NOI |  |  |  |  |  |  | $ | 116,097 |  |  | $ | 119,941 |  |  | $ | (3,844)
Adjusted NOI % change |  |  |  |  | (3.2)% |  |  |  |  |  |
Property count(3) | 102 |  | 102 |  |  |  | 139 |  | 139 |  |
End of period occupancy(4) | 93.2% |  | 97.7% |  |  |  | 93.4% |  | 95.7% |  |
Average occupancy(4) | 93.7% |  | 97.7% |  |  |  | 93.8% |  | 95.6% |  |
Average occupied square feet | 7,549 |  | 7,841 |  |  |  | 9,017 |  | 9,561 |  |
Average annual total revenues per occupied square foot(5) | $ | 90 |  | $ | 89 |  |  |  | $ | 92 |  | $ | 90 |  |
Average annual base rent per occupied square foot(6) | $ | 64 |  | $ | 64 |  |  |  | $ | 69 |  | $ | 67 |  |

_______________________________________
(1)Total Portfolio includes results of operations from disposed properties through the disposition date.
(2)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our reportable segments. See Note 14 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI.
(3)From our third quarter 2024 presentation of Merger-Combined Same-Store, we added: (i) four stabilized redevelopments placed in service and (ii) one stabilized development placed in service, and we removed: (i) eight buildings that were placed into redevelopment and (ii) six assets that were classified as held for sale.
(4)Refer to “Non-GAAP Financial Measures” above for the definition of Merger-Combined Same-Store. Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(5)Average annual total revenues does not include non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
(6)Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
Merger-Combined Same-Store Adjusted NOI decreased primarily as a result of the following:
•lower occupancy; partially offset by
•annual rent escalations; and
•lower operating expenses related to savings from our internalization of property management.
Total Portfolio Adjusted NOI decreased primarily as a result of the aforementioned impacts to Merger-Combined Same-Store and the following Merger-Combined Non-Same-Store impacts:
•decreased Adjusted NOI from our 2024 dispositions;
•decreased Adjusted NOI from buildings undergoing development and redevelopment in 2024 and 2025; and
•higher operating expenses.
57

Table of Contents
The following table summarizes results at and for the nine months ended September 30, 2025 and 2024 (dollars and square feet in thousands, except per square foot data):

| Merger-Combined SS |  | Total Portfolio(1)
| Nine Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | Change |  | 2025 |  | 2024 |  | Change
Rental and related revenues | $ | 532,732 |  |  | $ | 519,783 |  |  | $ | 12,949 |  |  | $ | 640,123 |  |  | $ | 663,619 |  |  | $ | (23,496) |
Healthpeak’s share of unconsolidated joint venture total revenues | 5,761 |  |  | 5,880 |  |  | (119) |  |  | 16,992 |  |  | 14,404 |  |  | 2,588 |
Noncontrolling interests’ share of consolidated joint venture total revenues | — |  |  | — |  |  | — |  |  | — |  |  | (196) |  |  | 196 |
Operating expenses | (143,544) |  |  | (141,130) |  |  | (2,414) |  |  | (181,412) |  |  | (177,571) |  |  | (3,841) |
Healthpeak’s share of unconsolidated joint venture operating expenses | (1,845) |  |  | (1,933) |  |  | 88 |  |  | (5,793) |  |  | (4,663) |  |  | (1,130) |
Noncontrolling interests’ share of consolidated joint venture operating expenses | — |  |  | — |  |  | — |  |  | — |  |  | 52 |  |  | (52) |
Adjustments to NOI(2) | (34,984) |  |  | (31,531) |  |  | (3,453) |  |  | (42,844) |  |  | (51,624) |  |  | 8,780 |
Adjusted NOI | $ | 358,120 |  |  | $ | 351,069 |  |  | $ | 7,051 |  |  | 427,066 |  |  | 444,021 |  |  | (16,955) |
Less: Merger-Combined Non-SS Adjusted NOI |  |  |  |  |  |  | (68,946) |  |  | (92,952) |  |  | 24,006 |
Merger-Combined SS Adjusted NOI |  |  |  |  |  |  | $ | 358,120 |  |  | $ | 351,069 |  |  | $ | 7,051 |
Adjusted NOI % change |  |  |  |  | 2.0% |  |  |  |  |  |
Property count(3) | 100 |  | 100 |  |  |  | 139 |  | 139 |  |
End of period occupancy(4) | 93.1% |  | 97.7% |  |  |  | 93.4% |  | 95.7% |  |
Average occupancy(4) | 95.7% |  | 97.8% |  |  |  | 95.9% |  | 95.9% |  |
Average occupied square feet | 7,583 |  | 7,695 |  |  |  | 9,262 |  | 9,735 |  |
Average annual total revenues per occupied square foot(5) | $ | 89 |  | $ | 86 |  |  |  | $ | 90 |  | $ | 87 |  |
Average annual base rent per occupied square foot(6) | $ | 65 |  | $ | 63 |  |  |  | $ | 68 |  | $ | 66 |  |

_______________________________________
(1)Total Portfolio includes results of operations from disposed properties through the disposition date.
(2)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our reportable segments. See Note 14 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI.
(3)From our third quarter 2024 presentation of Same-Store, we added: (i) three stabilized redevelopments placed in service and (ii) one stabilized development placed in service, and we removed: (i) eight buildings that were placed into redevelopment and (ii) six assets that were classified as held for sale.
(4)Refer to “Non-GAAP Financial Measures” above for the definition of Merger-Combined Same-Store. Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(5)Average annual total revenues does not include non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
(6)Base rent does not include tenant recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).
Merger-Combined Same-Store Adjusted NOI increased primarily as a result of the following:
•annual rent escalations; partially offset by
•higher operating expenses, net of savings from our internalization of property management; and
•lower occupancy.
Total Portfolio Adjusted NOI decreased primarily as a result of the following:
•decreased Adjusted NOI from our 2024 dispositions; and
•decreased Adjusted NOI from buildings undergoing development and redevelopment in 2024 and 2025; partially offset by
•the aforementioned increases to Merger-Combined Same-Store.
58

Table of Contents
Continuing Care Retirement Community

The following table summarizes results at and for the three months ended September 30, 2025 and 2024 (dollars in thousands, except per unit data):

| Merger-Combined SS |  | Total Portfolio
| Three Months Ended September 30, |  | Three Months Ended September 30,
| 2025 |  | 2024 |  | Change |  | 2025 |  | 2024 |  | Change
Resident fees and services | $ | 150,458 |  |  | $ | 142,845 |  |  | $ | 7,613 |  |  | $ | 150,458 |  |  | $ | 142,845 |  |  | $ | 7,613 |
Operating expenses | (113,518) |  |  | (109,163) |  |  | (4,355) |  |  | (113,910) |  |  | (109,720) |  |  | (4,190) |
Adjustments to NOI(1) | — |  |  | 95 |  |  | (95) |  |  | — |  |  | 95 |  |  | (95) |
Adjusted NOI | $ | 36,940 |  |  | $ | 33,777 |  |  | $ | 3,163 |  |  | 36,548 |  |  | 33,220 |  |  | 3,328 |
Plus (less): Merger-Combined Non-SS adjustments |  |  |  |  |  |  | 392 |  |  | 557 |  |  | (165) |
Merger-Combined SS Adjusted NOI |  |  |  |  |  |  | $ | 36,940 |  |  | $ | 33,777 |  |  | $ | 3,163 |
Adjusted NOI % change |  |  |  |  | 9.4 % |  |  |  |  |  |
Property count(2) | 15 |  | 15 |  |  |  | 15 |  | 15 |  |
Average occupancy(3) | 86.7% |  | 85.2% |  |  |  | 86.7% |  | 85.2% |  |
Average occupied units(4) | 6,121 |  | 6,001 |  |  |  | 6,121 |  | 6,013 |  |
Average annual rent per occupied unit | $ | 98,322 |  | $ | 95,215 |  |  |  | $ | 98,322 |  | $ | 95,025 |  |

_______________________________________
(1)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our reportable segments. See Note 14 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI.
(2)From our third quarter 2024 presentation of Merger-Combined Same-Store, no properties were added or removed.
(3)Refer to “Non-GAAP Financial Measures” above for the definition of Merger-Combined Same-Store. Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(4)Represents average occupied units as reported by the operators for the three-month period.
Merger-Combined Same-Store Adjusted NOI and Total Portfolio Adjusted NOI increased primarily as a result of the following:
•increased rates for resident fees; and
•higher occupancy; partially offset by
•higher costs of labor, repairs and maintenance, management fees, and other operating expenses.
59

Table of Contents
The following table summarizes results at and for the nine months ended September 30, 2025 and 2024 (dollars in thousands, except per unit data):

| Merger-Combined SS |  | Total Portfolio
| Nine Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | Change |  | 2025 |  | 2024 |  | Change
Resident fees and services | $ | 448,240 |  |  | $ | 422,512 |  |  | $ | 25,728 |  |  | $ | 448,240 |  |  | $ | 422,512 |  |  | $ | 25,728 |
Operating expenses | (334,436) |  |  | (319,349) |  |  | (15,087) |  |  | (335,618) |  |  | (320,809) |  |  | (14,809) |
Adjustments to NOI(1) | (844) |  |  | (1,642) |  |  | 798 |  |  | (844) |  |  | (1,645) |  |  | 801 |
Adjusted NOI | $ | 112,960 |  |  | $ | 101,521 |  |  | $ | 11,439 |  |  | 111,778 |  |  | 100,058 |  |  | 11,720 |
Plus (less): Merger-Combined Non-SS adjustments |  |  |  |  |  |  | 1,182 |  |  | 1,463 |  |  | (281) |
Merger-Combined SS Adjusted NOI |  |  |  |  |  |  | $ | 112,960 |  |  | $ | 101,521 |  |  | $ | 11,439 |
Adjusted NOI % change |  |  |  |  | 11.3 % |  |  |  |  |  |
Property count(2) | 15 |  | 15 |  |  |  | 15 |  | 15 |  |
Average occupancy(3) | 86.3% |  | 85.2% |  |  |  | 86.3% |  | 85.3% |  |
Average occupied units(4) | 6,093 |  | 6,023 |  |  |  | 6,093 |  | 6,035 |  |
Average annual rent per occupied unit | $ | 98,088 |  | $ | 93,533 |  |  |  | $ | 98,089 |  | $ | 93,347 |  |

_______________________________________
(1)Represents adjustments we make to calculate Adjusted NOI in accordance with our definition of Adjusted NOI, which is used by our CODM to evaluate performance of our reportable segments. See Note 14 to the Consolidated Financial Statements for further information, including information reconciling our Adjusted NOI for reportable segments to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures. Refer also to “Non-GAAP Financial Measures” above for the definition of Adjusted NOI.
(2)From our third quarter 2024 presentation of Same-Store, no properties were added or removed.
(3)Refer to “Non-GAAP Financial Measures” above for the definition of Merger-Combined Same-Store. Total Portfolio occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
(4)Represents average occupied units as reported by the operators for the nine-month period.
Merger-Combined Same-Store Adjusted NOI and Total Portfolio Adjusted NOI increased primarily as a result of the following:
•increased rates for resident fees; and
•higher occupancy; partially offset by
•higher costs of labor, management fees, repairs and maintenance, utilities, and other operating expenses.
60

Table of Contents
Other Income and Expense Items

The following table summarizes the results of our other income and expense items for the three and nine months ended September 30, 2025 and 2024 (in thousands):

| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | Change |  | 2025 |  | 2024 |  | Change
Interest income and other | $ | 15,529 |  |  | $ | 14,301 |  |  | $ | 1,228 |  |  | $ | 47,156 |  |  | $ | 27,884 |  |  | $ | 19,272 |
Interest expense | 76,784 |  |  | 74,105 |  |  | 2,679 |  |  | 224,540 |  |  | 209,922 |  |  | 14,618 |
Depreciation and amortization | 262,317 |  |  | 280,019 |  |  | (17,702) |  |  | 796,779 |  |  | 782,736 |  |  | 14,043 |
General and administrative | 19,907 |  |  | 23,216 |  |  | (3,309) |  |  | 66,789 |  |  | 73,233 |  |  | (6,444) |
Transaction and merger-related costs | 2,420 |  |  | 7,134 |  |  | (4,714) |  |  | 18,169 |  |  | 122,113 |  |  | (103,944) |
Impairments and loan loss reserves (recoveries), net | (54) |  |  | 441 |  |  | (495) |  |  | (117) |  |  | 11,346 |  |  | (11,463) |
Gain (loss) on sales of real estate, net | 11,500 |  |  | 62,325 |  |  | (50,825) |  |  | 13,136 |  |  | 187,624 |  |  | (174,488) |
Other income (expense), net | 1,160 |  |  | 982 |  |  | 178 |  |  | (9,658) |  |  | 83,502 |  |  | (93,160) |
Income tax benefit (expense) | 1,206 |  |  | (1,938) |  |  | 3,144 |  |  | (3,256) |  |  | (18,364) |  |  | 15,108 |
Equity income (loss) from unconsolidated joint ventures | (176,291) |  |  | (3,834) |  |  | (172,457) |  |  | (176,691) |  |  | (1,407) |  |  | (175,284) |
Noncontrolling interests’ share in earnings | (7,274) |  |  | (6,866) |  |  | (408) |  |  | (21,856) |  |  | (18,036) |  |  | (3,820) |

Interest income and other
Interest income and other increased for the three and nine months ended September 30, 2025 primarily as a result of: (i) secured loans funded in 2024 and 2025 and (ii) seller financing provided in connection with the disposition of two outpatient medical buildings in November 2024, partially offset by principal repayments on loans receivable in 2024 and 2025. Interest income and other further increased for the nine months ended September 30, 2025 as a result of (i) seller financing provided in connection with the disposition of 59 outpatient medical buildings in July 2024 and (ii) mezzanine and secured loans receivable acquired as part of the Merger.
Interest expense
Interest expense increased for the three months ended September 30, 2025 primarily as a result of: (i) the issuance of $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035, which closed in February 2025, (ii) the issuance of $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033, which closed in August 2025, and (iii) higher borrowings under the commercial paper program, partially offset by: (i) the repayment of $348 million aggregate principal amount of 3.40% senior unsecured notes in February 2025 and (ii) the repayment of $452 million aggregate principal amount of 4.00% senior unsecured notes in June 2025. Interest expense further increased for the nine months ended September 30, 2025 as a result of: (i) debt assumed as part of the Merger, including $1.25 billion aggregate principal amount of senior unsecured notes, $400 million aggregate principal amount of the 2028 Term Loan, and $128 million aggregate principal amount of mortgage debt and (ii) borrowings under the 2029 Term Loan, which closed in March 2024.
Depreciation and amortization
Depreciation and amortization expense decreased for the three months ended September 30, 2025 primarily as a result of dispositions of real estate in 2024 and 2025, partially offset by development and redevelopment projects placed in service during 2024 and 2025. Depreciation and amortization expense increased for the nine months ended September 30, 2025 primarily as a result of assets acquired as part of the Merger.
General and administrative
General and administrative expenses decreased for the three and nine months ended September 30, 2025 primarily as a result of (i) lower compensation expense and (ii) merger-related synergies.
Transaction and merger-related costs
Transaction and merger-related costs decreased for the three and nine months ended September 30, 2025 primarily as a result of costs of combining operations with Physicians Realty Trust that were incurred in 2024. The decrease in transaction and merger-related costs for the nine months ended September 30, 2025 was partially offset by costs incurred in 2025 related to investments we are no longer pursuing.
61

Table of Contents
Impairments and loan loss reserves (recoveries), net
Impairments and loan loss reserves (recoveries), net decreased for the nine months ended September 30, 2025 as a result of a decrease in loan loss reserves under the current expected credit losses model, which is primarily due to (i) reserves recognized in 2024 on loans receivable acquired as part of the Merger, (ii) changes in operating performance and fair values of the underlying collateral of the Company’s loans receivable, and (iii) recoveries related to loans repaid during the nine months ended September 30, 2025, partially offset by new and extended loans during 2024 and 2025.
Gain (loss) on sales of real estate, net
Gain on sales of real estate, net decreased during the three and nine months ended September 30, 2025 as a result of (i) no dispositions of real estate during the three months ended March 31, 2025, (ii) the $3 million gain on sale of one outpatient medical land parcel which was sold during the three months ended June 30, 2025, and (iii) the $12 million gain on sales of two outpatient medical buildings which were sold during the three months ended September 30, 2025, as compared to (i) the $3 million gain on sales of two outpatient medical buildings which were sold during the three months ended March 31, 2024, (ii) the $122 million gain on sales of a portfolio of seven lab buildings and 11 outpatient medical buildings which were sold during the three months ended June 30, 2024, and (iii) the $60 million gain on sales of a portfolio of 59 outpatient medical buildings which were sold during the three months ended September 30, 2024. Refer to Note 5 to the Consolidated Financial Statements for additional information regarding dispositions of real estate and the associated gain (loss) on sales recognized.
Other income (expense), net
Other income (expense), net decreased for the nine months ended September 30, 2025 primarily as a result of a gain upon change of control related to the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January 2024, partially offset by casualty-related losses recognized in 2025.
Income tax benefit (expense)
Income tax benefit increased for the three months ended September 30, 2025 primarily as a result of the income tax benefit from the other-than-temporary impairment charge on the Needham Land Parcel JV, as discussed below, partially offset by an increase in operating income associated with our CCRCs. Income tax expense decreased for the nine months ended September 30, 2025 primarily as a result of: (i) the income tax expense incurred in connection with the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January 2024, (ii) the tax benefit from casualty-related losses recognized in 2025, and (iii) the aforementioned impacts to the income tax benefit from the other-than-temporary impairment charge affecting the three months ended September 30, 2025.
Equity income (loss) from unconsolidated joint ventures
Equity income (loss) from unconsolidated joint ventures decreased for the three and nine months ended September 30, 2025 primarily as a result of other-than-temporary impairment charges on two lab unconsolidated joint ventures, the South San Francisco JVs and the Needham Land Parcel JV, partially offset by the preferred return on the HQ Point Preferred Equity Investment.
Noncontrolling interests’ share in earnings
Noncontrolling interests’ share in earnings increased for the nine months ended September 30, 2025 primarily as a result of increased income from consolidated joint ventures acquired as part of the Merger.
Liquidity and Capital Resources
We anticipate that our cash flows from operations, available cash balances, and cash from our various financing activities will be adequate for the next 12 months and for the foreseeable future for purposes of: (i) funding recurring operating expenses; (ii) meeting debt service requirements; and (iii) satisfying funding of distributions to our stockholders and non-controlling interest members. Distributions are made using a combination of cash flows from operations, funds available under our bank line of credit (the “Revolving Facility”) and commercial paper program, proceeds from the sale of properties, and other sources of cash available to us.
In addition to funding the activities above, our principal liquidity needs for the next 12 months are to:
•fund capital expenditures, including tenant improvements and leasing costs;
•fund future acquisition, transactional, and development and redevelopment activities; and
•fund loans receivable and other investment commitments.
Our longer term liquidity needs include the items listed above as well as meeting debt service requirements.
62

Table of Contents
We anticipate satisfying these future needs using one or more of the following:
•cash flows from operations;
•sale of, or exchange of ownership interests in, properties or other investments;
•borrowings under our Revolving Facility and commercial paper program;
•issuance of additional debt, including unsecured notes, term loans, and mortgage debt; and/or
•issuance of common or preferred stock or its equivalent, including sales of common stock under the ATM Program (as defined below).
Our ability to access the capital markets impacts our cost of capital and ability to refinance maturing indebtedness, as well as our ability to fund future acquisitions and development through the issuance of additional securities or secured debt. Changes in general market and economic conditions as well as credit ratings impact our ability to access capital and directly impact our cost of capital. Our 2029 Term Loan, our two senior unsecured delayed draw term loans with an aggregate principal amount of $500 million (the “2027 Term Loans”), our 2028 Term Loan, and our Revolving Facility accrue interest at the Secured Overnight Financing Rate (“SOFR”) plus a margin that depends on the credit ratings of our senior unsecured long-term debt. We also pay a facility fee on the entire commitment under our Revolving Facility that depends upon our credit ratings. As of October 22, 2025, we had long-term credit ratings of Baa1 from Moody’s and BBB+ from S&P Global, and short-term credit ratings of P-2 from Moody’s and A-2 from S&P Global.
A downgrade in credit ratings by Moody’s or S&P Global may have a negative impact on (i) the interest rates of our Revolving Facility, 2027 Term Loans, 2028 Term Loan, and 2029 Term Loan, (ii) facility fees for our Revolving Facility, and (iii) the pricing of notes issued under our commercial paper program and senior unsecured notes. While a downgrade in our credit ratings would adversely impact our cost of borrowing, we believe we would continue to have access to the unsecured debt markets, and we could also seek to enter into one or more secured debt financings, issue additional securities, including under our ATM Program, or dispose of certain assets to fund future operating costs, capital expenditures, or acquisitions, although no assurances can be made in this regard. Refer to “Market Trends and Uncertainties” above for a more comprehensive discussion of the potential impact of economic and market conditions on our business.
Changes in Material Cash Requirements and Off-Balance Sheet Arrangements
Debt. Our material cash requirements related to debt increased by $416 million to $9.1 billion at September 30, 2025, when compared to December 31, 2024, primarily as a result of: (i) the issuance of $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035, (ii) the issuance of $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033, and (iii) a $218 million increase in notes outstanding under our commercial paper program, partially offset by the repayment upon maturity of: (i) $452 million aggregate principal amount of 4.00% senior unsecured notes and (ii) $348 million aggregate principal amount of 3.40% senior unsecured notes. See Note 10 to the Consolidated Financial Statements for additional information about our debt commitments.
Development and redevelopment commitments. Our material cash requirements related to development and redevelopment projects and Company-owned tenant improvements decreased by $28 million to $256 million at September 30, 2025, when compared to December 31, 2024, primarily as a result of construction spend on projects in development and redevelopment, partially offset by commitments on projects placed into development and redevelopment during the period.
Construction loan commitments. Our material cash requirements to provide additional principal on loans for redevelopment and capital expenditure projects increased by $36 million to $121 million at September 30, 2025, when compared to December 31, 2024. This increase was the result of outstanding commitments on secured loans executed during the nine months ended September 30, 2025, partially offset by a reduction in remaining commitments due to loan fundings and repayments during the nine months then ended. See Note 7 to the Consolidated Financial Statements for additional information.
Other investment commitments. During the nine months ended September 30, 2025, we funded $45 million of our $50 million HQ Point Preferred Equity Investment. At September 30, 2025, our remaining funding commitment related to the HQ Point Preferred Equity Investment was $5 million, which is expected to be funded in 2025. See Note 8 to the Consolidated Financial Statements for additional information. Additionally, as of September 30, 2025, we had aggregate investments of $3 million in funds that make venture capital investments in various early-stage technology solutions (“Other Equity Investments”). At September 30, 2025, our remaining funding commitment related to the Other Equity Investments was $9 million, which is expected to be funded over the next four years. See Note 16 to the Consolidated Financial Statements for additional information.
63

Table of Contents
Redeemable noncontrolling interests. Our material cash requirements related to redeemable noncontrolling interests increased by $25 million to $28 million at September 30, 2025, when compared to December 31, 2024. The values of these redeemable noncontrolling interests are subject to change based on the assessment of redemption value at each redemption date. As of September 30, 2025, the estimated redemption value of the redeemable noncontrolling interests that have met the conditions for redemption is $15 million. The estimated redemption value of the redeemable noncontrolling interests that will meet the conditions for redemption upon completion of each of the related development projects is $13 million. See Note 12 to the Consolidated Financial Statements for additional information.
Distribution and Dividend Requirements. Our dividend policy on our common stock is to distribute a percentage of our cash flow to ensure that we meet the dividend requirements of the Code, relative to maintaining our REIT status, while still allowing us to retain cash to fund capital improvements and other investment activities. Under the Code, REITs may be subject to certain federal income and excise taxes on undistributed taxable income. In February 2025, our Board of Directors declared an increase in the quarterly common stock cash dividend, from $0.300 to $0.305 per share, resulting in an annualized dividend of $1.220 per share. Commencing in April 2025, our Board of Directors also transitioned to a practice of paying the quarterly common stock cash dividend on a monthly basis, which are declared quarterly. Our future common stock cash dividends, if and as declared, may vary and will be determined by the Board based upon the circumstances prevailing at the time, including our financial condition. There have been no other changes to our distribution and dividend requirements during the nine months ended September 30, 2025.
Off-Balance Sheet Arrangements. We own interests in certain unconsolidated joint ventures as described in Note 8 to the Consolidated Financial Statements. Four of these joint ventures have aggregate mortgage debt of $871 million, of which our share is $200 million. Except in limited circumstances, our risk of loss is limited to our investment in the applicable joint venture. Additionally, as of September 30, 2025, we had 16 outstanding letter of credit obligations totaling $16 million.
There have been no other material changes, outside of the ordinary course of business, during the nine months ended September 30, 2025 to the material cash requirements or material off-balance sheet arrangements disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024 under “Material Cash Requirements” and “Off-Balance Sheet Arrangements” in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Cash Flow Summary
The following summary discussion of our cash flows is based on the Consolidated Statements of Cash Flows and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below.
The following table sets forth changes in cash flows (in thousands):

| Nine Months Ended September 30,
| 2025 |  | 2024 |  | Change
Net cash provided by (used in) operating activities | $ | 957,875 |  |  | $ | 786,966 |  |  | $ | 170,909 |
Net cash provided by (used in) investing activities | (629,053) |  |  | 119,975 |  |  | (749,028) |
Net cash provided by (used in) financing activities | (353,395) |  |  | (833,919) |  |  | 480,524 |

Operating Cash Flows
Our cash flows from operations are dependent upon the occupancy levels of our buildings, rental rates on leases, our tenants’ performance on their lease obligations, the level of operating expenses, and other factors. Our net cash provided by operating activities increased $171 million for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 primarily as a result of: (i) a decrease in merger-related costs, (ii) an increase in Adjusted NOI from properties acquired as part of the Merger and acquisitions of real estate in 2025, (iii) developments and redevelopments placed in service during 2024 and 2025, (iv) annual rent increases, and (v) new leasing and renewal activity. The increase in net cash provided by operating activities was partially offset by: (i) an increase in cash paid for interest and (ii) a decrease in Adjusted NOI from dispositions of real estate in 2024 and 2025.
64

Table of Contents
Investing Cash Flows
Our cash flows from investing activities are generally used to fund acquisitions, developments, and redevelopments of real estate, net of proceeds received from sales of real estate and repayments on loans receivable. Our net cash used in investing activities increased $749 million for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 primarily as a result of the following: (i) a decrease in proceeds from sales of real estate, (ii) an increase in cash used for development and redevelopment of real estate, (iii) proceeds received from the Callan Ridge JV transaction in 2024, (iv) an increase in cash used for real estate asset acquisitions, (v) lower net repayments on loans receivable, and (vi) an increase in cash used for investments in unconsolidated joint ventures. The increase in net cash used in investing activities was partially offset by cash paid in connection with the Merger in 2024.
Financing Cash Flows
Our cash flows from financing activities are generally impacted by issuances and/or repurchases of equity, borrowings and repayments under our bank line of credit and commercial paper program, senior unsecured notes, term loans, and mortgage debt, net of dividends paid to common shareholders. Our net cash used in financing activities decreased $481 million for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 primarily as a result of the following: (i) higher net issuances under the commercial paper program, (ii) an increase in proceeds received from the issuances of senior unsecured notes, (iii) lower repurchases of common stock under our share repurchase programs, (iv) lower distributions to noncontrolling interests, and (v) higher contributions from noncontrolling interests. The decrease in net cash used in financing activities was partially offset by: (i) an increase in cash used to repay senior unsecured notes that reached maturity in 2025, (ii) a decrease in proceeds received from the issuance of term loans, and (iii) an increase in dividends paid on common stock.
Debt
In February 2025, we repaid $348 million aggregate principal amount of 3.40% senior unsecured notes at maturity. Also in February 2025, we issued $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035. In June 2025, we repaid $452 million aggregate principal amount of 4.00% senior unsecured notes at maturity. In August 2025, we issued $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033.
See Note 10 to the Consolidated Financial Statements for additional information about our outstanding debt.
Approximately 95% and 99% of our consolidated debt was fixed rate debt as of September 30, 2025 and 2024, respectively. At September 30, 2025, our fixed rate debt and variable rate debt had weighted average effective interest rates of 4.20% and 4.79%, respectively. At September 30, 2024, our fixed rate debt and variable rate debt had weighted average effective interest rates of 4.05% and 7.41%, respectively. As of September 30, 2025, we had the following swapped to fixed rates through interest rate swap instruments: (i) the $750 million 2029 Term Loan, (ii) the $500 million 2027 Term Loans, (iii) the $400 million 2028 Term Loan, and (iv) $142 million of variable rate mortgage debt. These interest rate swap instruments are designated as cash flow hedges. For purposes of classification of the amounts above, variable rate debt with a derivative financial instrument designated as a cash flow hedge is reported as fixed rate debt due to us having effectively established a fixed interest rate for the underlying debt instrument. For a more detailed discussion of our interest rate risk, see “Quantitative and Qualitative Disclosures About Market Risk” in Item 3 below.
Supplemental Guarantor Information
Healthpeak OP is the issuer of senior unsecured notes that were offered and sold on a registered basis under the Securities Act as described in Note 10 to the Consolidated Financial Statements. The obligations of Healthpeak OP to pay principal, premiums, if any, and interest on such senior unsecured notes are guaranteed on a full and unconditional basis by the Company, DOC DR Holdco, and DOC DR OP Sub. Additionally, DOC DR OP Sub is the issuer, as successor to the Physicians Partnership upon the Merger, of the senior unsecured notes issued by the Physicians Partnership prior to, and assumed by Healthpeak as part of, the Merger as described in Note 10 to the Consolidated Financial Statements. The obligations of DOC DR OP Sub to pay principal, premiums, if any, and interest on such senior unsecured notes are guaranteed on a full and unconditional basis by the Company, Healthpeak OP, and DOC DR Holdco.
Subsidiary issuers of obligations guaranteed by the parent are not required to provide separate financial statements, provided that the parent guarantee is “full and unconditional”, the subsidiary obligor is a consolidated subsidiary of the parent company, the guaranteed security is debt or debt-like, and consolidated financial statements of the parent company have been filed. Accordingly, separate consolidated financial statements of Healthpeak OP, DOC DR Holdco, and DOC DR OP Sub have not been presented.
65

Table of Contents
As permitted under Rule 13-01 of Regulation S-X, we have excluded the summarized financial information for the Company, Healthpeak OP, DOC DR Holdco, and DOC DR OP because the Company, Healthpeak OP, DOC DR Holdco, and DOC DR OP have no material assets, liabilities, or operations other than the debt financing activities described in the first paragraph of Note 10 to the Consolidated Financial Statements and their investments in non-guarantor subsidiaries, and management believes such summarized financial information would be repetitive and would not provide incremental value to investors.
Equity
At September 30, 2025, we had 695 million shares of common stock outstanding, equity totaled $8.2 billion, and our equity securities had a market value of $13.6 billion.
At-The-Market Program
In February 2023, we terminated our previous at-the-market equity offering program and established a new at-the-market equity offering program (the “ATM Program”) that allows for the sale of shares of common stock having an aggregate gross sales price of up to $1.5 billion. In addition to the issuance and sale of shares of our common stock, we may also enter into one or more forward sales agreements (each, an “ATM forward contract”) with sales agents for the sale of our shares of common stock under our ATM Program. The ATM Program was most recently amended in February 2025 to add certain banks as sales agents, a forward seller, and a forward purchaser under the ATM Program.
During the three and nine months ended September 30, 2025, we did not issue any shares of our common stock under any ATM program.
At September 30, 2025, $1.5 billion of our common stock remained available for sale under the ATM Program. Actual future sales of our common stock will depend upon a variety of factors, including but not limited to market conditions, the trading price of our common stock, and our capital needs. We have no obligation to sell any shares under our ATM Program.
See Note 12 to the Consolidated Financial Statements for additional information about our ATM Program.
Noncontrolling Interests
Healthpeak OP. During the nine months ended September 30, 2025, certain of our employees (“OP Unitholders”) were issued approximately 2 million noncontrolling, non-managing member units in Healthpeak OP (“OP Units”). When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their OP Units for cash or shares of our common stock, at our option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of our common stock or cash equal to the fair value of a share of common stock at the time of redemption. We classify the OP Units in permanent equity because we may elect, in our sole discretion, to issue shares of our common stock to OP Unitholders who choose to redeem their OP Units rather than using cash. As of September 30, 2025, there were approximately 4 million OP Units outstanding, and 265 thousand had met the criteria for redemption.
DownREITs. At September 30, 2025, non-managing members held an aggregate of approximately 11 million units in eight limited liability companies for which we hold controlling interests and/or are the managing member. The DownREIT units are exchangeable for an amount of cash approximating the then-current market value of shares of our common stock or, at our option, shares of our common stock. At September 30, 2025, the outstanding DownREIT units were convertible into approximately 13 million shares of our common stock.
66

Table of Contents
Share Repurchase Program
On July 24, 2024, our Board of Directors approved a new share repurchase program (the “2024 Share Repurchase Program”) to supersede and replace our previous program. Under the 2024 Share Repurchase Program, we may acquire shares of our common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Exchange Act or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), up to an aggregate purchase price of $500 million. Purchases of common stock under the 2024 Share Repurchase Program may be exercised at our discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The 2024 Share Repurchase Program expires in July 2026 and may be suspended or terminated at any time without prior notice. During the three months ended September 30, 2025, there were no repurchases of common stock under the 2024 Share Repurchase Program. During the nine months ended September 30, 2025, we repurchased 5.09 million shares of our common stock at a weighted average price of $18.50 per share for a total of $94 million. At September 30, 2025, $406 million of the Company’s common stock remained available for repurchase under the 2024 Share Repurchase Program.
Shelf Registration
On February 8, 2024, the Company and Healthpeak OP jointly filed a prospectus with the SEC as part of a registration statement on Form S-3, using an automatic shelf registration process. This shelf registration statement expires on February 8, 2027 and at or prior to such time, we expect to file a new shelf registration statement. On February 5, 2025, the Company and Healthpeak OP jointly filed a post-effective amendment to the shelf registration statement to add certain subsidiaries of the Company as co-registrants and register their guarantees of the debt securities of the Company and/or Healthpeak OP as additional securities that may be offered under the prospectus included in the shelf registration statement. Under the “shelf” process, we may sell any combination of the securities described in the prospectus through one or more offerings. The securities described in the prospectus include future offerings of: (i) the Company’s common stock, preferred stock, depositary shares, warrants, debt securities, and guarantees by the Company and certain of its subsidiaries of debt securities issued by Healthpeak OP, and (ii) Healthpeak OP’s debt securities and guarantees by Healthpeak OP and certain other subsidiaries of the Company of debt securities issued by the Company.
67

Table of Contents
Non-GAAP Financial Measures Reconciliations
The following is a reconciliation from net income (loss) applicable to common shares, the most directly comparable financial measure calculated and presented in accordance with GAAP, to Nareit FFO, FFO as Adjusted, and AFFO (in thousands):

| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Net income (loss) applicable to common shares | $ | (117,256) |  |  | $ | 85,675 |  |  | $ | (43,335) |  |  | $ | 237,985 |
Real estate related depreciation and amortization | 262,317 |  |  | 280,019 |  |  | 796,779 |  |  | 782,736 |
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures | 12,574 |  |  | 12,127 |  |  | 37,304 |  |  | 32,520 |
Noncontrolling interests’ share of real estate related depreciation and amortization | (3,807) |  |  | (4,534) |  |  | (12,686) |  |  | (13,705) |
Loss (gain) on sales of depreciable real estate, net | (11,500) |  |  | (62,325) |  |  | (13,136) |  |  | (187,624) |
Loss (gain) upon change of control, net(1) | — |  |  | 430 |  |  | — |  |  | (77,548) |
Taxes associated with real estate dispositions(2) | — |  |  | (145) |  |  | (335) |  |  | 11,512 |
Impairments (recoveries) of real estate, net(3) | 175,827 |  |  | — |  |  | 175,827 |  |  | — |
Nareit FFO applicable to common shares | 318,155 |  |  | 311,247 |  |  | 940,418 |  |  | 785,876 |
Distributions on dilutive convertible units and other | 4,551 |  |  | 4,577 |  |  | 13,735 |  |  | 11,670 |
Diluted Nareit FFO applicable to common shares | $ | 322,706 |  |  | $ | 315,824 |  |  | $ | 954,153 |  |  | $ | 797,546 |
Impact of adjustments to Nareit FFO: |  |  |  |  |  |  |
Transaction and merger-related items(4) | $ | 2,420 |  |  | $ | 2,725 |  |  | $ | 18,169 |  |  | $ | 108,923 |
Other impairments (recoveries) and other losses (gains), net(5) | (54) |  |  | 441 |  |  | 125 |  |  | 11,741 |
Casualty-related charges (recoveries), net(6) | (1,771) |  |  | 1,792 |  |  | 6,375 |  |  | 588 |
Total adjustments | $ | 595 |  |  | $ | 4,958 |  |  | $ | 24,669 |  |  | $ | 121,252 |
FFO as Adjusted applicable to common shares | $ | 318,750 |  |  | $ | 316,205 |  |  | $ | 965,087 |  |  | $ | 907,128 |
Distributions on dilutive convertible units and other | 4,551 |  |  | 4,571 |  |  | 13,715 |  |  | 11,537 |
Diluted FFO as Adjusted applicable to common shares | $ | 323,301 |  |  | $ | 320,776 |  |  | $ | 978,802 |  |  | $ | 918,665 |
FFO as Adjusted applicable to common shares | $ | 318,750 |  |  | $ | 316,205 |  |  | $ | 965,087 |  |  | $ | 907,128 |
Stock-based compensation amortization expense | 4,046 |  |  | 3,755 |  |  | 10,410 |  |  | 11,935 |
Amortization of deferred financing costs and debt discounts (premiums) | 7,981 |  |  | 7,408 |  |  | 23,708 |  |  | 19,247 |
Straight-line rents | (14,282) |  |  | (10,346) |  |  | (30,836) |  |  | (32,891) |
AFFO capital expenditures | (27,261) |  |  | (23,510) |  |  | (76,125) |  |  | (76,744) |
CCRC entrance fees(7) | 12,711 |  |  | 11,046 |  |  | 36,449 |  |  | 30,548 |
Deferred income taxes | (179) |  |  | 585 |  |  | 4,989 |  |  | 2,330 |
Amortization of above (below) market lease intangibles, net | (8,105) |  |  | (7,887) |  |  | (28,402) |  |  | (23,325) |
Other AFFO adjustments | (1,687) |  |  | (1,277) |  |  | (1,303) |  |  | (4,947) |
AFFO applicable to common shares | 291,974 |  |  | 295,979 |  |  | 903,977 |  |  | 833,281 |
Distributions on dilutive convertible units and other | 4,550 |  |  | 4,576 |  |  | 13,735 |  |  | 11,671 |
Diluted AFFO applicable to common shares(7) | $ | 296,524 |  |  | $ | 300,555 |  |  | $ | 917,712 |  |  | $ | 844,952 |

Refer to footnotes on the next page.
68

Table of Contents
_______________________________________
(1)The nine months ended September 30, 2024 includes a gain upon change of control related to the sale of a 65% interest in two lab buildings in San Diego, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations.
(2)The nine months ended September 30, 2024 includes non-cash income tax expense related to the sale of a 65% interest in two lab buildings in San Diego, California.
(3)The three and nine months ended September 30, 2025 includes other-than-temporary impairment charges on certain unconsolidated real estate joint ventures. During the three months ended September 30, 2025, we concluded that the decline in fair values of these joint ventures was other-than-temporary due to the length of time and extent of which the fair values have been less than carrying value. Other-than-temporary impairment charges on our unconsolidated joint ventures are recognized in equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations.
(4)The three and nine months ended September 30, 2025 and 2024 include costs related to the Merger, which are primarily comprised of advisory, legal, accounting, tax, information technology, post-combination severance and stock compensation expense, and other costs of combining operations with Physicians Realty Trust that were incurred during the period. The nine months ended September 30, 2025 also includes $6 million of costs incurred related to certain investments we are no longer pursuing. For the three and nine months ended September 30, 2024, these costs were partially offset by termination fee income of $4 million and $13 million, respectively, associated with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024, for which the lease terms were modified to accelerate expiration of the lease to December 2024. This termination fee income is included in rental and related revenues on the Consolidated Statements of Operations, but is excluded from FFO as Adjusted.
(5)The three and nine months ended September 30, 2025 and 2024 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.
(6)Casualty-related charges (recoveries), net are recognized in other income (expense), net, equity income (loss) from unconsolidated joint ventures, and noncontrolling interests' share in earnings in the Consolidated Statements of Operations.
(7)During the year ended December 31, 2024, we changed our definition of AFFO to adjust for the non-refundable entrance fees collected in excess of (less than) the related amortization as we believe the cash collection of these fees is a more meaningful representation of the performance of the CCRC reportable segment in the determination of AFFO. Diluted AFFO applicable to common shares utilizing the prior definition for the three months ended September 30, 2025 and 2024 was $283.8 million and $289.5 million, respectively. Diluted AFFO applicable to common shares utilizing the prior definition for the nine months ended September 30, 2025 and 2024 was $881.3 million and $814.4 million, respectively.
Critical Accounting Estimates
The preparation of financial statements in conformity with U.S. GAAP requires our management to use judgment in the application of critical accounting estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates could affect our financial position or results of operations. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our consolidated financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. A discussion of accounting estimates that we consider critical in that they may require complex judgment in their application or require estimates about matters that are inherently uncertain is included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.” During the three months ended September 30, 2025, we added additional considerations to our critical accounting estimate as described below:
Impairment of Unconsolidated Joint Ventures
On a quarterly basis, we review our equity method investments for indicators of impairment. If an equity method investment shows indicators of impairment, we compare the fair value of the equity method investment to its carrying value. When we determine a decline in fair value below carrying value is other-than-temporary, an impairment is recorded. In our evaluation, we consider various factors, including the performance of each investment, our investment strategy, and market conditions, including the impact to market rents, capitalization rates, and supply and demand for rentable space.
The fair values of our equity method investments are determined based on discounted cash flows which are subjective and consider assumptions regarding forecasted occupancy, market rents, capitalization rates, discount rates, expected capital expenditures, and land values. While we believe our assumptions are reasonable, changes in these assumptions may have a material impact on our consolidated financial statements.
69

Table of Contents
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to various market risks, primarily from the potential loss arising from adverse changes in interest rates. We use derivative and other financial instruments in the normal course of business to mitigate interest rate risk. We do not use derivative financial instruments for speculative or trading purposes. Derivatives are recorded on the Consolidated Balance Sheets at fair value (see Note 18 to the Consolidated Financial Statements).
To illustrate the effect of movements in the interest rate markets, we performed a market sensitivity analysis on our hedging instruments. We applied various basis point spreads to the underlying interest rate curves of our derivative portfolio in order to determine the change in fair value. At September 30, 2025, a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by up to $43 million.
Interest Rate Risk. At September 30, 2025, our exposure to interest rate risk was primarily on our variable rate debt. At September 30, 2025, we had the following swapped to fixed rates through interest rate swap instruments: (i) the $750 million 2029 Term Loan, (ii) the $500 million 2027 Term Loans, (iii) the $400 million 2028 Term Loan, and (iv) $142 million of variable rate mortgage debt. The interest rate swap instruments are designated as cash flow hedges, with the objective of managing the exposure to interest rate risk by converting the interest rates on our variable rate debt to fixed interest rates. At September 30, 2025, both the fair value and carrying value of the interest rate swap assets was $8 million and both the fair value and carrying value of the interest rate swap liabilities was $10 million.
Our remaining variable rate debt at September 30, 2025 was comprised of borrowings under our commercial paper program and certain of our mortgage debt. Interest rate fluctuations will generally not affect our future earnings or cash flows on our fixed rate debt and assets until their maturity or earlier prepayment and refinancing. If interest rates have risen at the time we seek to refinance our fixed rate debt, whether at maturity or otherwise, our future earnings and cash flows could be adversely affected by additional borrowing costs. Conversely, lower interest rates at the time of refinancing may reduce our overall borrowing costs. Interest rate changes will affect the fair value of our fixed rate instruments. At September 30, 2025, a one percentage point increase in interest rates would decrease the fair value of our fixed rate debt by approximately $281 million and a one percentage point decrease in interest rates would increase the fair value of our fixed rate debt by approximately $301 million. Additionally, at September 30, 2025, a one percentage point increase or decrease in interest rates would change the fair value of our fixed rate loans receivable by up to $14 million. These changes would not materially impact earnings or cash flows. Conversely, changes in interest rates on variable rate debt would change our future earnings and cash flows, but not materially impact the fair value of those instruments. Assuming a one percentage point increase in the interest rates related to our variable rate debt, and assuming no other changes in the outstanding balance at September 30, 2025, our annual interest expense would increase by approximately $5 million.
70

Table of Contents
Item 4. Controls and Procedures
Disclosure Controls and Procedures. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2025. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2025.
Changes in Internal Control Over Financial Reporting. During the quarter ended June 30, 2025, we completed the implementation of a new enterprise resource planning (“ERP”) system to replace our previous ERP system. The implementation resulted in considerable changes to our processes and control environment, including the implementation of new applications, interfaces, and reports. The new ERP was used during the second and third quarters of 2025, and the new and modified processes and controls implemented were used to prepare our consolidated financial statements for the three and nine months ended September 30, 2025 included in this report.
Except for those changes, there have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
71

Table of Contents
PART II. OTHER INFORMATION
Item 1A. Risk Factors
We have described in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, the primary risk factors that could materially affect our business, financial condition, or future results. There have been no material changes to those risk factors.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a)
None.
(b)
None.
(c)
The following table sets forth information with respect to purchases of our common stock made by us or on our behalf during the three months ended September 30, 2025.

Period Covered |  | Total Number of Shares Purchased |  | Average Price Paid per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1) |  | Maximum Number (or Approximate Dollar Value) of Shares that May Yet be Purchased Under the Plans or Programs(1)
July 1-31, 2025 |  | — |  |  | $ | — |  |  | — |  |  | $ | 405,831,746 |
August 1-31, 2025 |  | — |  |  | — |  |  | — |  |  | 405,831,746 |
September 1-30, 2025 |  | — |  |  | — |  |  | — |  |  | 405,831,746 |
|  | — |  |  | $ | — |  |  | — |  |  | $ | 405,831,746 |

_______________________________________
(1)On July 24, 2024, our Board of Directors approved the 2024 Share Repurchase Program under which we may acquire shares of our common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Exchange Act or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), up to an aggregate purchase price of $500 million. Purchases of common stock under the 2024 Share Repurchase Program may be exercised at our discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The 2024 Share Repurchase Program expires in July 2026 and may be suspended or terminated at any time without prior notice. During the three months ended September 30, 2025, there were no repurchases of common stock under the 2024 Share Repurchase Program. During the nine months ended September 30, 2025, we repurchased 5.09 million shares of our common stock at a weighted average price of $18.50 per share for a total of $94 million. At September 30, 2025, $406 million of our common stock remained available for repurchase under the 2024 Share Repurchase Program.
Item 5. Other Information
Insider Trading Arrangements
During the three months ended September 30, 2025, none of our directors or Section 16 officers adopted, modified, or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement.
72

Table of Contents
Item 6. Exhibits

2.1+ |  | Agreement and Plan of Merger, dated February 7, 2023, by and among Healthpeak Properties, Inc., New Healthpeak, Inc. and Healthpeak Merger Sub, Inc. (incorporated herein by reference to Exhibit 2.1 to Healthpeak’s Current Report on Form 8-K12B filed February 10, 2023).
2.2+ |  | Agreement and Plan of Merger, dated as of October 29, 2023, by and among Healthpeak Properties, Inc., DOC DR Holdco, LLC (formerly Alpine Sub, LLC), DOC DR, LLC (formerly Alpine OP Sub, LLC), Physicians Realty Trust and Physicians Realty L.P. (incorporated herein by reference to Exhibit 2.1 to Healthpeak’s Current Report on Form 8-K filed October 30, 2023).
3.1 |  | Articles of Amendment and Restatement of Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.) effective February 10, 2023 (incorporated herein by reference to Exhibit 3.1 to Healthpeak’s Current Report on Form 8-K12B filed February 10, 2023).
3.2 |  | Articles of Amendment of Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.) effective February 10, 2023 (incorporated herein by reference to Exhibit 3.2 to Healthpeak’s Current Report on Form 8-K12B filed February 10, 2023).
3.3 |  | Articles of Amendment of Healthpeak Properties, Inc., effective February 29, 2024 (incorporated herein by reference to Exhibit 3.1 to Healthpeak’s Current Report on Form 8-K filed March 1, 2024).
3.4 |  | Amended and Restated Bylaws of Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.), dated February 10, 2023 (incorporated herein by reference to Exhibit 3.4 to Healthpeak’s Current Report on Form 8-K12B filed February 10, 2023).
3.5 |  | Amendment to the Bylaws of Healthpeak Properties, Inc., effective March 1, 2024 (incorporated herein by reference to Exhibit 3.2 to Healthpeak’s Current Report on Form 8-K filed March 1, 2024).
4.1 |  | S econd Supplemental Indenture, dated August 14, 2025, by and among Healthpeak OP, LLC, the Guarantors, and U.S. Bank Trust Company, National Association, as trustee (incorporated herein by reference to Exhibit 4.1 to Healthpeak’s Current Report on Form 8-K filed August 14, 2025).
4.2 |  | F orm of 4.750% Senior Notes due 2033 (incorporated herein by reference to Exhibit 4.2 to Healthpeak’s Current Report on Form 8-K filed Augu s t 14, 2025).
10.1* |  | Amendment No. 1 to Third Amended and Restated Credit Agreement, dated as of October 3, 2025, by and among Healthpeak OP, LLC, Healthpeak Properties, Inc., DOC DR Holdco, LLC, DOC DR, LLC, the lenders listed therein, and Bank of America, N.A., as administrative agent.
10.2* |  | Amendment No. 4 to Term Loan Agreement, dated as of October 3, 2025, by and among Healthpeak OP, LLC, Healthpeak Properties, Inc., DOC DR Holdco, LLC, DOC DR, LLC, the lenders listed therein, and Bank of America, N.A., as administrative agent.
10.3* |  | Fifth Amendment to Third Amended and Restated Credit Agreement, dated as of October 1, 2025, by and among DOC DR, LLC, DOC DR Holdco, LLC, Healthpeak Properties, Inc., Healthpeak OP, LLC, the lenders listed therein, and KeyBank National Association, as administrative agent.
22.1* |  | List of Issuers of Guaranteed Securities
31.1* |  | Certification by Scott M. Brinker, Healthpeak’s Principal Executive Officer, pursuant to Securities Exchange Act Rule 13a-14(a).
31.2* |  | Certification by Kelvin O. Moses, Healthpeak’s Principal Financial Officer, pursuant to Securities Exchange Act Rule 13a-14(a).
32.1** |  | Certification by Scott M. Brinker, Healthpeak’s Principal Executive Officer, pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.
32.2** |  | Certification by Kelvin O. Moses, Healthpeak’s Principal Financial Officer, pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.
101.INS* |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH* |  | XBRL Taxonomy Extension Schema Document.
101.CAL* |  | XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF* |  | XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB* |  | XBRL Taxonomy Extension Labels Linkbase Document.

73

Table of Contents

101.PRE* |  | XBRL Taxonomy Extension Presentation Linkbase Document.
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

_______________________________________
+ Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5) and Item 601(b)(2), as applicable.
* Filed herewith.
** Furnished herewith.
74

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 24, 2025 | Healthpeak Properties, Inc.
| /s/ SCOTT M. BRINKER
| Scott M. Brinker
| President and Chief Executive Officer
| (Principal Executive Officer)
| /s/ KELVIN O. MOSES
| Kelvin O. Moses
| Chief Financial Officer
| (Principal Financial Officer)
| /s/ SHAWN G. JOHNSTON
| Shawn G. Johnston
| Executive Vice President and
| Chief Accounting Officer
| (Principal Accounting Officer)

75